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Summary
A landmark study published over ten years ago established a link
between mutations of the LKB1 gene and the Peutz-Jeghers cancer
syndrome. Since then, much effort has been devoted to understand-
ing the functional roles of the protein encoded by the LKB1 gene.
LKB1 is a Ser/Thr kinase that is activated by binding to the pseu-
dokinase STRAD and the scaffolding protein MO25. LKB1 activates
AMPK and twelve other members of the AMPK family of kinases,
thus controlling cellular energy and cell polarity. Much attention has
been focused towards protein kinases activated by LKB1, although the
mechanism by which STRAD and MO25 activate LKB1 remains un-
known. The work described in this thesis was conducted with the aim
of understanding the interactions of LKB1 with STRAD and MO25,
and the mechanisms by which the latter two activate LKB1. I have
tried to accomplish these aims using a structural biology approach.
In chapter III of this thesis I show the structure of the regulatory
STRADα/MO25α complex, and in chapter IV the structure of the
heterotrimeric LKB1/STRADα/MO25α complex. The structure of
STRADα reveals for the first time the determinant features of kinase
inactivity, and provides an example of how pseudokinases can exert
their functions through their conformation rather than phosphoryla-
tion. STRADα adopts a closed conformation typical of active protein
kinases, and binds LKB1 as a pseudosubstrate. STRADα binding
promotes the active conformation of LKB1, which is further stabilised
by MO25α interacting with the LKB1 activation loop. This repre-
sents a previously undescribed mechanism of kinase activation that
may be relevant to understanding the evolution of other pseudoki-
nases. Finally the structure of the LKB1 heterotrimer reveals how
mutations found in Peutz-Jeghers syndrome and other cancers impair
LKB1 function.
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1 Introduction
1.1 The protein kinase family
1.1.1 Historical overview of protein phosphorylation
More than five decades ago protein phosphorylation was described as a
covalent and reversible regulatory mechanism of enzyme activity. The
first identified protein kinase was Casein (phospho) kinase by Kennedy
and Burnett in 1954 (Kennedy and Burnett, 1954). The breakthrough
however, came from laboratories studying glycogen breakdown in mus-
cle and liver tissues, that lead to the description of the active and
inactive forms of glycogen phosphorylase by Fischer and Krebs (1955)
and Sutherland and Wosilait (1955). Fischer and Krebs in particular
could demonstrate that the inactive b form of glycogen phosphory-
lase could be converted to the active a form in the presence of ATP,
Mg2+ and a protein they named phosphorylase kinase. The process
of γ-phosphryl group transfer to a serine residue of phosphorylase b
was later described by Fischer et al. (1959). Subsequent findings that
the opposite reaction (phosphate releasing) was carried out by protein
phosphatases (Ingebritsen and Cohen, 1983) made clear phosphory-
lation was a dynamic process of post-translational modification. In
1981 the first example that a kinase (v-src) could phosphorylate tyro-
sine residues was provided by Tony Hunter (Hunter and Sefton, 1980),
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thus completing the identification of the three most commonly phos-
phorylated amino acids to date (Fig. 1.1).
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Figure 1.1: Structures of phosphory-
lated amino acids
The identification of the c-AMP de-
pendent protein kinase (PKA) (Walsh
et al., 1968), that could phosphory-
late and activate phosphorylase ki-
nase, provided an example of kinase
signalling cascades (also referred to as
signal transduction pathways)—a pro-
cess very widely used in almost all eukaryotic organisms to transmit,
integrate and communicate intra/extracelluar stimuli. The later se-
quencing of the PKA gene (Shoji et al., 1981) had perhaps the biggest
impact in kinase biology, since it allowed researchers, geneticists in
particular, to understand that other proteins under investigation were
indeed kinases.
1.1.2 Phylogeny of protein kinases—the human kinome
As more protein kinases were identified, it became clear in the 1980s
that this was a diverse family involved in regulating many cellular
processes (for more examples the reader is referred to the reviews
by Hunter and Cooper, 1985 and Cohen, 2002). Despite their func-
tional diversity, it was soon realised that kinases were related and have
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evolved in part from a common origin (Barker and Dayhoff, 1982;
Hanks et al., 1988). As the scientific community moved towards a
genomic area in the 1990s, numerous protein kinases were identified
and functions were assigned to regulating almost all aspects of cel-
lular life. The draft release of the human genome sequence in 2001
(Lander et al., 2001; Venter et al., 2001) allowed Gerard Manning and
colleagues to provide a complete catalogue of protein kinases by pub-
lishing the human kinome a year later (Manning et al., 2002) (Fig.
1.2). In this iconic diagram (Fig. 1.2), kinases are divided in eight
major groups according to their sequence similarities: AGC (includes
PKA, PKG (protein kinase G) and PKC (protein kinase C) families),
CAMK (Ca2+/calmodulin-regulated kinases), CK1 (casein kinase 1
family), CMGC (includes CDKs (cyclin-dependent kinases), MAPKs
(mitogen-activated protein kinases), GSK (glycogen synthase kinase)
and CDK-like kinases), STE (related to yeast sterile kinases), TK
(tyrosine kinases), TKL (tyrosine kinase-like) and aPKs (atypical
protein kinases).
To date, there are 518 known human protein kinases (Manning et al.,
2002), representing approximately 2–2.5% of the estimated total num-
ber of genes (20000–25000) in the human genome (International Hu-
man Genome Sequencing Consortium, 2004). Interestingly, ∼10% of
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HASPIN
Figure 1.2: The human kinome dendogram
A catalogue of human kinases grouped according to their sequence similarities. An additional
list of “atypical” kinases is also provided. In red are protein kinases that have alterations in at
least one catalytic motif and predicted to be inactive—these are referred to as pseudokinases.
The kinase LKB1, pseudokinases STRADα/β and the AMPK family of kinases, key subjects
of this thesis, are marked with a black line. Figure adapted from Manning et al., 2002,
and Boudeau et al., 2006. The human kinome is freely accessible from the following URL:
http://kinase.com/human/kinome/
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protein kinases lack at least one of the motifs required for catalysis—
these are termed pseudokinases (Manning et al., 2002; Boudeau et al.,
2006). The protein kinase family represents the third most common
known functional domain in the human genome (Lander et al., 2001).
1.2 Structural features of a kinase domain
1.2.1 Overall fold of a protein kinase
The first structure of a protein kinase was the structure of protein
kinase A (PKA) and was solved in 1991 by Knighton and colleagues
(Knighton et al., 1991b,a). PKA also represents the most well studied
kinase in terms of structure-function relationship and is presented here
as a general model of protein kinase structure (Fig. 1.3). Protein
kinases share a common catalytic domain, that has a bilobal structure
made up of a small N-terminal lobe, and a larger, C-terminal lobe
(Fig. 1.3). The two lobes are connected by a short loop (∼10 residues)
referred to as the hinge region, allowing flexibility with respect to each
other.
The ligand (ATP) binding pocket is highly conserved amongst all
active kinases and some pseudokinases. ATP binds between the two
small and large lobes with the adenine ring buried inside a large hy-
drophobic pocket, thus completing the so-called hydrophobic spine
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Figure 1.3: Structure of a typical protein kinase
Structure of protein kinase A (PKA; PDBID = 1ATP) determined by Knighton et al., 1991
(Knighton et al., 1991a) in complex with the PKI inhibitor peptide (red). The kinase core
domain is coloured green and the secondary structure, N- and C-lobes are labelled. The N-
(orange) and C-terminal (blue) flanking regions are labelled αA and CFT respectively. The
activation loop (A-loop) is coloured cyan and the glycine-rich (G-rich loop) is coloured magenta.
The hydrophobic residue (Phe327) present in the CFT, and is part of the active site tether
(AST) is shown as sticks. A bound ATP molecule is shown as sticks with yellow carbons. The
same nomenclature (Knighton et al., 1991b; Yang et al., 2009) is used throughout this thesis
unless specified otherwise.
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(Kornev et al., 2006) of the kinase domain (the ATP binding site is
discussed in detail in section 1.2.6). Two Mg2+ ions, required for
phosphoryl transfer, coordinate active site residues and the phosphate
groups of ATP. The N-terminal lobe is comprised of a five-stranded
antiparallel β-sheet with a conserved αC helix spanning the domain
between β-strands β3 and β4 (Fig. 1.3). With the exception of the
loop between the αC helix and the β4 strand that is anchored firmly
to the C-terminal lobe, the two lobes show few further interactions.
The larger C-terminal lobe contains mostly α-helices and has a rel-
atively rigid structure. This lobe contributes a small two-stranded
β-sheet (β7/β8, Fig. 1.3) and together with residues from the loops
before/after this sheet contribute to a mainly hydrophobic environ-
ment suitable for binding the adenine ring of ATP. The catalytic and
metal binding motifs, together with the substrate binding site are
located in the C-lobe (Fig. 1.3) (Knighton et al., 1991a). The acti-
vation segment (Fig. 1.3) is perhaps the most mobile structure of the
kinase domain and its conformation is subject to post-translational
modification as well as allosteric regulation. Correct positioning of
the activation segment is a prerequisite for the correct alignment of
substrate binding and active sites.
The kinase core domain is often surrounded by N- and C-terminal
1 Introduction 9
flanking sequences, that interact with the kinase domain. These are
the N-terminal αA helix and the C-terminal flanking tail (CFT) (Fig.
1.3).
1.2.2 Conserved motifs of protein kinases
In 1988, Hanks et al., provided a multiple sequence alignment of
65 protein kinases, revealing conserved features of the kinase fam-
ily (Hanks et al., 1988). Analysis of sequence conservation revealed 11
(later updated to 12 (Taylor and Radzio-Andzelm, 1994)) functional
motifs, and according to these revelations the protein kinase domain
was divided into sub-domains (Fig. 1.4) (Hanks et al., 1988; Taylor
and Radzio-Andzelm, 1994).
β1 β2 β3 β5β4αB αC αD αE αEF αF αG αH αI
I II III IV V VIa VIb
β6 β9β7 β8
VII VIII IX X XI
Glycine rich 
loop
Catalytic
loop
Activation 
segment
Conserved 
motifs
Secondary
structure
Sub-domains
(ϕ) Hydrophobic, (Φ) Large hydrophobic (FYW), (δ) Hydrophilic, (X) any amino acid; Numbering corresponds to PKA sequence
 
Figure 1.4: Kinase domain secondary structure, sub-domains and conservation of key
motifs
The secondary structure is labelled and the consensus sequence of common motifs and key
conserved loops are given. These were deduced from multiple sequence alignments of represen-
tative protein kinases from each branch of the human kinome. The sub-domain nomenclature
as described by Hanks et al., 1988 and Taylor and Radzio-Andzelm, 1994 is indicated. The
figure was partially adapted from Kannan et al., 2007.
After the structure of PKA (Fig. 1.3) was solved, the function of
these motifs became more apparent. In sub-domain I the small glycine
residues from the glycine-rich loop ensure no steric clashes occur with
the β/γ phosphate groups of ATP (Fig. 1.3). In sub-domain II, a
1 Introduction 10
lysine residue from the VAIK motif (Lys72 in PKA, Lys31 in CDK2),
makes two important interactions—an electrostatic interaction with a
conserved glutamate residue (Glu91 in PKA, Glu51 in CDK2) from
helix αC (sub-domain III) and a second interaction with the α phos-
phate group of ATP. Because this motif is found in a β-strand, the
alanine and lysine side chains in the VAIK motif, point, by definition,
within the ATP binding pocket. This explains the requirement of a
small, mainly hydrophobic residue (usually alanine) in this motif that
avoids steric clashes with ATP.
Figure 1.5: Activation segment of a
protein kinase. Image was taken from
Nolen et al., 2004 and the same nomen-
clature is used throughout this thesis.
The catalytic loop resides in sub-
domain VIb, C-terminal to the β6
present in the C-lobe and contains
the catalytic (HRD) motif, with the
aspartate (PKA Asp166) acting as
the catalytic base. The catalytic
motif is followed by a conserved ly-
sine residue (PKA Lys168) that po-
sitions the γ-phosphate of ATP and
an asparagine residue (PKA Asn171) required for coordination of one
of the two Mg2+ ions (Fig. 1.4). The second Mg2+ ion is coordinated
mainly by the Mg2+ binding loop (sub-domain VII), also referred to
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as the DFG motif that follows immediately the β9 strand (Fig. 1.4).
The aspartate residue (PKA Asp184) is pivotal for catalysis. The
DFG motif located just before the β9 strand, starts the very impor-
tant activation segment of the kinase domain, that ends with the APE
motif prior to helix αEF (Fig. 1.5). This 20-25 amino acid region
(DFG ... APE) hosts three important conserved functional motifs—
the DFG Mg2+ binding loop, the activation loop (or “T” loop) where
activatory phosphorylation takes place, and the substrate binding loop
(P+1) loop (Nolen et al., 2004) (Fig. 1.5).
1.2.3 Plasticity of a kinase domain
Lys33/Glu51
ion bridge
Glu51
ATP
N-lobe
C-lobe
αC
Figure 1.6: Open (magenta) and closed
(green) conformations of CDK2
With the determination of PKA
structures (Knighton et al., 1991b,a)
it became clear the position of the
N-terminal to the C-terminal lobe
was dependent on the presence and
nature of the ligand in the ATP
binding site (Prade et al., 1997;
Zheng et al., 1993). Zheng et al.,
1993 crystallised PKA in the pres-
ence/absence of ATP, thus revealing for the first time two states of the
enzyme, an active “closed” conformation observed in complex with
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ATP:Mg2+ and an inactive “open” conformation, in the absence of
Mg2+ATP. This is in agreement with the observation that interactions
between the two lobes are largely mediated by ATP, and that in the
absence of ATP, the two lobes are relatively uncoupled. Interestingly,
also “intermediate” conformations were observed in the PKA struc-
tures in complex with a broad, non-specific natural product inhibitor
staurosporine (Prade et al., 1997), suggesting that protein kinase in-
hibitors utilised the conformational flexibility of the protein kinase do-
main. Thus “locking” the kinase domain in a particular intermediate
conformation could be exploited for the design of more specific kinase
inhibitors (discussed by Liu and Gray, 2006). Other protein kinases
have been crystallised in the open/closed conformations (reviewed by
Johnson et al., 1996, Huse and Kuriyan 2002 and Nolen et al., 2004)
and this is illustrated in Fig. 1.6. There are two hallmark features
of a typical closed conformation, that have so far been observed in all
active kinases: formation of the Glu/Lys ion bridge connecting helix
αC and the N-lobe β sheet (Fig. 1.6) and the formation of a short
β6/β9 sheet between the catalytic loop (β6) and activation segment
(β9) (Fig. 1.5).
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1.2.4 Activity modulators of protein kinases
Protein kinases have evolved different mechanisms to properly align
the catalytic machinery and the substrate binding site. In most cases,
protein kinases are regulated by phosphorylation of residues in their
activation loop. This can contribute to the correct positioning of helix
αC, but more importantly it aligns the activation segment in a partic-
ular orientation, away from the ATP binding pocket. In some kinases
the conserved catalytic Asp residue in the catalytic loop (Asp166 in
PKA) is preceded by an Arg residue (Arg165 in PKA)—these are
termed RD-kinases (Johnson et al., 1996) and the basic pocket sur-
rounding the site of T-loop phosphorylation has been termed the “RD
pocket” (Johnson et al., 1996; Nolen et al., 2004). The RD pocket
is formed by residues contributed by helix αC (PKA His87) and ba-
sic residues from the activation segment (PKA Lys189) (Knighton
et al., 1991b), thus the activatory phosphate can be seen as an inter-
connecting module of activation segment and the catalytic loop, while
at the same time influencing inter-lobe conformational changes.
Many inactive protein kinases lack a proper alignment of the Glu
residue due to rotation, disorder or twisting of the regulatory helix
αC. For instance, in the inactive cyclin dependent protein kinase 2
(CDK2) structure, Glu51 (from helix αC) points away from the ATP
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binding site (De Bondt et al., 1993) and assumes an “open” conforma-
tion (Fig. 1.6). After binding of CDK2 to activatory cyclins, rotation
of the αC helix aligns Glu51 to interact with Lys33, which is now per-
fectly aligned to interact with ATP (Jeffrey et al., 1995) (Fig. 1.6).
The formation of this Lys/Glu ion bridge represents one of the hall-
marks of the “closed” active conformation (Johnson et al., 1996; Huse
and Kuriyan, 2002; Nolen et al., 2004). In addition, protein kinases
unrelated to CDK2 are regulated by an induced alignment of the helix
αC, such as AGC kinases (Bayliss et al., 2003) and tyrosine kinases
(Filippakopoulos et al., 2008). Interestingly, in the case of CDK2 men-
tioned above, both phosphorylation by upstream CDK kinases as well
as binding of activity modulators such as cyclins, are required to as-
sume a “closed” active conformation and a proper alignment of the ac-
tivation segment, that is optimal for substrate binding and phosphoryl
transfer (Jeffrey et al., 1995; Russo et al., 1996). In addition, protein
kinases unrelated to CDK2 are regulated by an induced alignment
of helix αC and activation loop phosphorylation. Examples include
Aurora-A/B (AGC kinases) regulated by the TXP2/INCEP binding
modules respectively (Bayliss et al., 2003; Sessa et al., 2005) and tyro-
sine kinases such as the proto-oncogene Fes/Fps that is regulated by
an SH2 domain present in the same polypeptide chain (Filippakopou-
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los et al., 2008).
While activation loop phosphorylation either by auto-phosphorylation
or phosphorylation by other kinases is a common mechanism of reg-
ulating kinase activity, regulatory mechanisms other than the ones
described above exist. For instance, phosphorylase kinase (PhK) does
not require T-loop phosphorylation for activity, but contains a glu-
tamine residue in its activation loop that substitutes for the nega-
tive charge usually provided by the phosphate group (Owen et al.,
1995). The assumed position of the activation segment via regula-
tory/activity modulators is one of the main subjects of this thesis.
1.2.5 N- and C-terminal flanking regions
Interesting features of a kinase domain are interacting flanking se-
quences at its N- and C-termini (Fig. 1.3), that in some cases mod-
ulate protein kinase activity. The C-terminal flanking tail (CFT) is
a conserved feature of AGC kinases and wraps around both lobes of
the kinase domain (Fig. 1.3) (Kannan et al., 2007b). Kannan et al.,
defined three sites that tether the CFT to the kinase domain: C-
lobe tether (CLT), active site tether (AST) and N-lobe tether (NLT)
(Kannan et al., 2007b). The latter contains the conserved hydrophobic
motif that binds to a hydrophobic pocket present in the N-lobe and
regulates (AGC) kinase activity (reviewed by Biondi and Nebreda,
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2002 and Gold et al., 2006). The C-lobe tethers the initial residues
of the CFT and the most dynamic part of the CFT is the active site
tether (AST). An important feature of the AST is the interaction of a
large hydrophobic residue (Trp/Phe) with ATP (Kannan et al., 2007b;
Yang et al., 2009), that closes the hydrophobic ATP binding pocket
(Fig. 1.3). Interestingly, yeast genetic screens identified a loss-of-
function mutant that corresponds to the equivalent residue (Phe327)
in PKA (Yang et al., 2009). Yang et al., have provided an explanation
for this phenotype, and have demonstrated the Phe327Ala exhibits
significant reduction in catalytic efficiency (Yang et al., 2009).
N- and C-terminal regions have been documented to (up/down)-
regulate kinase activity in many different ways. There are well known
examples of SH2 and SH3 domains, present in the same polypeptide
of tyrosine kinases that contribute to inactive kinase conformations
(Sicheri and Kuriyan, 1997). Other examples include the microtubule
affinity-regulating (MARK1-4) isoforms, that contain a ubiquitin as-
sociated (UBA) domain at their C-terminus that interacts with the N-
lobe of the kinase domain (Panneerselvam et al., 2006) and is required
for activation by the upstream kinase LKB1 (Jaleel et al., 2006).
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1.2.6 The ATP binding site
Understanding the molecular interactions of ATP binding to a pro-
tein kinase domain is important for unveiling details of the reaction
mechanism. In addition, most available protein kinase inhibitors are
ATP competitive and utilise the same binding pocket to inhibit ki-
nase activity and function. The adenine base of ATP is bound by all
kinases in an analogous fashion, sandwiched by hydrophobic residues
from the N- terminal and C-terminal lobes (Fig. 1.7A) Two hydro-
gen bonding interactions can be observed between the polar adenine
nitrogen groups and the protein backbone of the kinases hinge-region
(Fig. 1.7B). The adenine N1 accepts a hydrogen from the backbone
amide, whereas the adenine amino group donates a hydrogen to the
backbone carbonyl. Interestingly, almost all known protein kinase in-
hibitors have been found to mimic the adenine N1 interaction with
the protein, and many protein kinase inhibitors mimic both interac-
tions (Komander et al., 2003, 2004; Liu and Gray, 2006). In addition,
the ribose ring of ATP interacts via hydrogen bonds with (generally)
acidic amino acids (Fig. 1.7B).
While the adenine ring of ATP is held via hydrophobic forces, the
phosphate groups on the other hand, are coordinated mainly via hy-
drogen bonding interactions with active site residues as well as two
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Figure 1.7: Conserved interactions in the ATP binding pocket
A) Stereo view of hydrophobic interactions between ATP (represented as sticks) and residues
from the ATP binding pocket of PKA (represented as sticks and transparent surface). Phe327
(from the C-terminal flanking tail) is the only residue not part of the kinase domain and
coloured blue.
B) Stereo view of conserved interactions between the ATP phosphate moiety (represented as
sticks), residues from the ATP binding pocket (represented as sticks), Mg2+ ions (blue spheres)
and nearby water molecules (red spheres). Dashes represent hydrogen bonds. The structure
of PKA/ATP:Mg2+ (PDBID 1ATP (Knighton et al., 1991b)) is shown in both (A) and (B).
Mg2+ ions (Fig. 1.7B). As mentioned above, of particular impor-
tance is the lysine residue from the VAIK motif that coordinates the
α-phosphate, thus linking the ligand binding to the regulatory αC he-
lix. The β/γ-phosphate groups are tethered by Mg2+ ions that are
held in place by the conserved apartate residue from the DFG mo-
tif, aided by a conserved asparagine (catalytic loop) and surrounding
1 Introduction 19
water molecules (Fig. 1.7B). The presence of Mg2+ is required for
correct positioning of the γ-phosphate and its transfer, and mutation
of the Mg2+ binding residue (PKA Asp185) leads to (near) complete
loss of activity. Another residue (PKA Lys168), in hydrogen bond-
ing distance to the γ-phosphate (Fig. 1.7B), plays a key role in γ-
phosphate/substrate binding, at least for Ser/Thr kinases (Johnson
et al., 2001).
1.2.7 Substrate binding to Protein Kinase A
The first protein kinase structure reported by Knighton et al., (Knighton
et al., 1991b) provided significant insights into substrate binding and
recognition (Knighton et al., 1991a). The structure of PKA was de-
termined in complex with a 24 residue pseudo-substrate inhibitor pep-
tide (termed PKI), which has an alanine instead of a phosphorylatable
Ser/Thr residue (Knighton et al., 1991a). The residues determining
substrate specificity were identified, and a nomenclature was devised
applicable to all kinases. The phosphorylated residue of the peptide
occupies the P-site, and the neighbouring sites were accordingly num-
bered p+1, p+2 and p-1, p-2, etc, depending if they were C- or N-
terminal to the site of phosphorylation, respectively (Fig. 1.8A). As
mentioned above, the peptide binding region lies almost entirely in the
larger lobe of the kinase domain (Fig. 1.8). The N-terminal part of
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the peptide folds into a short α-helix, which is required for high affin-
ity binding, and also forms multiple contacts with exposed aromatic
residues of the C-terminal lobe.
P
P+1
P+2
P+3
P-1
P-2P-3
ATP
γP
PKI
P+1 loop 
αC
αG αEF
αG
αEF
ATP
GTP
ROCK-I
RhoE
A-loop 
PKA
A B
Figure 1.8: Substrate binding to protein kinases
A) Structure of PKA (coloured green and represented as cartoons with transparent surface)
and bound PKI inhibitor peptide (red cartoon) (PDBID 1ATP) Knighton et al. (1991a). P =
position of the phosphorylatable residue. In this case this is an alanine residue since PKI is a
pseudosubstrate. The activation and p+1 loops are coloured cyan and red respectively.
B) Complex structure of ROCK-I kinase with its substrate RhoE (PDBID = 2V55) determined
by Komander et al., 2008.
Recently, complexes between protein kinases and protein substrates
have been solved. In 2005, Dar et al., reported the structure of the
RNA-dependent protein kinase (PKR) complexed to the translation
initiation factor α-2 subunit (eIF2α) (Dar et al., 2005). Another ex-
ample is the structure of the Rho-associated protein kinase (ROCK-I)
in complex with the Rho-related GTP-binding protein (RhoE) (Ko-
mander et al., 2008) (Fig. 1.8B). Interestingly, in both cases helix
αG (C-lobe) was involved in substrate interaction, suggesting a role
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for this helix in substrate binding, additional to the p+1 loop (Fig.
1.8B).
1.2.8 Mechanism of phosphate transfer
For the phosphoryl transfer in protein kinases, two mechanisms are
possible: the associative, concerted mechanism (SN2) in which the
γ-phosphate is transferred to the substrate hydroxyl-group under in-
version of its stereochemistry via a single step. The transition state for
this mechanism consists of a penta-covalent phosphorane moiety with
three negative charges (Fig. 1.9). The second possible mechanism is
a dissociative two-step mechanism (SN1), in which a trigonal-planar
metaphosphate (PO3
−) is formed by breaking the P-O bond (Fig. 1.9).
Figure 1.9: Possible reaction mechanisms of phosphate transfer
Schematic representations of the associative (SN2) and dissociative (SN1) mechanism dis-
cussed by Knowles., 1980. Adapted from Cook et al., 2002..
Evidence for both reaction mechanisms are available from studies
with transitions state analogues such as nitrate (NO3
−) and aluminium
fluoride (AlF3), both planar compounds assumed to resemble the tran-
sition state of a phosphoryl reaction. Structures are available, for a
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quaternary complex of CDK2 with a substrate peptide, ADP, Mg2+,
and nitrate (Cook et al., 2002), supporting a mainly dissociative mech-
anism. Similarly, the structure of PKA in complex with a substrate
peptide, ADP, Mg2+ and aluminium fluoride (AlF3) has been deter-
mined and supports a mainly associative mechanism (Madhusudan
et al., 2002). The mechanisms are not mutually exclusive and can
partially co-exist.
1.3 Protein kinases in disease
Given the key roles protein kinases play in orchestrating almost all as-
pects of cellular life, it is no surprise that a large number of these genes
are mutated in disease. Because of the diverse functionality, these
include both gain- and loss-of-function mutations. A list of protein
kinases and phosphatases that are mutated in various human diseases
is given in Table 1.1, with the aim of illustrating the crucial impor-
tance of protein phosphorylation as one of the key post-translational
modifications. In more complex human disorders such as cancer, both
germline and somatic mutations in genes coding for kinases can lead
to the breakdown of protein kinase signalling networks and progress
to severe malignant conditions. Another classic example of a multi-
factorial disease where signalling by kinases is of crucial importance,
is type II diabetes that is caused by a combination of normal ageing
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processes and genetic factors, coupled with the side effects of obesity
and lack of exercise. Altogether these lead to a breakdown of protein
phosphorylation signalling cascades controlled by insulin.
Disease causing mutations in protein kinases continue to be found at
high frequencies. For instance, in a recent enterprise by the Wellcome
Trust Sanger Institute for the Cancer Genome Project, the protein
kinase family represents the highest number of genes with somatic
mutations in 339481 human tumour samples and 4775 genes analysed
(statistics from the Catalogue of Somatic Mutations in Cancer (COS-
MIC) database accessible online at http://www.sanger.ac.uk/genetics
/CGP/cosmic/ (Forbes et al., 2008). In some types of cancers (e.g.
lung cancer), mutations in as many as 141 protein kineses (out of the
total 518) were found (Davies et al., 2005). It is worth noting how-
ever, not all of the found mutations were cancer driving mutations.
Finally, mutated and activated protein kinases have proved to be pos-
sible targets for the development of new anticancer therapies, and the
first Abl tyrosine kinase inhibitor (Imatinib) was approved as a drug
for the treatment of chronic myeloid leukaemia (CML) in 2001. It
is thought that over 25% of all drug targets currently under investi-
gation by the pharmaceutical companies comprise protein kinases, a
figure likely to be significantly higher in oncology (Cohen, 2002b).
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Table 1.1: Some of the inherited human diseases caused by mutations in protein
kinases and phosphatases. Table adapted from Alessi and Zeqiraj, 2007. Data
can be retrieved from the Online Mendelian Inheritance in Man (OMIM) database
(http://www.ncbi.nlm.nih.gov/omim/). STRADα and LKB1 entries are highlighted.
Disease Kinase
Myotonic muscular dystrophy Myotonin protein kinase
X-linked agammaglobulinaemia Bruton’s tyrosine kinase
Hirschsprung’s disease, men RET2
Autosomal recessive severe combined
immunodeficiency (SCID)
ZAP70
Polycythaemia vera JAK2
X-linked SCID JAK3
Polyhydramnios, megalencephaly and
symptomatic epilepsy (PMSE)
STRADα
Craniosynostosis FGF receptor kinase
Papillary renal cancer Met receptor kinase
Chronic myelogenous leukaemia TEL/PDGF receptor kinase
Myelogenous leukaemia Abelson tyrosine kinase
Non-Hodgkin’s lymphoma ALK
Peutz-Jeghers syndrome LKB1
Coffin-Lowry syndrome RSK2
Ataxia telangiectasia ATM
Li-Fraumeni syndrome CHK2
Williams syndrome LIMK1
Leprechaunism, diabetes Insulin receptor kinase
Wolff-Parkinson-White syndrome AMPK
Gordon hypertension syndrome WNK1 and WNK4
Wolcott-Rallison syndrome EIF2AK3
Melanoma and other sporadic cancers B-Raf and CDKN2A
Hereditary early-onset Parkinson’s disease PINK1 and LRRK2
Pulmonary hypertension TGFβ receptor BMPR-II
Neuronal development disorders CDKL5
Familial advanced sleep phase syndrome CK1δ
5-10% non-small-cell lung cancers EGF receptor kinase
Hyporesponsiveness to bacterial infection IRAK4
Colon, breast and other sporadic cancers PI3K (p110α subunit)
Disease Phosphatase
X-linked myotubular myopathy MTM1 tyrosine phosphatase
Cowden’s disease PTEN phosphatase
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1.4 The LKB1 gene—disease implications
1.4.1 Discovery of the LKB1 gene
The LKB1 gene was first identified in 1996 by Jun-ichi Nezu from
Chugai Pharmaceuticals, Tokio, Japan, in a screen aimed at identify-
ing new kinases. The sequence was given the pseudo-acronym LKB1
(not standing for a specific name), and was deposited in the NCBI
public database (NCBI accession code = NM 000455; GenBank ID
U63333.1) without the publication of a research paper. A single LKB1
gene (also referred to as serine/threonine kinase 11, STK11), is present
in the human genome. The LKB1 gene is composed of 11 exons (23
kb) and is located in chromosome 19 (gene locus 19p13.3). The hu-
man LKB1 protein comprises 433 residues (mouse 436 residues) with
the catalytic kinase domain encompassing residues 43–309 (Fig. 1.10).
Interestingly, the catalytic domain shares less homology to other pro-
tein kinases, explaining why LKB1 is localised within the centre of the
human kinome dendogram and does not belong to any of the seven
groups classified by Manning et al. 2002 (Fig. 1.2). A sequence
similarity search of eukaryotic genomic databases using the BLAST
tools (http://blast.ncbi.nlm.nih.gov/Blast.cgi) with sequences of the
N- and C-terminal regions of LKB1 reveals no similarities to known
functional domains. LKB1 is widely expressed at varying levels in
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all foetal and adult tissues examined (Hemminki et al., 1998; Jenne
et al., 1998). An additional isoform of LKB1 (denoted LKB1 short)
is found in testis and this is a result of alternative mRNA splicing
after exon VIII (Towler et al., 2008; Denison et al., 2009). The two
isoforms share 100% sequence identity between residues 1–370 (Fig.
1.10) (Towler et al., 2008; Denison et al., 2009).
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Figure 1.10: Sequence alignment of the LKB1 splice isoforms
Sequences of the LKB1 short isoform found predominantly in testis and LKB1 long found in
all tissues (Towler et al., 2008; Denison et al., 2009). The kinase domain is underlined in pink,
whereas the N- and C-terminal regulatory domains (NRD and CRD) are underlined in purple.
The sequence of the nuclear localisation signal (NLS) is underlined in red.
1 Introduction 27
1.4.2 LKB1 is the causative gene for PJS
Peutz-Jeghers syndrome (PJS) is a rare genetic disorder inherited in
an autosomal dominant fashion and is discussed in section 1.4.3 be-
low. The first genetic link between PJS and LKB1 was provided in
1997 when three studies reported the gene locus (19p13.3) responsible
for the condition (Amos et al., 1997; Hemminki et al., 1997; Mehenni
et al., 1997). Intensive sequencing of all genes present in that locus
(29 in total), from samples derived from PJS patients, demonstrated
that 11 out of the 12 PJS families studied had mutations in the gene
coding for LKB1. The findings were described in the landmark paper
of Akseli Hemminki (a graduate student in Lauri Aaltonen’s labo-
ratory) and collegues (Hemminki et al., 1998). In the same year, a
second group, which had originally collaborated with the Aaltonen
laboratory, also reported mutations of the LKB1 gene in PJS subjects
(Jenne et al., 1998). Moreover, point mutations that alter key cat-
alytic residues, (e.g. Asp174Asn (Mehenni et al., 1998)) suggested a
strong link between LKB1 kinase activity and PJS. In the last decade,
a large number of studies have reported mutations of the LKB1 gene
in PJS patients as well as sporadic cancers with the largest number
of genetic alterations occurring in the kinase domain. Thus far, 62
missense mutations, 77 frameshift mutations, 36 nonsense mutations
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and 19 in-frame deletions of the LKB1 gene have been identified from
samples of PJS and other cancer patients (these are summarised in
Fig. 1.11).
Early studies of PJS patients have reported that only about half of
the individuals carry LKB1 germline mutations, suggestive that other
tumour suppressor genes are responsible for causing PJS in the re-
maining patients (Alhopuro et al., 2005; Wang et al., 1999). However,
with recently improved methods the detection of LKB1 alterations
in PJS patients has soared by up to 80% (Hearle et al., 2006; Volikos
et al., 2006; Sanchez-Cespedes, 2007), thus lessening the probability of
a second PJS locus. Interestingly, a recent study has reported an acti-
vating germline mutation in the smooth muscle myosin gene (MYH11)
in a patient with PJS-like features (Alhopuro et al., 2008). Two mis-
sense and two frmeshift functionally evaluated MYH11 mutations were
found to possess increased actin-activated ATPase activity (Wallace
et al., 2005; Alhopuro et al., 2008), as well as unregulated (phosphory-
lation dependent) motor activity (Alhopuro et al., 2008). Mutations in
the MYH11 may therefore be responsible for causing polyposis in the
remaining PJS patients, although more work is necessary to conclude
that MYH11 is indeed the missing PJS gene.
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Figure 1.11: List of disease causing mutations in the LKB1 gene
Mutations identified in the human LKB1 gene in patients with PJS and sporadic cancers
are represented schematically on the primary structure of the LKB1 protein: (A) missense
mutations, (B) frameshift mutations, (C) nonsense mutations and (D) in-frame deletions.
Silent mutations, splicing mutations and large exonic deletions are not listed. Data were ac-
quired from the published literature, the Catalogue of Somatic Mutations in Cancer (COSMIC)
database (Forbes et al., 2008), (Boudeau et al., 2003b),(Alessi et al., 2006) and references
therein. The nuclear localisation signal (residues 38–42) is shown as a hatched rectangle and
the kinase domain of LKB1 (residues 43–309) is coloured pink. The most frequently found so-
matic mutations to date (“hot-spots”) are coloured red. NRD, N-terminal regulatory domain;
CRD, C-terminal regulatory domain; fs, frameshift; st, stop.
E) To aid representation of the LKB1 kinase domain, an annotation of all the standard sub-
domains (Hanks et al., 1988) is provided.
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1.4.3 Peutz-Jeghers syndrome
PJS is an autosomal dominant inherited disease characterised by hamar-
tomatous polyposis of the Gastro-Intestinal (GI) tract and “soft”/mucosal
tissue pigmentation. PJS symptoms were first observed in twin sis-
ters with unique “ink-black pigmentation of the lips and mouth” and
reports date back to the late 19th century (reviewed by Hemminki,
1999). However, the relationship between mucocutaneous pigmenta-
tion and polyposis was first described by Dr Johannes Peutz in a Dutch
family in 1921 (Peutz, 1921) and further characterised in the 1940s by
Dr Harold Jeghers and co-workers (Jeghers et al., 1949).
The presenting features of PJS are melanin pigmentation primarily
around the mouth, eyes and nostrils, but also around the anus, buccal
mucosa, vulva fingers and toes (Peutz, 1921; Jeghers et al., 1949). The
major clinical symptoms however, are polyp formation in the GI tract
that cause intussusception, obstruction, abdominal pain, GI bleeding
and polyp extrusion (Buck et al., 1992; Harned et al., 1995). PJS pa-
tients require close monitoring of polyp growth by enteroscopies and
the only treatment available is the surgical removal of polyps, although
this is accompanied by a very high recurrence rate (Katajisto et al.,
2007). Interestingly, recent studies have reported that rapamycin (in-
hibitor of the mTOR kinase) reduces polyp burden as well as polyp
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size in mouse models of PJS (Wei et al., 2008, 2009; Robinson et al.,
2009; Shackelford et al., 2009), suggesting this type of treatment may
be beneficial to PJS patients.
While the occurrence of polyps does not constitute a life threatening
condition, patients with PJS are more predisposed to developing ma-
lignant tumours in multiple tissues (Tomlinson and Houlston, 1997;
Hemminki, 1999; Westerman et al., 1999a). PJS is a relatively rare
condition with a current estimated rate of 1 in ∼10000–120000 live
births (Hemminki, 1999).
1.4.4 Somatic LKB1 mutations
Unexpectedly, LKB1 somatic mutations are increasingly being found
in tumour samples of non-PJS patients and an estimated 6% of sam-
ples from a variety of cancers analysed so far, have somatic LKB1
mutations (Table 1.2). As expected, the frequency of LKB1 muta-
tions in the GI tract is relatively high, 25% (number of samples n =
21; Table 1.2). Interestingly, cervical and skin cancers display higher
than average frequency rates (16% and 10% respectively; Table 1.2).
From the 205 mutated samples catalogued thus far by the COSMIC
database, Asp194Tyr (Mg2+ binding residue) and Phe354Leu (posi-
tioned C-terminal to the kinase domain) amino acid substitutions ap-
pear to be more frequent than others, together with nonsense muta-
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tions at position 37 and 170 (Fig. 1.11). This could however, represent
a finding that is skewed towards the lung cancer samples since these
represent 58% of the total number of mutated samples (Table 1.2).
Table 1.2: LKB1 somatic mutations found in tissue samples and cell lines
derived from cancer patients. Numbers were acquired from the Catalogue
of Somatic Mutations in Cancer (COSMIC) database∗ accessible online at
http://www.sanger.ac.uk/genetics/CGP/cosmic/ (Forbes et al., 2008).
Primary tissue Number of samples Mutated samples Frequency
Biliary tract 29 1 3%
Cervix 203 32 16%
GI tract∗∗ 21 5 24%
Kidney 71 1 1%
Large intestine 438 12 3%
Liver 10 1 1%
Lung 1132 120 11%
Oesophagus 24 1 4%
Ovary 162 4 2%
Pancreas 151 6 4%
Prostate 5 1 §20%
Skin 146 15 10%
Small intestine 29 1 3%
Stomach 184 3 2%
Testis 45 1 2%
Upper aerodigestive tract 57 1 2%
Totals 3311 205 6%
∗The latest update for the STK11 gene was 28th of May 2009
∗∗Gastrointestinal tract (site unknown)
§ Insufficient number of samples
A well established link between LKB1 inactivation and non-small-
cell lung carcinoma (NSCLC) is now evident (Sanchez-Cespedes et al.,
2002; Sanchez-Cespedes, 2007; Ji et al., 2007), with some studies
claiming that mutations in the LKB1 gene occur in 30% of NSCLC
cases. The frequency of LKB1 mutations found in all lung cancers
however, is likely to be ∼ 10% (Table 1.2). It must be noted that
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a large number of LKB1 mutations found in NSCLC co-occur with
v-Kirs2 Kirsten rat sarcoma (K-Ras) viral oncogene homologue mu-
tations (Ji et al., 2007). Therefore, it can be expected that a large
number of these LKB1 mutations will be passenger rather than driv-
ing mutations.
1.4.5 Cellular and animal models of the LKB1 tumour suppressor
Given the large number of inactivating mutations (Fig. 1.11) of the
LKB1 kinase associated with PJS and other types of cancers, it is clear
the LKB1 gene represents a key tumour suppressor. Cellular and ani-
mal models generated in various laboratories have also demonstrated
this. LKB1 is capable of inducing a G1 cell cycle arrest when over ex-
pressed in HeLa and G361 cells, which lack endogenous LKB1 (Tiainen
et al., 1999). In addition, mouse knockout studies have shown that
heterozygous LKB1+/− mice develop polyps similar to those observed
in PJS patients (Rossi et al., 2002; Bardeesy et al., 2002). Moreover,
conditional bi-allelic LKB1 inactivation in mice, results in tumour
transformation in a number of tissues including: lung (Ji et al., 2007),
skin (Gurumurthy et al., 2008) pancreas (Hezel et al., 2008), endome-
trial lining (Contreras et al., 2008), prostate (Pearson et al., 2008)
and more recently mammary gland (McCarthy et al., 2009). This is
consistent with the types of human cancers where LKB1 inactivating
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mutations have been reported (Table 1.2). Finally, studies with crosses
of LKB1+/− mice and mice models of well known tumour suppressors
such as PTEN+/−, PTEN−/− (Huang et al., 2008) and p53+/−, p53−/−
(Takeda et al., 2006; Wei et al., 2005), show tumour susceptibility and
accelerated tumourigenesis.
1.5 The LKB1 signalling pathway
1.5.1 LKB1 forms complexes with STRAD and MO25
The genetic link between the LKB1 gene and PJS syndrome prompted
investigation by many laboratories aimed at understanding the func-
tion/regulation of this kinase. The breakthrough came with the dis-
covery that Ste20 related adaptor (STRAD) and the scaffolding mouse
protein 25 (MO25; also known as calcium binding protein 39 (CAB39))
bind to LKB1 (Baas et al., 2003; Boudeau et al., 2003a). The for-
mation of this heterotrimeric complex leads to stabilisation and full
activation of LKB1 (Baas et al., 2003; Boudeau et al., 2003a). In
humans, there are two closely related isoforms of STRAD (STRADα
and STRADβ) and MO25 (MO25α and MO25β) that similarly in-
teract with LKB1 (Boudeau et al., 2004). Interestingly, binding of
STRAD and MO25 causes complete exclusion of LKB1 from the nu-
cleus to the cytoplasm, suggesting LKB1 may be carrying out its chief
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functions outside the nucleus (Baas et al., 2003; Boudeau et al., 2003a,
2004).
Although it is clear that STRADα/β and MO25α/β form highly
stable complexes with LKB1, the details of these interaction sites re-
main unknown. In 2003, Baas et al., reported the non-kinase N- and
C-terminal domains are not required for LKB1/STRADα interaction,
suggesting a prominent role of the LKB1 kinase domain in complex
formation (Baas et al., 2003). STRADα forms a stable complex with
MO25 in the absence of LKB1 (Baas et al., 2003), although the phys-
iological role of this binary complex alone is unclear. The last three
residues (Trp-Glu-Phe, termed the WEF motif) of STRADα bind to
MO25α with high (∼0.5–1.0 µM) affinity (Milburn et al., 2004). In-
terestingly, the presence of STRADα is required in order to detect
MO25α binding to LKB1 in a HEK 293 co-expression assay (Boudeau
et al., 2003a). A study carried out by Boudeau et al., demonstrated
through mutagenesis studies an arginine residue (Arg240) present on
MO25 is involved in LKB1 binding (Boudeau et al., 2004).
The discovery of STRAD and MO25 as the two subunits of the LKB1
complex played a significant role in subsequent studies that resulted
in the identification of LKB1 substrates (discussed in sections 1.5.7
and 1.5.8), previously hindered by the difficulties in detecting LKB1
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kinase activity.
1.5.2 The STRAD isoforms are pseudokinases
Both STRADα and STRADβ, together with 46 other members of the
human kinome (Manning et al., 2002) are classified as pseudokinases,
because they lack key residues required for catalysis (Manning et al.,
2002; Boudeau et al., 2006). The subject of pseudokinases remains
controversial, since for some proteins that lack catalytic residues and
hence are classified as pseudokinases, protein kinase activity has been
observed. In the case of WNK (With No (K) Lys) protein kinases,
protein kinase activity has been measured, and their role in activat-
ing SPAK and OSR1 kinases by phosphorylation (Vitari et al., 2005),
contributes to the regulation of ion transport and blood pressure (re-
viewed by Richardson and Alessi, 2006). Interestingly, the WNK1
crystal structure revealed that the function of the initially missing
Lys residue from the VAIK motif (subdomain II) is replaced by a Lys
residue present in the neighbouring subdomain I (Min et al., 2004).
Thus, it is possible the initial prediction (∼10%) of the number of
kinases classified as pseudokinases, is likely to be an overestimate as
more examples of pseudokinses displaying kinase activity are being re-
ported (e.g. IRAK2 (Kawagoe et al., 2008), CASK (Mukherjee et al.,
2008)). However, the exact mechanism of activity for IRAK2 and
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CASK remains unexplained. In the case of the latter which lacks the
Mg2+ binding motif, phosphoryl transfer was reportedly catalysed in
a Mg2+ independent manner (Mukherjee et al., 2008).
STRADα is predicted to lack residues in four catalytic motifs (three
are missing in STRADβ), and is classified in the severely substituted
group (group G) by Boudeau et al., together with 13 other pseudok-
inases (Boudeau et al., 2006). STRADα can bind ATP and MgATP
although no kinase activity has been detected so far, despite numer-
ous attempts ((Boudeau et al., 2004) and Dr J. Boudeau unpublished
results). Therefore, the functional significance of STRADα nucleotide
binding remains unclear.
Beside the two STRADα/β isoforms that share 41% sequence iden-
tity (54% sequence similarity), there are 4 different splice isoforms
of STRADα and 3 different splice isoforms of STRADβ deposited in
the NCBI (http://www.ncbi.nlm.nih.gov/) and Uniprot (http://www.
uniprot.org/) sequence databases (Fig. 1.12A). All STRADα isoforms
share the same pseudokinase domain, and differ mainly in the N- and
C-terminal regions (Fig. 1.12A). Similarly, STRADβ isoform differ-
ences are found in the non-pseudokinase regions, with the exception
of STRADβ isoform 3 that lacks the first 138 residues (Fig.1.12B). It
is not clear whether STRADβ3 is present at the protein level, as this
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B
Figure 1.12: STRADα/β splice isoforms
Sequences of the STRADα (A) and STRADβ (B) splice isoforms. The start and finish of the
pseudokinase domains are indicated in magenta. Common motifs of a typical kinase domain
(in order of appearance for STRADα: glycine-rich loop, VAIK (VTVR) motif, HRD (HRS)
motif, DFG (GLR) motif, APE (SPE) motif and the WEF motif), are coloured red. Two
STRADα export signal sequences (residues 21–29 and 417–426) are coloured blue (Dorfman
and Macara, 2008).
1 Introduction 39
fragment is predicted to lack part of the N-lobe of the kinase domain
(Fig.1.12B) and may be unstable.
At present, the function of the different splice isoforms of STRADα/β
are unclear. One study found that some STRADα isoforms (9 reported
in total) affected LKB1 localisation and stimulated LKB1 activity at
different levels (Marignani et al., 2007). However, it is dificult to
study these further, since only 4 sequences have been deposited and
are publicly available (Fig.1.12A). It is possible that the different N-
and C-termini contribute to changes in the localisation patterns of
LKB1, given that two export signal sequences (STRADα residues 21-
29 and 417-426) have been recently identified in these regions (Fig.
1.12) (Dorfman and Macara, 2008).
Interestingly, STRADα3 and STRADβ2 lack the WEF motif, previ-
ously shown to be required for MO25α binding (Boudeau et al., 2003a;
Milburn et al., 2004; Boudeau et al., 2004). LKB1 activity should re-
main unaffected in the presence of these isoforms, since deletion of the
WEF motif from STRADα1 does not alter LKB1 activity (Boudeau
et al., 2003a, 2004). The majority of studies thus far (including the
ones presented in this thesis) have been carried out using STRADα1
and STRADβ1. These are referred to here as simply STRADα and
STRADβ unless specified otherwise.
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1.5.3 Deletion of the STRADA/LYK5 gene causes PMSE syndrome
Recently, it was reported that a severe human developmental and
epileptic syndrome termed Polyhydramnios-Megalencephaly- Symp-
tomatic Epilepsy (PMSE), was caused by a homozygous partial dele-
tion in the STRADα gene (LYK5), truncating 180 C-terminal residues
of the protein (Puffenberger et al., 2007). Individuals affected by this
condition suffer from severe mental retardation, gross movement disor-
ders and childhood mortality (Puffenberger et al., 2007). Histological
staining of neuronal tissues of PMSE patients has suggested elevated
mTOR pathway activity (Puffenberger et al., 2007) that could poten-
tially result from loss of LKB1 kinase activity (see section 1.5.9). The
exact molecular mechanisms of how this mutation affects STRADα
structure/function or its ability to activate LKB1 has not been stud-
ied.
1.5.4 MO25—a multifunctional protein that is evolutionary conserved
H. sapiens (MO25)
D. rerio (MO25; 69%)
D. melanogaster (dMO25; 69%)
C. elegans (cMO25; 58%)
S. cerevisiae (HYM1; 29%)
C. albicans (HYM1; 42%)
S. pombe (pMO25; 50%)
Figure 1.13: Conservation of MO25.
Names and the percentage identity
to the human sequence are given in
brackets.
MO25α and MO25β are two highly
similar proteins that share 79% se-
quence identity (88% sequence simi-
larity). MO25α was first identified as
a gene expressed at the early cleav-
1 Introduction 41
age stage of mouse embryogenesis and
predicted, incorrectly, to bind Ca2+ ions (Miyamoto et al., 1993). In
the late 1990s it was noticed as a protein with unusually high degree
of evolutionary conservation (Karos and Fischer, 1996; Nozaki et al.,
1996; Karos and Fischer, 1999). Sequences of the D. rerio (MO25),
D. melanogaster (dMO25), C. elegans (cMO25), S. pombe (pMO25),
C. albicans (HYMA) and S. cerevisiae (HYM1) genes are 69%, 69%,
58%, 50%, 42% and 29% identical to human MO25α respectively (Fig.
1.13). In 1996, Karos and Fischer reported a mutant filamentous fungi
(Aspergillus nidulans) where conidiospore development was affected
at the metula stage. The gene responsible was sequenced and named
HymA (hypha-like metulae) to describe the hypha-like phenotype of
these undifferentiated metulae (Karos and Fischer, 1996). In follow up
studies, the same authors demonstrated that the S. cerevisiae Hym1
is an essential gene suggesting it carried out important functions that
were evolutionary conserved (Karos and Fischer, 1999).
Recent studies have described interesting genetic interactions of MO25
with other kinases—intriguingly, like STRADα/β, these belong to the
STE group of kinases (Fig. 1.2). One of these is the germinal cen-
tre (GC) kinase Fray, that together with dMO25 regulate Drosophila
asymmetric division (Yamamoto et al., 2008). The human Fray orth-
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logue is the oxidative stress response (OSR1) kinase, one of the closest
kinases to STRADα/β (Fig. 1.2). In fission yeast pMO25 is part of
a signalling network (NAK1-Orb6-Mob2p), important for cell mor-
phogenesis, polarity control and cell separation (Kanai et al., 2005).
pMO25 has been shown to form a complex with NAK1, homologue of
MST1-4 and YSK kinases in humans, and this interaction is impor-
tant for NAK1 localisation and activity (Kanai et al., 2005). Together
pMO25 and NAK1 are important for the kinase activity of Orb6p,
a kinase homologous to Warts/Lats (Drosophila) and NDR human
(AGC group) kinases (Kanai et al., 2005).
Similar genetic interactions have been demonstrated in S. cerevisiae,
between Hym1 and Cbk1 that is similar to the Warts/Lats/NDR ki-
nases (Bidlingmaier et al., 2001). In budding yeast this constitutes a
large signalling network, designated Regulation of Ace2p activity and
cellular Morphogenesis (RAM), and includes Hym1, Cbk1, Kic1, Tao3,
Mob2 and Sog2 (Jorgensen et al., 2002; Nelson et al., 2003). Interest-
ingly, Kic1 is related to the STE20 kinases and may well represent an
active STRADα orthologue in yeast.
Recently, ten Kloster and collegues have demonstrated through a
yeast two hybrid screen that MO25α interacts with human MST4, and
together MO25 and LKB1 are responsible for localisation of MST4
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to the apical membrane (ten Klooster et al., 2009). This leads to
MST4 phosphorylation of Ezrin and cellular brush border formation
(ten Klooster et al., 2009). However, given the multitude of MO25
interactions with other kinases in lower organisms, it is possible that
MO25 regulates these kinases independently of LKB1. Future studies
in higher eukaryotes may indeed establish additional roles for MO25
in activating/regulating kinases other than LKB1.
N-terminus N-terminus
C-terminusC-terminusWEF
motif WEF
motif
A B
Concave Concave
Convex ConvexR240
R240
Figure 1.14: Structure of MO25α—an α-helical repeat protein
A) Ribbon diagram of the MO25 structure determined by Milburn et al., 2004. STRADα
C-terminal WEF motif (residues 428-431) are shown as sticks with green carbons.
B) Surface representations of the MO25 structure coloured by sequence conservation (dark
blue = invariant, white = non conserved) from C. elegans to H. sapiens.
1.5.5 Structure of MO25α—an α-helical repeat protein
The discovery that MO25α/β isoforms form complexes with STRADα/β
and LKB1 and required for the activation of the later (Baas et al.,
2003; Boudeau et al., 2003a), provided more functional insights and
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suggested a scaffolding role for MO25. The crystal structure of MO25α
(Milburn et al., 2004) revealed an α-helical repeat protein (Fig. 1.14A),
that at a superficial topological level resembles other scaffolding pro-
teins such as Pum1, β-catenin and importin-α (Graham et al., 2000;
Conti and Kuriyan, 2000; Wang et al., 2001). A common structural
feature for this class of scaffolding proteins (not related by sequence),
is their distinctive horse-shoe shape with a concave and convex side
(Fig. 1.14). Interestingly, these proteins bind their macromolecular
partners through their concave surface (Graham et al., 2000; Conti
and Kuriyan, 2000; Wang et al., 2001). Milburn et al., were able to
crystallise MO25 in the presence of a C-terminal peptide of STRADα
previously known to interact with MO25 (Baas et al., 2003), and
showed the last three residues (termed the WEF motif) bind to a
conserved, hydrophobic pocket present in the MO25 convex surface
(Fig. 1.14) (Milburn et al., 2004). Therefore, the structure suggested,
the unoccupied and highly conserved concave surface of MO25 (Fig.
1.14B) could harbour binding sites for STRAD and LKB1 (Milburn
et al., 2004). Further structural and biochemical analysis identified a
residue present in the concave surface of MO25α (Arg240; Fig. 1.14),
that could be involved in interacting with LKB1 (Boudeau et al., 2004;
Milburn et al., 2004).
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1.5.6 LKB1 regulation by post-translational modification
Most protein kinases are phosphorylated in their activation loop, lead-
ing to their activation. Alessi and collegues identified Thr212 present
in the LKB1 activation loop, as a putative target for transfer of the
activatory phosphate (Boudeau et al., 2004). Interestingly, no phos-
phorylation of Thr212 could be detected and mutation of this residue
to an unphosphorylatable residue (alanine) and phospho-mimicking
(glutamine) residue had little/no effect to LKB1 activity (Boudeau
et al., 2004). Thus, these results supported the notion that LKB1 is
activated allosterically by binding to STRAD and MO25 rather than
phosphorylation of the activation loop. The molecular mechanisms by
which this is achieved has not been described thus far and is one of
the main subject of this thesis.
LKB1 can auto-phosphorylate on residues Ser185, Thr336 and Ser402
(Sapkota et al., 2002a; Alessi et al., 2006) and is phosphorylated by
other kinases at residues Ser31, Ser307, Ser325, Thr363 and Ser428
(Sapkota et al., 2001, 2002b; Alessi et al., 2006; Xie et al., 2009) (Fig.
1.15). In addition, LKB1 contains a prenylation site, Cys431, that was
shown to be modified by a farnesyl group (Collins et al., 2000; Sapkota
et al., 2001) (Fig. 1.15). Individual mutations of these sites either to
alanine or aspartate/glutamate residues (to mimic phosphorylation of
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Figure 1.15: LKB1 complex domain architecture and post-translational modifications
Domain architecture of the components of the LKB1 complex. Post translational modifications
of LKB1 and STRADα are shown (references are provided in section 1.5.6). NRD = N-terminal
regulatory region, CRD = C-terminal regulatory region, NLS = Nuclear localisation signal, NES
= Nuclear export signal.
Ser/Thr residues respectively) do not significantly affect LKB1 activ-
ity. Some phosphorylation sites however, have been shown to respond
to specific cellular stresses such as phosphorylation by ATM of Thr363
in response to DNA damage (Sapkota et al., 2002b).
Recently, Zheng et al., and Esteve-Puig et al., reported that ERK
MAP kinase could phosphorylate Ser325 (Zheng et al., 2009; Esteve-
Puig et al., 2009). The authors show that in melanoma cells expressing
oncogenic (V600E) B-Raf, phosphorylation of Ser325 (by ERK) and
Ser428 (by p90RSK) resulted in lower activation of AMPK (Zheng
et al., 2009; Esteve-Puig et al., 2009). These findings could be the
beginning of an interesting avenue of LKB1 signalling—the ultimate
aim being explaining how cancer cells continue to grow in energy-
deprived conditions that could lead to new cancer treatment therapies
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(Martin et al., 2009b).
1.5.7 LKB1 activates the AMP-activated protein kinase
Activation of AMPK requires phosphorylation of Thr172 within the
activation segment of the catalytic subunit (Hawley et al., 1996). The
identification of the long sought-after upstream kinase that phospho-
rylates and activates AMPK, came about from elegant work in yeast
genetics. In yeast, there are three protein kinases Elm1, Pak1/Sak1,
and Tos3 that phosphorylate and activate the yeast AMPK homo-
logue (SNF1) (Hong et al., 2003; Sutherland et al., 2003). It was
quickly realised that members of the Ca2+/calmodulin-dependent pro-
tein kinase kinase (CaMKK) family and LKB1 kinases could be mam-
malian orthologues to these yeast kinases (Hong et al., 2003; Suther-
land et al., 2003). Before the discovery of STRAD and MO25 as acti-
vatory components of the LKB1 complex (Baas et al., 2003; Boudeau
et al., 2003a), no appreciable phosphorylation and activation of AMPK
by LKB1 was detected due to poor LKB1 activity (Dr G. Sapkota
and Dr S. Hawley, unpublished results). Soon after the discovery of
the LKB1/STRAD/MO25 complex, AMPK was identified as the first
physiological substrate of LKB1 (Hawley et al., 2003; Woods et al.,
2003; Shaw et al., 2004). More importantly, LKB1 could phospho-
rylate the activatory threonine residue (Thr172) present in AMPK
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activation loop (Hawley et al., 2003; Woods et al., 2003; Shaw et al.,
2004), phosphorylation of which is also observed at low levels of cellu-
lar energy, that is accompanied by activation of AMPK (Hawley et al.,
1996). These findings were subsequently confirmed in animal studies,
whereby in LKB1 conditional mouse knockouts in muscle (Sakamoto
et al., 2005) and liver tissues (Shaw et al., 2005), the activity of AMPK
was severely reduced, thus demonstrating that LKB1 was the major
upstream kinase of AMPK in vivo in these tissues (Sakamoto et al.,
2005; Shaw et al., 2005).
Two other protein kinases, CaMKKβ (Hawley et al., 2005; Woods
et al., 2005) and the transforming growth factor-β-activated kinase
(TAK1) (Momcilovic et al., 2006; Xie et al., 2006) have been reported
as upstream kinases for AMPK activation. While there is compelling
evidence for CaMKKβ as an alternative AMPK activating kinase to
LKB1, mainly in response to elevated Ca2+ levels, the implication
of TAK1 requires further investigation. Interestingly, LKB1 rather
than CaMKKβ is thought to be the upstream kinase for AMPK in
conditions of energy stress. Because LKB1 is believed to be constitu-
tively active, other means of regulation involving dephosphorylation
of Thr172 by protein phosphatase 2C (PP2C) (Sanders et al., 2007)
and regulation via glycogen binding to the AMPKβ subunit (McBride
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et al., 2009) have been described for AMPK.
1.5.8 LKB1 is a master kinase
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Figure 1.16: LKB1 activates the AMPK family of
kinases by phosphorylating their activation loop
Closer examination of the
kinome tree, reveals the
AMPKα1/2 isoforms are clus-
tered with other related
protein kinases within the
CAMK group (Fig. 1.2),
suggesting these too may be
LKB1 substrates. Subse-
quent work carried out in the
Alessi group, showed that
the LKB1 complex efficiently phosphorylated 12 of these AMPK-
related kinases (Lizcano et al., 2004; Jaleel et al., 2005) (Fig. 1.16),
named: BRSK1/2 (brain specific kinase 1/2) isoforms, MARK1-4 (mi-
crotubule affinity regulating kinase) isoforms, NUAK1 also referred
to as ARK5 (AMPK-related kinase 5), NUAK2, also referred to as
SNARK (sucrose-non-fermenting AMP-activated protein kinase re-
lated protein kinase), QIK (qin induced kinase), QSK, SIK (salt in-
ducible kinase), SNRK (sucrose non-fermenting related kinase). These
findings are suggestive of LKB1 having the role of a master kinase ca-
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pable of activating many members of the AMPK-related protein kinase
family. Thus, LKB1 can influence a variety of cellular processes (Fig.
1.16) and some of these functions are presented below. For recent re-
views the reader is directed to articles by Shackelford and Shaw, 2009
and Jansen et al., 2009.
1.5.9 The LKB1-AMPK axis in regulating cellular energy
The name AMP-activated protein kinase (AMPK) was adopted in
1989 after it was discovered by Grahame Hardie and colleagues as the
(same) kinase that phosphorylated acetyl-CoA Carboxylase (ACC)
(Munday et al., 1988) and HMG reductase (HMGR) (Carling et al.,
1989), both rate limiting enzymes in the fatty acid and cholesterol
synthesis respectively. This shed light on earlier reports that the ACC
and HMGR phosphorylation events respond to changes in the levels
of adenylate nucleotides, first reported by Yeh et al., 1980.
Kinase domain AIS β-SID10 278 550 395 α1 
GBD αβ-SBS 270 184 157 75 β1 
CBS1 CBS2 CBS4 CBS3 
Bateman 1 Bateman 2 
331 γ1 
P
Figure 1.17: AMPK complex domain architecture
Domain architecture of the components of the AMPK complex (α1/β1/γ1). Phosphorylation
of residue Thr172 by upstream kinases on the α1 subunit is indicated. AIS = Autoinhibitory
sequence (residues 312-335), β-SID = β subunit interacting domain, GBD = glycogen binding
domain, α/β-SBS = α/β subunit binding sequence, CBS = Cystathione-β-Synthase motifs.
AMPK is a holoenzyme composed of three subunits—a catalytic α
(protein kinase) subunit, a β subunit that contains a glycogen binding
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domain (GBD) and a third γ subunit, that contains four cystathione-
β-synthase (CBS) domains responsible for binding ATP/AMP (Fig.
1.17). Although the domain architecture (Fig. 1.17) is similar across
eukaryotes, multiple subunit isoforms with different patterns of tis-
sue distributions exist (reviewed by Hardie, 2007 and Stienberg and
Kemp, 2009). Recently, studies by Xiao and collegues (Xiao et al.,
2007), Amodeo et al., (Amodeo et al., 2007) and Townley and Shapiro
(Townley and Shapiro, 2007), have provided valuable information of
how the heterotrimeric α/β/γ subunits of human, and yeast AMPK
core complexes assemble. In addition, crystal structures in complex
with AMP and ATP nucleotides have described the molecular basis of
AMPK regulation by adenylate nucleotides (Xiao et al., 2007; Amodeo
et al., 2007; Townley and Shapiro, 2007). In particular, the AMPK
core structure reported by Xiao et al., 2007, in complex with both
ATP and AMP revealed that two of the CBS motifs of the γ sub-
unit were able to bind ATP under normal physiological conditions—
these could be exchanged with AMP, whereas one of the CBS domains
contained an nonexchangeable AMP binding site (Xiao et al., 2007).
More recently, the crystal structure of the S. pombe kinase domain to-
gether with the autoinhibitory sequence (AIS, Fig. 1.17) C-terminal
to AMPK was reported by Chen et al., 2009. The AIS (residues 312-
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335) binds to both N- and C-lobes of the kinase domain and possibly
by constraining the movement of helix αC contributes to an overall
inactive conformation Chen et al. (2009).
At present, almost weekly scientific reports continue to implicate
AMPK in a variety of functions. To date, there is compelling evidence
that AMPK is involved in controlling cellular and tissue metabolism,
regulation of glucose uptake, transcription, cell growth and prolifera-
tion and recently the establishment and maintenance of cell polarity
(Fig. 1.18; reviewed by (Hardie, 2007b; Steinberg and Kemp, 2009;
Shackelford and Shaw, 2009)). In addition, AMPK plays important
physiological roles at the whole body level by integrating stress re-
sponses such as exercise, nutrient and hormonal signals to control food
intake and energy expenditure (reviewed by (Hardie and Sakamoto,
2006; Steinberg and Kemp, 2009). Unsurprisingly, AMPK is a key
emerging drug target for the treatment of diabetes and other metabolic
syndromes (for recent reviews see (Hardie, 2007a) and (Zhang et al.,
2009)). Ultimately, the end result of AMPK activation by LKB1 is
to switch on catabolic pathways that generate ATP, while switching
off biosynthetic pathways and other processes that consume ATP, in
response to cellular energy stress (Fig. 1.18). This energy switch is in
response to ATP consuming metabolic reactions producing ADP that
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is converted to AMP by the enzyme adenylate kinase, contributing
to a higher AMP:ATP ratio. It is the AMP:ATP ratio that serves as
the main sensor mechanism detected by AMPK regulating the cellular
and whole tissue metabolism (Fig. 1.18).
A prominent role of LKB1 is the inhibition of the mammalian tar-
get of rapamycin (mTor) kinase via AMPK, leading to inhibition of
protein synthesis (Fig. 1.18). Thus, the LKB1-AMPK axis ensures
that cell growth and proliferation is coupled to the availability of cel-
lular energy by feeding regulatory input to the mTor kinase. This is
done by directly phosphorylating raptor (component of mTor complex
2) (Gwinn et al., 2008), as well as inactivating the tuberous sclerosis
complex (TSC) that lies upstream of the mTor pathway (reviewed by
(Alessi et al., 2006; Shaw, 2009)).
1.5.10 The role of LKB1 in polarity
Another key role of LKB1 is to control cell polarity (Hezel et al.,
2008; Martin and St Johnston, 2003; Baas et al., 2004a), which may
be mediated by AMPK (Zheng and Cantley, 2007) as well as some of
the AMPK related kinases (Fig. 1.18). The MARK1-4 kinases that
are activated by LKB1 (Lizcano et al., 2004), are perhaps the most
studied of the AMPK-related kinases (Baas et al., 2004b). Important
physiological roles for these kinases were first demonstrated in orthol-
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Figure 1.18: LKB1 dependent signalling pathways
LKB1 is re-localised to the cytoplasm by STRAD and MO25. The LKB1 complex phospho-
rylates and activates AMPK in response to raises in the AMP:ATP ratio. AMPK controls
a series of metabolic reactions, (green arrow = target activation, red blunt-headed arrow =
target inactivation). A brief description of the effect in the respective metabolic reactions is
noted. LKB1 can also phosphorylate and activate the AMPK related kinases (BRSK1/2 and
MARK1-4) that control cell polarity. MO25 interacts with MST4 and in an LKB1 depen-
dent manner can regulate Ezrin phosphorylation and brush border formation. An interaction
between STRAD and E-catherin has been established and thought to control AMPK phos-
phorylation in adherens junctions. Other kinases that phosphorylate LKB1 and AMPK are
indicated. The figure was adapted and redrawn from Alessi et al., 2006, Hardie, 2007b and
Shackelford and Shaw, 2009. References are provided in their respective sections.
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ogous genes from yeast, worms and flies. The MARK orthologues of
C. elegans and D. melanogaster are members of the partition-defective
kinase family and are called Par-1. The nematode Par-1 orthologue
controls the partitioning of the C. elegans zygote (Kemphues et al.,
1988), whereas the D. melanogaster Par-1 regulates cell polarity (Shul-
man et al., 2000; Martin and St Johnston, 2003). In higher eukaryotes,
the MARK2 isoform is reportedly important for maintaining polarity
in neuronal (Biernat et al., 2002) and epithelial cells (Mandelkow et al.,
2004), as well as the organisation of the microtubule network (Cohen
et al., 2004).
More recently, a role for the BRSK1/2 (SAD-B/A) in neuronal cell
polarity has been described (Barnes et al., 2007; Shelly et al., 2007).
According to these reports, BRSK1/2 control neuronal polarisation
and axon guidance via a pathway that is dependent on LKB1 Ser428
phosphorylation by PKA (Barnes et al., 2007; Shelly et al., 2007). It
is important to note that this is unlikely to depend on LKB1 direct
activation of the BRSK isoforms, since LKB1 Ser428 phosphorylation
does not alter LKB1 kinase activity (Fogarty and Hardie, 2009). It is
possible the phosphorylation of this site alters the sub-cellular locali-
sation and/or association of LKB1 with other regulatory components.
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1.6 Project aims
At the start of this project (September 2005), little was known of how
the tumour suppressor kinase LKB1, interacted with its regulatory
partners, STRAD and MO25. Neither was the mechanism of LKB1
activation clear—LKB1 unlike other kinases requires no phosphory-
lation. Thus, the central aim of this work was to express, purify,
crystallise and solve the structure of the LKB1/STRAD/MO25 het-
erotrimeric complex.
Through a structural and biochemical approach, the results of which
are covered by Chapters III, IV and V of this thesis, I have sought to
answer the following questions:
 How do STRAD/MO25 bind LKB1?
 What is the mechanism by which a pseudokinase (STRAD) acti-
vates a kinase (LKB1)?
 What is the mechanism by which the scaffolding protein MO25
activates LKB1?
 How do oncogenic mutations affect LKB1 activity, and/or com-
plex formation?
 Why/how did pseudokinases evolve?
Chapter II
Materials and Methods
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2 Materials and methods
2.1 Reagents
Listed are standard chemicals and enzymes used for protein cloning,
expression, purification, analysis, crystallisation and enzyme activity
measurments.
2.1.1 Cloning
Solid agarose was purchased from BDH (VWR, UK), TAE-buffer was
kindly prepared by the media kitchen (University of Dundee). HiFi
Taq polymerase was purchased from Roche Diagnostics (Lewes, UK).
DNA 1kb ladder was supplied from Promega. QIAGEN Mini-Prep
Plasmid and Gel-extraction kits were obtained from Qiagen Ltd. (Craw-
ley, UK).
2.1.2 Gene expression, protein production and purification
Bovine serum albumin (BSA), DNase I, bicine, trizma base, N-(2-
hydroxyethyl)-piperazine-N’-2-ethane-sulfonic acid (HEPES), sodium
chloride (NaCl), sucrose and glycerol were purchased from Sigma-
Aldrich Co. Ltd. (Dorset, UK). Complete protease inhibitors cocktail
tablets were purchased from Roche Molecular Biochemicals (Lewes,
UK) or alternatively a protease inhibitor mix was kindly made by
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Helge Dorfmu¨ller (section 2.3.2) and contained benzamidine, phenyl-
methanesulfonyl fluoride (PMSF) (Sigma) and Leupeptin (Peptide In-
stitute Inc.). Ethylenediamine-tetraacetic acid (EDTA), ethyleneglycol-
tetraacetic acid (EGTA) and hydrochloric acid (HCl) were purchased
from BDH Chemicals Ltd. Dioxin-free Isopropyl thio-β-D-galactoside
(IPTG), dithiothreitol (DTT) and 2-mercaptoethanol were obtained
fromMelford Laboratories (Ipswich, UK). Tris(2-carboxyethyl)phosphine
hydrochloride (TCEP) was from Calbiochem-Merck Chemicals Ltd,
(Nottingham, UK). Bradford reagent was from Pierce (Chester, UK).
Glutathione sepharose 4B (GSH sepharose) was from GE Healthcare
(Buckinghamshire, UK) and Ni-NTA agarose was from Qiagen Ltd.
(Crawley, UK). PreScission and Tobacco Etch Virus (TEV) proteases
were kindly produced as recombinant proteins with an N-terminal
GST and 6-His tag respectively by Sharon Shepherd (University of
Dundee).
2.1.3 Protein analysis
40% (w/v) 29 : 1 acrylamide was from Flowgen Bioscience (Not-
tingham, UK). N,N,N’,N’-tetramethylethylenediamine (TEMED), β-
mercaptoethanol (BME) and sodium dodecyl sulphate (SDS) were
bought from BDH (Poole, UK). Ammonium persulphate (APS) was
from Sigma-Aldrich (UK). NuPAGE sample reducing agent and Nu-
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PAGE LDS sample buffer (5×) were purchased from Invitrogen or
made up as 6× concentrated stocks (section 2.3.6). PageRuler un-
stained protein ladder was from Fermentas (Paisley, UK). Precision
protein standards (pre-stained, broad range) were purchased from Bio-
Rad (Herts, UK). SuperSignal(R)West Pico Chemiluminescent Sub-
strate (ECL) was from Thermo Fisher and X-ray (medical) film from
Konika/Minolta.
2.1.4 Protein crystallisation
Crystallistion screens Crystal Screen I & II, Index, MembFac and Peg
Ion were purhcased from Hampton Research (California, USA), Wiz-
ard I & II were from Emerald BioSystems (Washington, USA), Protein
Complex was from Sigma-Aldrich Co. Ltd. (Dorset, UK) and ProPlex
was from Molecular Dimensions Ltd. (Suffolk, UK).
2.1.5 Phosphonucleotide binding assays
Adenosine-5’-triphosphate (ATP) and adenosine-5’-diphosphate (ADP)
were bought from Melford Laboratories (Ipswich, UK), and 2’,3’-O-
(2,4,6-trinitrophenyl) adenosine 5’-triphosphate (TNP-ATP) was from
Invitrogen Ltd. (Paisley, UK).
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2.1.6 Protein lysine methylation
Dimethylamine-borane complex (DMB; Fluka product 15584) and a
formaldehyde solution (37% stock; Fluka product 33220) were pur-
chased from Sigma-Aldrich (Dorset, UK).
2.2 Equipment
Two in-house diffractometers were used throughout this thesis to test
crystals. These were Rigaku Micromax 007 rotating anode generator
equipped with an R-AXIS IV++ image plate detector and a Rigaku
XStream nitrogen cryostream. 24-well hanging drop VDX Plates and
18 mm siliconised circle cover slips, goniometer heads, additional X-ray
equipment and tools were from Hampton Research (CA, USA). Sit-
ting drop MRC 96 well plates and Crystal Clear sealing tape were from
Jena Bioscience GmbH (Germany). The A¨KTA purifier/A¨KTA prime
purification systems and size exclusion chromatography columns were
from GE Healthcare (Buckinghamshire, UK). Centrifuge tubes, rotors
and centrifuges were from Beckmann (California, USA). Fluorescence
measurements of the ATP analogue 2’,3’-O-2,4,6-trinitrophenyl-ATP
(TNP-ATP) were carried out with a Varian Cary Eclipse fluorescence
spectrophotometer equipped with a thermostatic cuvette holder equili-
brated at 25 ◦C (Varian Inc. California, USA). Disposable (Kartell, 4-
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sided) cuvettes were ordered from VWR (Jencons, West Sussex, UK).
20 ml and 2 ml spin concentrators with a 10000 molecular weight
(MW) cut-off were bought from Viva Science (Hannover, Germany).
Disposable 10 ml and 25 ml EconoPac Chromatography Columns were
from BioRad (Herts, UK) and disposable desalting columns (prod-
uct nr. 17-0851-01) were from GE Healthcare. Syringe filter units
(GF-prefilter, 0.2 and 0.45 µm pore size) and buffer filtration devices
were from Sartorius (Goettingen, Germany). Slide-A-Lyzer dialysis
cassettes and Snake Skin dialysis tubing (MW cut-off 10000-50000
Da) were purchased from Pierce (Chester, UK). Transfer for western
blotting was performed in a wet-system using the X-Cell SureLock
MiniCell electrophoresis system and X-Cell II Blot Module were from
Invitrogen (Groningen, The Netherlands). X-ray films were developed
using an automatic film processor Konica Corporation (Japan). Cell
culture dishes (10 cm radius), six well plates and cell scrapers were
from Costar (Cambridge, MA, U.S.A.). SPR measurements were car-
ried out using a BIAcore T100 instrument (GE Healthcare, Bucking-
hamshire, UK).
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2.3 General solutions and buffers
2.3.1 Bacterial media
Luria Bertani broth (LB) media and LB-plates were kindly supplied by
the media kitchen (University of Dundee). The media contain 10.0 g
bacto-tryptone, 5.0 g bacto-yeast extract, 10.0 g NaCl, 950 ml ddH2O
and were adjusted to pH 7.0 with NaOH. The media was adjusted
to 1 l using ddH2O after autoclaving for 20 minutes at 2 bar. For
media containing the antibiotic Ampicillin (Amp) a stock was added
to a final concentration of 50 µg/ml (LB + Amp). LB + Amp-plates
contained 100 µg/ml Amp (LB + 2× Amp) and an additional 15 g/l
bacto-agar.
2.3.2 Protease inhibitor mix
A 20 mM stock of PMSF was dissolved in MeOH. Benzamidine (200
mM) and leupeptin (1 mM) were dissolved in ddH2O. The following
protocol is for making 50 ml of 100× concentrated stocks divided in
100 aliquots. Stock solutions were mixed in a 50 ml Falcon tube as
follows: 1 ml of PMSF, 10 ml benzamidine, 238 µl leupeptin plus 13.4
ml of MeOH. 250 µl of water were pipetted into an Eppendorf tube, to
which 250 µl of protease inhibitors were added, thus giving a protease
inhibitor with final concentrations: 0.1 muM PMSF, 5 mu leupeptin
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and 1 mM benzamidine. The aliquots were snap frozen in liquid N2
and frozen until further use at -80 oC.
2.3.3 Agarose gel electrophoresis buffer and DNA sample buffer
TAE (Tris-acetate-EDTA) buffer was supplied as 10× concentrated
stock by the media kitchen (University of Dundee) and contained the
following chemicals dissolved in 1 l of ddH2O water: 48.4 g tris base,
11.4 ml of glacial acetic acid, 100 ml of 0.1 M EDTA (pH 8.0). To
obtain 10 ml of 6× concentrated DNA sample buffer, 25 g bromophe-
nol blue, 25 g of xylene cyanol FF and 4 g glycerol were dissolved in
ddH2O.
2.3.4 SDS-PAGE stock solutions
SDS-polyacrylamide fels for electrophoresis were made using the fol-
lowing stock solutions: 1.5 M Tris-HCl (pH 8.6), 2 M Tris-HCl (pH
6.8), 10% (w/v) SDS and 40% acrylamide solution containing bis-
acrylamide at 29:1 from Flowgen Bioscience and TEMED. A 10%
(w/v) APS solution was made fresh from solid APS on the day of
usage.
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2.3.5 Electrophoresis buffer
A 10× stock solution of tris-glycine SDS-polyacrylamide gel running
buffer was made by dissolving 30.3 g of tris-base, 144 g glycine and 10
g of SDS in a total volume of 1 l ddH20.
2.3.6 SDS sample buffer
SDS sample buffer (5× concentrated) contained 250 mM Tris-HCl pH
6.8, 10% (w/v) SDS, 50% (v/v) glycerol, 0.025% (w/v) bromophenol
blue, and 5% (v/v) 2-mercaptoethanol.
2.3.7 SDS-PAGE visualisation buffer
Proteins analysed by SDS-PAGE were stained using a Coomassie stain-
ing solution prepared by dissolving 2.5 g of Coomassie blue in 400 ml of
ddH2O, 100 ml of glacial acetic acid and 500 ml of MeOH and mixed
by stirring overnight. For destaining an identical solution without
Coomassie blue dye was used.
2.3.8 Transfer and wash buffer for western blotting
Tris-glycine transfer buffer (containing 20% methanol) was used to
transfer the proteins from SDS-PAGE gels onto a nitrocellulose mem-
brane. A 25× stock was made of 18.2 g tris and 90 g of glycine
dissolved in 500 ml of ddH20. Stripping buffer (1 liter) was prepared
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using 15 g glycine, 1 g SDS and 10 ml Tween-20 (final concentration
1.0%) and was adjusted using concentrated HCl to pH 2.2. TBS-T
wash buffer buffer was Tris-HCl pH 7.5, 0.15 M NaCl, and 2.5% (v/v)
Tween-20.
Table 2.1: Solutions for pouring five separation gels.
Acrylamide concentration
Stock solution 6% 8% 10% 12% 15%
40% acrylamide 5.3 ml 7.0 ml 8.8 ml 10.5 ml 13.1ml
1.5 M Tris-HCl, pH 8.6 8.8 ml 8.8 ml 8.8 ml 8.8 ml 8.8 ml
ddH20 20.5 ml 18.8 ml 17.0 ml 15.3 ml 12.6 ml
10% SDS 350 µl 350 µl 350 µl 350 µl 350 µl
TEMED 31 µl 31 µl 31 µl 31 µl 31 µl
10% APS 118 µl 118 µl 118 µl 118 µl 118 µl
Total volume 35 ml 35 ml 35 ml 35 ml 35 ml
Table 2.2: Solutions for pouring five stacking gels.
Stock Solution Volume
40% acrylamide 1419 µl
2 M Tris-HCl, pH 6.8 930 µl
ddH20 12 ml
10% SDS 150 µl
TEMED 15 µl
10% APS 128 µl
Total volume 15 ml
2.4 Pouring of gels for SDS-PAGE
SDS-PAGE gels were manually poured in 10% and 12% acrylamide
concentrations as required. Glass plates were assembled with rubber
gaskets and clamps according to the manufacturer’s protocol. Gels
were poured in two steps: First the solution for the separation gels was
prepared according to Table 2.1. The reagents were mixed gently but
thoroughly and poured into glass plates without delay. This was then
2 Materials and methods 67
covered with a thin layer of isopropanol to obtain a smooth surface
and left to polymerise for 15 minutes at room temperature (RT). The
isopropanol was carefully removed and the surface of the separating
gel was washed with water. For the second step, ingredients of the
stacking gel (Table 2.2) were mixed together, and after gentle mixing
this was poured on the top of the separating gel. To obtain the wells
for sample loading a 12 well comb was immediately inserted and the
gels were left for a further 15 minutes to polymerise. Gels were stored
in SDS-running buffer (see section 2.3.5) at 4 oC.
2.5 Lysis and purification buffers
2.5.1 Buffers for GST affinity chromatography and further purification of
proteins produced in Escherichia coli (E. coli)
The following buffers were prepared (and kept at 4 oC) for the purif-
cation of wild type and mutant forms of GST tagged STRADα and
MO25α.
Buffer A (lysis buffer): 50 mM Tris-HCl pH 7.8, 150 mM NaCl, 270
mM Sucrose, 20 mM imidazole, 1 mM benzamidine, 1.0 mM EGTA,
1.0 mM EDTA, 0.1% (v/v) β-mercaptoethanol, supplemented with
0.1 mM PMSF, 0.5 mg/ml lysozyme and 0.3 mg/ml DNAse-I.
Buffer B (low salt purification buffer): 50 mM Tris-HCl pH 7.8,
150 mM NaCl, 270 mM Sucrose, 1 mM benzamidine, 1.0 mM EGTA,
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1.0 mM EDTA, 0.1% (v/v) β-mercaptoethanol.
Buffer C (high salt purification buffer): 50 mM Tris-HCl pH 7.8,
500 mM NaCl, 270 mM Sucrose, 1 mM benzamidine, 1.0 mM EGTA,
1.0 mM EDTA, 0.1% (v/v) β-mercaptoethanol
Buffer D (ion exchange buffer): 50 mM Tris-HCl pH 7.8, 270 mM
Sucrose, 1 mM benzamidine and filtered using a cellulose filter with a
0.2 µm pore size.
Buffer E (ion exchange buffer): 50 mM Tris-HCl pH 7.8, 500
mM NaCl, 270 mM Sucrose, 1 mM benzamidine and filtered using a
cellulose filter with a 0.2 µm pore size.
Buffer F (gel filtration buffer): 25 mM Tris-HCl pH 7.8, 150 mM
NaCl 1 mM DTT and filtered using a cellulose filter with a 0.2 µm
pore size.
2.5.2 Buffers for Ni2+ metal affinity chromatography and further purification
of proteins produced in E. coli
The following buffers were prepared (and kept at 4 oC) for the purifi-
cation of the STRADα/MO25α complex.
Buffer A (lysis buffer): 50 mM Tris-HCl (pH 7.8), 50 mM NaCl,
5% glycerol, 20 mM imidazole, 1 mM benzamidine, 0.2 mM EGTA,
0.2 mM EDTA 0.075% (v/v) β-mercaptoethanol, supplemented with
0.1 mM PMSF, 0.5 mg/ml lysozyme and 0.3 mg/ml DNAse-I.
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Buffer B (purification buffer): Buffer A without supplements.
Buffer C (crystallisation buffer): 25 mM Tris-HCl pH 7.8, 1 mM
DTT and filtered using a cellulose filter with a 0.2 µm pore size.
2.5.3 Buffers for Ni2+ metal affinity chromatography and further purification
of proteins produced in Spodoptera frugiperda 21 (Sf21) cells
The following buffers were prepared (and kept at 4 oC) for the purifi-
cation of the LKB1/STRADα/MO25α complex.
Buffer A (MBS cell wash buffer) 20 mM Mes/NaOH pH 6.3, 140
mM NaCl, 40 mM KCl.
Buffer B (lysis buffer) 50 mM Tris-HCl pH 7.8, 150 mM NaCl,
5% glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM benzamidine, 0.1
mM PMSF, 5 µM leupeptin, 20 mM imidazole and 0.075% (v/v) β-
mercaptoethanol.
Buffer C (low salt purification buffer) 50 mM Tris-HCl pH 7.8,
150 mM NaCl, 5% glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM
benzamidine, 20 mM imidazole and 0.075% (v/v) β-mercaptoethanol.
Buffer D (high salt purification buffer) 50 mM Tris-HCl pH 7.8,
500 mM NaCl, 5% glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM
benzamidine, 20 mM imidazole and 0.075% (v/v) β-mercaptoethanol.
Buffer E (loading buffer): 50 mM Tris-HCl pH 7.8, 5% glycerol,
0.2 mM EDTA, 0.2 mM EGTA, 1 mM benzamidine and 1 mM DTT.
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Buffer F (ion exchange buffer): 50 mM Tris-HCl pH 7.8, 5%
glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM benzamidine, 1 mM
DTT and filtered using a cellulose filter with a 0.2 µm pore size.
Buffer G (ion exchange buffer): 50 mM Tris-HCl pH 7.8, 500 mM
NaCl, 5% glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM benzamidine
and 1 mM DTT and filtered using a cellulose filter with a 0.2 µm pore
size.
Buffer H (gel filtration buffer): 25 mM Tris-HCl pH 7.8, 350 mM
NaCl, 2 mM TCEP and filtered using a cellulose filter with a 0.2 µm
pore size.
2.5.4 Buffers for GST affinity chromatography of proteins produced in
HEK293 cells
The following buffers were prepared (and kept at 4 oC) for the purifica-
tion of GST-LKB1/Flag-STRADα/Myc-MO25α and GST-STRADα/Myc-
MO25α complexes.
Buffer A (lysis buffer): 50 mM Tris-HCl pH 7.5, 1 mM EGTA,
1 mM EDTA, 1% (w/v) Nonidet P-40 (substitute), 1 mM sodium
orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate,
0.27 M sucrose, 1 mM DTT, 1 mM benzamidine and 0.1 mM PMSF.
Buffer B (wash buffer): 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1
mM EGTA/EDTA and 1mM DTT.
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2.6 General cell culture and DNA transformation
2.6.1 Culturing of Sf9 and Sf21 cells
Sf9 and Sf21 cells (Invitrogen) were cultured in Sf-900 II media supple-
mented with 1 mM L-glutamine and 100 µ/ml antibiotic/antimycotic
solution (Invitrogen). Stocks were grown in suspension using 2 l Erlen-
meyer flasks (VWR (Corning), UK) and their growth was monitored
every 36-48 h to ensure cultures did not exceed confluence levels of 6-7
× 106 cells/ml. When confluent, cells were diluted (on average every
3 days) in fresh media to a density of 1.5-2.0 × 106 cells/ml.
2.6.2 Bacterial strains
E. coli strains used in this thesis were DH5α (for cloning) and BL21(DE3)pLysS
(for recombinant protein expression). Stocks were obtained from No-
vagen Promega (Southampton, UK) and Novagen Promega (Darm-
stadt, Germany) respectively. DH10BacTM competent cells were used
for MultiBac virus recombination and obtained from Invitrogen Ltd.
(Paisley, UK).
2.6.3 Preparation of competent E. coli cells
To grow a new batch of chemically competent E. coli cells (DH5α or
BL21(DE3)pLysS), frozen commercial stocks were streaked onto an
LB plate and incubated overnight at 37 ◦C. A single colony from this
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plate was inoculated in 5 ml of LB media in a 50 ml Falcon tube
overnight in a 37 ◦C shaking incubator (220 rpm). This culture was
transferred into 200 ml of LB-medium and grown until OD600 = 0.6-
0.8 was reached. Cells were then harvested in a sterile and pre-cooled
centrifuge bottle and centrifuged at 3400 g for 15 min at 4 ◦C. The
supernatant was removed and the cells were washed 4 times in ice cold
and sterile filtered 0.1 M CaCl2. The cell pellet was re-suspended in
12 ml of sterile filtered 0.1 M CaCl2 and 7 ml of autoclaved glycerol.
The re-suspended cells were transferred in 250 µl aliquots into sterile
microfuge tubes, snap frozen in liquid nitrogen and stored at −80 ◦C.
2.6.4 DNA transformation into competent E. coli cells
This protocol was used for plasmid DNA transformation into compe-
tent E. coli strains DH5α and BL21(DE3)pLysS (see section 2.6.3).
Competent cells were thawed on ice and aliquoted (30-50 µl) into
sterile 1.5 ml Eppendorf tubes. To these, approximately 100-200 ng of
plasmid DNA (around 1 µl of typical miniprep plasmid DNA, general
concentration between 100-300 ng/µl) were added. Cells were incu-
bated on ice for a further 15 minutes prior to heat-shocking at 42 oC
for 60-90 seconds in a water bath. The cells were recovered on ice for
an additional 5 minutes and plated onto LB + Ampicillin agar plates
(see section ??). The plates were incubated upside down overnight at
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37 oC to allow for colony growth.f
For transformation of DH10BacTM cells, 20 µl of cells were trans-
ferred into sterile 1.5 ml Eppendorf tubes, mixed with 2 µl of miniprep
plasmid DNA as above and incubated on ice for 15 min. Cells were
then heat-shocked for 45 s at 42 oC and transferred briefly on ice. 1
ml of SOCII media was added and the cells were transferred to a 14
ml round-bottom (loose-cap) Falcon tube, and incubated for 4 h at
37 oC to allow recovery of cells. 50 µl of recovered cells and serial
dilutions with SOCII media (1:10, 1:100 and 1:250) were then plated
in LB-agar plates supplemented with 50 µg/ml kanamycin, 10 µg/ml
tetracycline, 7 µg/ml gentamycin, 40 µg/ml IPTG, and 200 µg/ml
X-gal. Plates were wrapped in tin foil and incubated at 37 oC for 48
h and a further 48 h at 4 oC to allow colour formation, thus aiding
blue/white colony selection (section 2.6.6).
2.6.5 Glycerol stocks of bacterial expression cells
A single colony of transformed BL21(DE3)pLysS expression bacte-
rial cells was inoculated into 5 ml of LB + Amp medium and grown
overnight at 220 rpm at 37 ◦C. Overnight cultures were stored as 50%
glycerol stocks at −80 ◦C.
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2.6.6 Isolation of recombinant bacmid DNA
LB media was supplemented with 50 µg/ml kanamycin, 10 µg/ml
tetracycline and 7 µg/ml gentamycin and transferred into 4 ml aliquots
to round-bottom (loose-cap) Falcon tubes. Using a sterile loop, three
(definite) white colonies were individually picked and transferred into
each of the LB aliquots. Overnight cultures were grown at 37 oC in
a shaking (220 rpm) incubator and centrifuged for 10 min at 3500 g.
Supernatants were gently discarded and the pellets resuspended in 250
µl of Qiagen (resolubilisation) Buffer P1 (15 mM Tris-HCl, pH 8.0, 10
mM EDTA, 100 µg/ml RNase A), transferred to sterile Eppendorf
tubes and 250 µl of Qiagen (lysis) Buffer P2 (0.2 M NaOH, 1% SDS)
was added. Tubes were gently inverted 5-6 times and left on ice for
4 min. At room temperature (RT), 350 µl of Qiagen (neutralisation)
Buffer P3 (3 M potassium acetate, pH 5.5) was added, the tubes were
inverted gently as above and centrifuged at 13000 rpm for 10 min at 20
oC. The supernatants were transferred to sterile Eppendorfs and 400
µl of (lower phase) phenol:chloroform was added. Tubes were inverted
gently for 2 min and centrifuged again at 13000 rpm for 3 min. The
upper phase supernatant (450–500 µl) was then transferred to sterile
Eppendorfs and the remaining material was disposed in an appropriate
phenol waste bottle. Finally 1 ml of absolute ethanol (HPLC grade)
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was added and the tubes were stored at -20 oC overnight.
On the second day, the precipitated DNA was pelleted by centrifu-
gation at 4 oC for 10 min at 13000 rpm. The supernatant was decanted
and the pellet was washed twice by adding 1 ml of 70% ethanol and
centrifugation for 2 min at 13000 rpm at 4 oC and removal of as much
as possible supernatant on the second step. The pellet was air-dryed
for 0.5–2 h at RT, resolubilised in 40 µl of sterile ddH2O and stored
at -20 oC.
2.7 Molecular cloning (completed by Dr Maria Deak)
2.7.1 General molecular biology and vectors
Dr Maria Deak performed the molecular cloning and mutagenesis for
all the constructs used in this thesis. The TOPO technology (Invitro-
gen) was used for general subcloning procedures and the QuikChange
method (Stratagene) was used for site directed mutagenesis. The se-
quences of all constructs were verified by the DNA sequencing ser-
vice (School of Life Science, University of Dundee). Bacterial expres-
sion monocistronic vectors used in this thesis were pGEX6 (Phar-
macia Amersham) with a PreScission cleavage site after the GST
affinity tag, pOPT (no affinity tag) and pOPTH (6-His affinity tag).
The pOPCH (6-His affinity tag) polycistronic vector (Tan, 2001) was
2 Materials and methods 76
used for co-expression of STRADα/MO25α, and together with the
pOPT series were kindly provided by Dr Roger Williams and Dr Olga
Perisic, University of Cambridge, UK. The pFBDM vectors used for
the MultiBac technology (Berger et al., 2004) and co-expression of
LKB1/STRADα/MO25α were kindly provided by Dr Imre Berger and
Prof Timothy J. Richmond, ETH Zu¨rich, Switzerland.
2.7.2 Cloning of STRADα
STRADα (residues 54-431) was cloned as a GST (N-terminally) fused
gene in a pGEX vector containing an engineered PreScission pro-
tease site between GST and STRADα. Alternatively, STRADα and
STRADα mutants (residues 58-431) were cloned in a pOPH (Tan,
2001) vector fused to an N-terminal 6-His tag followed by a TEV pro-
tease recognition site with sequence MAHHHHHHMENLYFQG.
2.7.3 Cloning of STRADα/MO25α
A bi-cistronic expression system was used to co-express and purify the
STRADα/MO25α complex in E. coli. The cloning procedure was fol-
lowed as described by Tan (2001). Both STRADα and MO25α genes
were subcloned as separate cassettes from the pOPT single vectors
into a pOPCH polycistronic vector. Full length MO25α (residues 1-
341) was subcloned from a pOPT (no tag) vector as an NdeI/BamH1
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insert. STRADα (residues 59-431) with an N-terminal 6-His tag fol-
lowed by a TEV protease site (sequence MAHHHHHHMENLYFQG)
was subcloned from a pOPTH vector as a BspE1/Mlu1 insert.
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Xho1Sph1 polh
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Figure 2.1: Strategy for cloning LKB1/STRADα/MO25α in a polycistronic vector
A) STRADα and MO25α were subcloned in separate multiple cloning sites (MCS) in a pF-
BDM vector (Berger et al., 2004) using the indicated restriction enzymes. The vector was
subsequently digested using BstZ171/Spe1 enzymes and “opening” the multiplication module
(M).
B) Similarly LKB1 was subcloned in separate vector and both MCS1 and MCS2 (containing
LKB1) were digested using Pme1/Avr2 enzymes.
C) The digested LKB1 insert was ligated in the already “opened” multiplication module of the
pFBDM vector from (A), thus generating a final vector containing all three genes with their
individual promoters and an empty MCS.
2.7.4 Cloning of LKB1/STRADα/MO25α
The cloning procedure as described previously by Berger et al. (2004)
was followed. MO25α (residues 1-341) and STRADα (residues 59-431)
clones were inserted into the multiple cloning site (MCS) 1 and MSC2
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of a pFBDMSTRADα/MO25α vector respectively, using EcoR1/Not1 (STRADα)
and Xho1/Sph1 (MO25α) restriction sites. LKB1 (residues 43-346)
preceded by an N-terminal 6-His tag and a TEV protease site (se-
quence MAHHHHHHENLYFQG) was inserted separately into MSC2
of a different pFBDMLKB1 vector using EcoRI/EcoRI sites. Both
MSC1 and MSC2 (containg the LKB1 insert) were then cut using
Pme1/Avr2 restriction enzymes and ligated into the BstZ171/Spe1
digested dual (STRADα/MO25α containing) pFBDMSTRADα/MO25α
vector, thus generating a hybrid pFBDM vector containing all three
genes. A diagram sumarising this section is provided in Fig. 2.1.
2.8 Production of recombinant proteins and purification
2.8.1 Expression conditions of GST-STRADα and GST-MO25α
Wild type and mutant forms of STRADα (residues 54-431) and MO25α
(residues 1-341) were expressed individually as GST fusion proteins in
E. coli. Cells were grown in LB medium (section 2.3.1) to A600 = 0.7
at 37 oC, and protein expression was induced by the addition of 250
µM IPTG and incubated for a further 16 h at 26 oC.
2.8.2 Cell lysis and purification of GST-STRADα and GST-MO25α
Cells were harvested by centrifugation for 30 min at 3500 g and re-
suspended in ice-cold Buffer A (section 2.5.1). Cells were lysed by
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sonication (10 × 10 s pulses) and lysates were clarified (by centrifu-
gation at 26000 g) and incubated for 1 h on a rotating platform with
glutathione-Sepharose (0.5 ml/l of culture), pre-equilibrated in Buffer
B (section 2.5.1). Beads were then washed with 10 column volumes
(CV) of Buffer B and a further 50 column volumes of high salt Buffer
C containing 500 mM NaCl (section 2.5.1). Beads were re-equilibrated
in 10 CV of Buffer B and the proteins were eluted by incubating with
PreScission protease for 16 h. For nucleotide binding (section 2.12)
and SPR experiments (section 2.13), protein eluates were dialysed for
16 h against 5 l of assay buffer containing 50 mM Tris-HCl pH 7.8,
50 mM NaCl, 270 mM sucrose and 1 mM DTT, concentrated to 7
mg/ml, divided into aliquots and stored at −80 oC. For crystallog-
raphy studies, STRADα preperations were further purified by anion
exchange and size exclusion chromatography. A 5 ml HiTrapQ column
was used for anion exchange and STRADα (diluted 1:3 with no salt
Buffer D, section 2.5.1), was allowed to bind to the column at a flow
rate of 5 ml/min and eluted using a salt gradient (0-500 mM NaCl,
adjusted with Buffer E, section 2.5.1) over 30 column volumes. The
STRADα peak was pooled, concentrated to 2-3 ml and loaded onto
a Superdex S75 26/60 gel filtration column (equilibrated in Buffer
F, section 2.5.1). The purity of the eluting peak from each purifi-
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cation step was analysed by SDS-PAGE and (prior to crystallisaton)
MALDI-TOF analysis. A gel showing a typical STRADα preparation
for crystallisation is provided in chapter III (Fig. 3.4).
2.8.3 Co-expression conditions of His-STRADα/MO25α
N-terminally 6-His-tagged STRADα was co-expressed with untagged
full length MO25α in E. coli BL21(DE3)pLysS cells. Cells were grown
in LB medium (section 2.3.1) to A600 = 0.7 at 37
oC, before protein
expression was induced by the addition of 250 µM IPTG and incubated
for a further 16 h at 26 oC.
2.8.4 Cell lysis and purification of His-STRADα/MO25α
Cells were harvested by centrifugation for 30 min at 3500 g and re-
suspended in ice cold lysis Buffer A (section 2.5.2. Cells were lysed
using a French Press cell disrupter (18000 psi) and the lysate was
cleared by centrifugation at 26000 g for 30 min. The supernatant was
then passed through a pre-filter and a 0.2 µm filter before loading
onto a 5 ml HiTrap IMAC HP column (GE Healthcare) previously
charged with Ni2+. The column was then washed with 10 volumes of
wash Buffer B (section 2.5.2), and the STRADα/MO25α complex was
eluted by applying a gradient of 20-300 mM imidazole in wash Buffer
B. The eluted sample was analysed by SDS-PAGE, concentrated to 3
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ml and loaded onto a Superdex 75 26/60 gel filtration column, pre-
equilibrated in crystallisation Buffer C (section 2.5.2). A Coomassie
stained gel from a typical His-STRADα/MO25α complex purification
is provided in Chapter 3 of this thesis (Fig. 3.2).
2.8.5 Isolation of His-tagged and untagged STRADα for SPR measurements
His-STRADα and untagged STRADα (residues 59-431) used for SPR
measurements in section 2.13, were first isolated in complex with
MO25α as described in sections 2.8.3 and 2.8.4. After gel filtration
in buffer containing 50 mM Tris-HCl pH 7.8, 50 mM NaCl, 270 mM
sucrose and 0.075% (v/v) β-mercaptoethanol, the STRADα/MO25α
complex (20 mg) was resuspended in 20 ml of the same buffer with in-
creased (300 mM) NaCl concentration (resuspending buffer). This was
then passed through 2 ml of Ni2+-agarose beads, equilibrated in the
same resuspending buffer and the beads were washed with 50 column
volumes of resuspending buffer containing 500 mM NaCl and were
re-equilibrated with 10 column volumes of resuspending buffer. His-
STRADα was eluted in resuspending buffer supplemented with 150
mM imidazole. The eluted His-STRADα sample was equaly divided
and dialyzed against 5 l of assay buffer containing 50 mM Tris-HCl
pH 7.8, 50 mM NaCl, 270 mM sucrose and 1 mM DTT. Untagged
STRADα was obtained by incubation with TEV protease (1:30) for
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16 h at 4 oC. Uncleaved STRADα and the TEV protease were removed
by passing the post-cleavage sample through Ni2+-agarose beads. A
summary and SDS-PAGE analyis of the fore-mentioned procedure is
provided in Fig. 2.2. His-STRADα and untagged STRADα were fi-
nally dialyzed in assay buffer concentrated to 7 mg/ml, divided into
aliquots and stored at −80 oC. Protein concentrations were deter-
mined by measuring the absorbance of the purified proteins at 280 nm
(section 2.10.1) in assay buffer.
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Figure 2.2: Isolation of His-STRADα and untagged STRADα for SPR experiments
A) Purified His-STRADα/MO25α complex (input lane) was passed through NiNTA agarose
beads as described in section 2.8.5. The flowthrough was collected and shown in the lane
labelled FT. The bound His-STRADα (bound lane) was washed with high salt buffer con-
taining 500 mM NaCl to remove any remaining MO25α, prior to imidazole elution. The
eluted fractions (labelled) were run on a gel and their purity was assessed by Coomassie blue
staining/visualisation.
B) Eluted fractions were incubated overnight with TEV protease and electrophorised on a 12%
acrylamide gel. His-STRADα/MO25α complex and MO25α were run side-by-side as controls.
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2.8.6 Conditions and virus amplification for co-expression of the
LKB1/STRADα/MO25α complex
The MultiBac expression system (Berger et al., 2004) was used to
co-produce the LKB1/STRADα/MO25α complex in Sf21 insect cells.
Sf9 and Sf21 cells (Invitrogen) were cultured as described in section
2.6.1. Recombinant bacmid was generated in DH10BacTM cells and
extracted using the phenol:chloroform method described in section
2.6.6. Recombinant progeny 1 (P1) baculovirus was produced by
transfecting recombinant bacmid into Sf9 cells. The cells were washed
three times in media containing no antibiotics/antimycotics and 5 ml
of cells were seeded in 25 cm3 flasks at a density of 0.9 × 10 6 cells/ml
and allowed to attach for 30-45 min. Meanwhile, in a 12 well plate, 12
µl of Cellfectin reagent (Invitrogen) and 10 µl of bacmid DNA (section
2.6.6) were added to 500 µl of SF900II media and left at RT for 45 min.
A further 2 ml of SF900II media was added to the DNA/Cellfectin mix
and this was transferred to the attached cells from which the present
media had been aspirated. The attached cells, together with the 2.5
ml of added DNA/Cellfectin/media were incubated overnight at 27
oC in an incubater with appropriate humidity. The media was then
aspirated, cells were washed once with SF900II fresh media containing
antibiotic/antimycotic and 5 ml of this fresh media was finally added.
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The P1 virus was harvested after 6 days by centrifugation at 800 rpm
for 10 min. Aliquots (400 µl) of the decanted supernatant were made
and stored at −80 oC.
A P2 virus was generated by infecting Sf21 cells (1.0 × 106 cells/ml)
using the P1 virus (400 µl/100 ml cells). The supernatant from this
culture (P2 virus) was harvested 72 h post-infection, and 3 ml were
used to infect 600 ml of Sf21 cells (1.5 × 106 cells/ml), thus generating
a P3 virus 48 h post-infection. This culture was used (1:10) to infect
6 l of Sf21 cells for protein production.
2.8.7 Cell lysis and purification of the LKB1 heterotrimeric complex
Cells were grown in suspension 48 h post-infection, were washed once
in Buffer A (section 2.5.3) and harvested in ice-cold lysis Buffer B
(section 2.5.3). Cells were lysed using a continuous flow cell disruptor
at 35000 psi, and the lysate was clarified by centrifugation at 26000 g
for 30 min. The supernatant was incubated on a rolling platform for
1 h at 4 oC with 8 ml of NiNTA agarose beads, pre-equilibrated in low
salt Buffer C (section 2.5.3). The beads were washed with 10 CV of low
salt Buffer C and 60 CV of high salt Buffer D (section 2.5.3), followed
by a re-equilibrating step with 10 CV of low salt Buffer C. The protein
was eluted from a disposable column with 10 CV of low salt Buffer C
supplemented with 100 mM imidazole. Fractions were combined (∼60
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Figure 2.3: Purification of the LKB1/STRADα/MO25α complex
A) Elution of the LKB1 heterotrimeric comlplex from NiNTA beads using 120 mM imidazole.
B) Fractions from (A) were combined (first lane) and His-TEV protease was added (1:20)
and incubated for 48 h at 4 oC (third lane). His-TEV and uncleaved His-LKB1 complex were
removed using NiNTA beads (fourth lane) leaving cleaved LKB1 complex free of His-TEV
protease (second lane).
C) Eluted fractions from an anion exchange chromatography column. The LKB1 heterotrimeric
complex eluted at ∼250 NaCl. If trace amounts of uncleaved LKB1 were evident, the fractions
were pulled and passed through fresh NiNTA beads for a second time before loading on a gel
filtration column.
D) Peak fractions of eluted LKB1 heterotrimeric complex run on a Superdex-S200 26/60 gel
filtration column.
mg of protein) and 3 mg of His-tagged TEV protease was added prior
to dialysis against 5 l of loading Buffer E (section 2.5.3) for 48 h. The
TEV protease and uncleaved LKB1 were removed by passing through
2 ml of NiNTA beads prior to loading the sample on a 5 ml HiTrap-
Q column (GE Healthcare). Bound proteins were eluted over 30 CV
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using a salt gradient of 0-500 mM NaCl, generated with Buffers F and
G (section 2.5.3). The LKB1/STRADα/MO25α complex eluted as a
single peak at ∼250 mM NaCl. Peak fractions were analysed by SDS-
PAGE, pulled together and if neccessary passed through fresh NiNTA
beads for a second time to remove any remaining uncleaved His-LKB1
2.3. The sample was divided in half, concentrated to 3 ml and loaded
on a Superdex-S200 26/60 column (GE Healthcare), pre-equilibrated
in crystallisation Buffer H (section 2.5.3). Alternatively the protein
sample was methylated using the protocol described in section 2.9
before loading on a gel filtration column as described above. In both
cases the LKB1/STRADα/MO25α complex eluted as a single peak
and its purity was assessed by SDS-PAGE and MALDI-TOF linear
mass spectrometry. The purification procedure is summarised in Fig.
2.3. Additional analyses of LKB1 complex preparations are provided
in Chapter 4 of this thesis.
2.8.8 HEK293 cell culture, transfections and lysis (completed by Dr Beatrice
M. Filippi)
HEK293 cells were cultured on 10 cm diameter dishes in 10 ml DMEM
supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin, and 0.1 mg/ml streptomycin. For transfection
experiments, 3 to 9 µg of DNA was mixed with 20 µl of 1 mg/ml
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polyethylenimine (Polysciences) in 1 ml of plain DMEM for each dish,
and the mixture was left to stand for 30 min and added to the cells.
Cells were lysed 36 hours post-transfection in 1 ml of ice-cold lysis
Buffer A (section 2.5.4) per dish. The cell lysates were clarified by
centrifugation at 20000 g for 15 min at 4 oC, and the supernatants
divided into aliquots, frozen in liquid nitrogen and stored at -20 oC.
2.8.9 Expression of fusion proteins in HEK293 cells and affinity purification
(completed by Dr Beatrice M. Filippi)
10 cm diameter dishes of HEK293 cells were transiently transfected
with 3 µg of the pEBG-2T constructs (GST-LKB1) together with
3 µg of the indicated pCMV5 constructs (Flag-STRADα and Myc-
MO25α). Cells were harvested and lysed (section 2.8.8), 36 h post-
transfection. The clarified lysates were incubated for 1 h on a rotating
platform with glutathione-Sepharose (20 µl/dish of lysate) that was
previously equilibrated in lysis Buffer A (section 2.5.4). Beads were
then washed twice with wash Buffer B (section 2.5.4) and twice with
50 mM Tris-HCl, pH 7.5 For immunoblotting analysis, the beads were
resuspended in SDS sample buffer after this step and the samples
were immunoblotted as described in section 2.10.2. For protein kinase
assays and gel electrophoresis, the beads were washed twice with wash
Buffer B (section 2.5.4), and proteins were eluted from the resin by
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incubation with the same buffer containing 20 mM reduced glutathione
(pH re-adjusted to 7.5) and 270 mM sucrose. The beads were then
removed by filtration using a SpinX column with a 0.44 µm filter, and
the eluate was divided into aliquots and stored at −80 oC.
2.9 Lysine methylation protocol
Prior to lysine methylation the His-STRADα/MO25α samples were
dialyzed overnight against 5 l of buffer containing 25 mM Tris-HCl
pH 7.5, 50 mM NaCl, 10% glycerol, 1 mM benzamidine and 0.075%
(v/v) β-mercaptoethanol. The LKB1/STRADα/MO25α complex was
methylated after elution from the anion exchange column (described
in section 2.8.7 and the same elution buffer (containg 250 mM NaCl)
was used. STRADα was methylated in Buffer B (section 2.5.1).
The lysine methylation method previously described by Walter et al.
(2006) using dimethylamine-borane complex (DMB) and formalde-
hyde (section 2.1.6), was followed with minor modifications. The fol-
lowing protocol (carried out at 4 oC) is described for 1 ml of protein
solution. The methylation reaction was performed overnight at pro-
tein concentrations of 1 mg/ml or less in a 50 ml falcon tube. Twenty
microliters of freshly prepared 1 M dimethylamine-borane complex
(DMB) and 40 µl of 1 M formaldehyde were added to the protein so-
lution, and the reactions were gently mixed and incubated at 4 oC for
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2 h. A further 20 µl DMB and 40 µl formaldehyde were added and
the incubation continued for another 2 h. Following a final addition
of 10 µl DMB, the reactions were incubated overnight at 4 oC.
Th methylation reaction lead to significant amount of precipitated
protein, which was removed by centrifugation for 30 min at 3500 rpm
in a benchtop centrifuge. The supernatant was then concentrated
down to 2 ml and buffer exchanged in a disposable desalting column
(section 2.2). The eluates (containing the methylated protein, as de-
termined by a Bradford assay) were pulled together, concentrated
and buffer exchanged further in a Vivaspin concentrator. Finally
the sample was concentrated again to 2.5-3.0 ml before loading on
a gel filtration column as described in sections 2.8.2 (STRADα), 2.8.4
(His-STRADα/MO25α complex) and 2.8.7 (LKB1/STRADα/MO25α
complex).
2.10 Analysis and storage of protein preparations
2.10.1 Determination of protein concentrations
Protein and whole cell-lysate concentrations were determined using
the Bradford method. A standard curve was constrcuted according to
the manufacturers protocol, using 1 ml of the Bradford reagent thor-
oughly mixed with increasing amounts of known BSA concentrations
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(0-5 mg/ml). The absorbance at wavelength 595 nm (A595) was mea-
sured for a series of increasing protein concentrations and the values
were used to constrcut a calibration-curve for subsequent protein mea-
surements. A cuvette containing the same volume of water/buffer was
used as blank and subtracted from each measurement. Protein solu-
tions of highly concentrated samples were diluted to display an A595
reading within the linear range of Bradford measurements, generally
between 0.1-0.7 arbitrary absorbance units (AU).
Alternatively, protein concentrations were calculated using Beer-
Lambert’s law (Stryer et al., 2002, p69) by measuring the absorbance
of the purified proteins in assay buffer at 280 nm. Theoretical ex-
tinction coefficients (ε) were calculated using the ExPASy proteomics
server (http://www.expasy.org) and were: His-STRADα = 37735 M−1
cm−1, STRADα = 36245 M−1 cm−1 and MO25α = 22015 M−1 cm−1.
A cuvette (1 cm pathlength) containing buffer or ddH2O only was
used as blank. Highly concentrated protein solution were diluted ac-
cordingly to give an A280 reading between 0.1-0.6 AU (assumed linear
range; measured in a 1 cm pathlength cuvette) and the following for-
mula was used for calculating the final protein concentration.
Concentration(mg/ml) = (
A280
ε
)×MW (Da)×Dilutionfactor (1)
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2.10.2 Immunoblotting (completed by Dr Beatrice M. Filippi)
Cell lysates or purified proteins were subjected to SDS-PAGE and
transferred to nitrocellulose membranes over 2 h at 40 V. The mem-
branes were blocked for 1 hour in TBS-T buffer (section 2.3.8 con-
taining 10% (w/v) skimmed milk. The anti-GST (DSTT), anti-Flag
(Sigma) and anti-Myc antibodies (Roche) were diluted 1000-fold be-
fore the membranes were immunoblotted in the same buffer containing
the forementioned antibodies, for 16 h at 4 oC. Membranes were then
washed six times with TBS-T buffer and incubated with the appropri-
ate horseradish peroxidase-conjugated secondary antibodies (Pierce)
in TBS-T buffer containing 10% (w/v) skimmed milk. After repeat-
ing the washing steps, detection was performed using the enhanced
chemiluminescence reagent (ECL) and the films were developed using
a film automatic processor (SRX-101; Konica Minolta Medical).
2.10.3 MALDI-TOF analysis
Matrix-assisted laser desorption/ionisation and time-of-flight (MALDI-
TOF) analysis were carried out in the Fingerprints and Proteomics Fa-
cility, University of Dundee, UK, by Dr Kenny Beattie and Dr David
Campell.
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2.10.4 Analytical ultracentrifugation (AUC)
Sedimentation-equilibrium determinations were carried out by Dr Mark
Agacan, AUC facility, University of Dundee, UK. An Optima XL-
1 analytical ultracentrifuge (Beckman Coulter) with absorbance op-
tics was used. The sedimentation-velocity experiments were run at
45000 rpm at 293 K and the data were analysed with the program
SEDFIT (Schuck, 2000). Samples were prepared in 25 mM Tris-HCl
pH 7.8, 150 mM NaCl, 2 mM DTT and centrifuged at 14000 rpm
in a benchtop centrifuge at 4 oC for 30 min prior to AUC analy-
sis. Various concentrations (0.75-3.0 mg/ml) of the unmethylated and
methylated LKB1/STRADα/MO25α purified for crystallisation (sec-
tion 2.8.7) were analysed in the absence/presence of 0.1 mM ATP and
1 mM MgCl2.
2.10.5 Dynamic light scattering
Dynamic light scattering (DLS) analysis were carried out at 293 K
using a Proterion DynaPro-LSR DLS instrument coupled with a mi-
crosampler and analysed using DLS Proterion’s Dynamics V6 software
(both from Proterion, Piscataway, NJ, USA). 12 or 45 µl quartz sam-
ple cells (cuvettes) were used, and samples were prepared in 25 mM
Tris-HCl pH 7.8, 150 mM NaCl, 2 mM DTT. Prior to DLS analysis
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samples were centrifuged at 14000 rpm in a benchtop centrifuge at 4
oC for 30 min.
2.10.6 Storage of purified protein preparations
Recombinantly expressed and purified protein preparations were “snap”
frozen in liquid nitrogen (generally at concentrations 1-3 mg/ml), and
the aliquots were stored at −80 ◦C in buffers containing 270 mM Su-
crose. In the absence os sucrose, 10% (v/v final concentration) of
glycerol was added. Aliquots were thawed at 4 ◦C when required.
2.11 Enzyme assays
2.11.1 Assaying LKB1 by measuring phosphorylation of the LKBtide peptide
(completed by Dr Beatrice M. Filippi)
The activity of recombinant LKB1/STRADα/MO25α complexes was
assayed towards the LKBtide peptide substrate (SNLYHQGKFLQT-
FCGSPLYRRR) (Lizcano et al., 2004). All assays were performed
by using 0.35 µg of recombinant proteins expressed and purified from
HEK293 cells as described in section 2.8.9. Phosphotransferase ac-
tivity towards the LKBtide peptide was measured in a total assay
volume of 50 µl consisting of 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA,
0.1% (v/v) 2-mercaptoethanol, 10 mMmagnesium acetate, 0.1 mM [γ-
32P]ATP (200 cpm/pmol) and 0.2 mM LKBtide peptide. The assays
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were carried out at 30 oC and were terminated after 15 minutes by ap-
plying 40 µl of the reaction mixture onto P81 membranes. These were
washed in phosphoric acid, and the incorporated radioactivity was
measured by scintillation counting as described previously for MAP
kinase by Alessi et al. (1995). One Unit (U) of activity represents the
incorporation to the substrate of 1 nmol of γ-32P per minute.
2.11.2 Assaying LKB1 by measuring activation of the heterotrimeric AMPK
kinase (Completed by Dr Beatrice M. Filippi)
γ1
β2
α1
Figure 2.4: Typical AMPK purification
The rat AMPK heterotrimeric com-
plex (α1β2γ1 subunits) was purified
from E. coli (Neumann et al., 2003)
and provided by the Division of Sig-
nal Transduction Thereapy, Univer-
sity of Dundee (Fig. 2.4). The
AMPK activity was measured following its phosphorylation with
LKB1 as reported by Lizcano et al. (2004). 0.3 µg of AMPK com-
plex, were incubated with or without 10 ng of wild type or mutant
LKB1/STRADα/MO25α complex in an assay buffer containing 50
mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol
with the addition of 5 mM magnesium acetate and 0.1 mM cold ATP,
in a final volume of 20 µl. After incubation at 30 oC for 30 min-
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utes the AMPK kinase activity was determined by adding 30 µl of
the same assay buffer containing 5 mM magnesium acetate, 0.1 mM
[γ-32P]ATP (300 cpm/pmol) and 0.2 mM AMARA peptide (AMA-
RAASAAALARRR) (Dale et al., 1995) as substrate. After incubation
for 20 min at 30 oC, incorporation of γ-32P into the peptide substrate
was determined by applying the reaction mixture onto P81 phospho-
cellulose paper and scintillation counting as described in section 2.11.1.
Similarly, one Unit (U) of activity represents the incorporation to the
substrate of 1 nmol of γ-32P per minute.
2.11.3 Purification and kinase activity assays of STRADα
STRADα residues 59-431 (wild type and mutant forms) preceded by
a 6-His purification tag, were expressed in E. coli BL21(DE3)pLysS
cells. The expression and purification procedure was followed as de-
scribed in sections 2.8.3 and 2.8.4 for the STRADα/MO25α complex.
After the imidazole elution step 2.8.3, STRADα was assayed for activ-
ity. Approximately 3-5 µg of PKA, wild type or mutant His-STRADα
were assayed in a 25 µl reaction mixture containing 50 mM Tris-HCl
pH 7.5, 0.1% (v/v) 2-mercaptoethanol, 0.1 mM EGTA, 10 mM mag-
nesium acetate, and 0.2 mM [γ-32P]ATP (5000 cpm/pmol) in the pres-
ence of 5 µg of bovine MBP. In assays where 3 µg of bacterially ex-
pressed MO25α (Milburn et al., 2004) was present, this was incubated
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with STRADα for 30 minutes at 4 oC before the reaction was started.
In assays where magnesium acetate was omitted, 2 mM EDTA was
added instead. After incubation for 60 min at 30 oC, reactions were
terminated by the addition of 6 µl of LDS sample buffer (5 times
concentrated) and reaction mixtures (30 µl) were electrophoresed on
SDS-polyacrylamide gels. These were dried and analyzed by autora-
diography to quantify STRADα autophosphorylation or MBP phos-
phorylation.
2.12 Measurement of STRADα binding to phosphonucleotides
2.12.1 Nucleotide binding experiments
Fluorescent measurements of bound TNP-ATP were obtained at 25
oC in assay buffer and with the addition of 0.5-1.0 mM MgCl2 where
indicated, using 1 cm pathlength cuvettes in a VARIAN Cary Eclipse
Fluorescence spectrophotometer. Fluorescence was recorded from 500-
600 nm (slit width = 20 nm; PMT = 800 V) after excitation at 410
nm (slit width = 10 nm). In all cases, signal from the TNP-ATP
buffer control was subtracted as background. For binding studies,
STRADα and STRADα mutants were assayed at 2 µM. In cases
where STRADα/MO25α complexes were assayed, wild type or mu-
tant MO25α (2 µM) were pre-incubated for at least 2 h at 4 oC prior
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to a fluorescence binding experiment. For saturation binding exper-
iments, concentrated stocks of TNP-ATP were added stepwise, cov-
ering a range of concentrations from 0.05-30 µM. For displacement
experiments, the concentration of TNP-ATP was fixed at 5 µM, and
ATP or ADP was titrated in, covering a range of concentrations from
0.05-500 µM. In all assays, concentrated stocks of nucleotides were
added in steps of 0.5-1.0 µl to 1 ml of reaction mixture, ensuring that
the total added volume did not exceed 1% of the total volume of the
reaction.
A B
Figure 2.5: Typical TNP-ATP displacement experiment
A) Fluorescence emission spectra (excitation 410 nm) of TNP-ATP (5 µM) bound to STRADα
(4 µM) with/without stepwise addition of unlabelled ATP as described in section 2.12.1.
B) Emisson at λ = 540 nm was plotted as a function of added ATP. A dose response curve,
fitted using equation 3 (section 2.12.2) gave an inhibitory concentration (IC50) = 6.6 ± 0.5
µM. Data are presented as the mean ± SEM of three separate measurements.
Data collected form a typical experiment for constructing a dose
response curve of TNP-ATP displacement by ATP is provided in Fig.
2.5.
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2.12.2 Data analysis for the nucleotide binding experiments
Data were analysed using the GraphPad-PRISM software, and to cal-
culate the Kd values for TNP-ATP, data from saturation binding
experiments were fitted to the following quadratic equation suitable
for tight binding interactions with ligand depletion (Copeland, 2000,
p.92).
[RL] =
([R] + [L] +K d)−
√
([R] + [L] +Kd)2 − 4[R][L]
2
(2)
Where [RL] equals the concentration of receptor/ligand complex, cal-
culated as the fractional occupancy (Fx/Fmax) × [R]. [R] equals the
total binding capacity, fixed at 1.5 µM. [L] equals the concentration of
added TNP-ATP. In the displacement studies, equilibrium constant
values for ATP and ADP were calculated by first determining the
logIC50 value, using a standard dose response equation:
Fx/Fmax = minimum+
maximum−minimum
1 + 10([N ]−logIC50)
(3)
where [N] equals the concentration of added nucleotide and Fx/Fmax
represents the fractional occupancy. Equilibrium constants for the
competing ATP and ADP (KNd ), were fitted using the rearranged
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Cheng-Prusov equation (Cheng and Prusoff, 1973) below:
logIC50 = log(10
logKNd × 1 + [TNP − ATP ]
K TNP−ATPd
) (4)
2.13 Surface Plasmon Resonance (SPR) measurements
2.13.1 BIAcore assays of STRADα/MO25α interaction (completed by Dr Iva
Navratilova)
W
T
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Figure 2.6: Purification of MO25α for assays
SPR measurements were per-
formed using a BIAcore T100
instrument. Wild type and
mutant forms of MO25α (Fig.
2.6) were immobilized on a
CM5 sensor chip using stan-
dard amine-coupling chemistry
and 10 mM HBS, pH 7.4 was
used as the running buffer.
The carboxymethyl dextran
surface was activated with a 7
min injection of a 1:1 ratio of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC)/0.1 M N-hydroxy succinimide
(NHS). MO25α (5-7 µM) was coupled to the surface with a 1 min
injection of protein diluted in 10 mM sodium acetate (pH 5.5). Re-
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maining activated groups were blocked with a 7 min injection of 1 M
ethanolamine (pH 8.5). MO25α was immobilised on three flow-cells
of a CM5 chip at densities 1700-2500 response units (RU) performed
at 25 oC, leaving one flow cell as a reference to subtract any possible
non-specific binding.
STRADα was prepared in running buffer containing 50 mM Tris,
pH 7.8, 50 mM NaCl, 270 mM sucrose, 1 mM DTT (section 2.8.5
and Fig. 2.2) with added 0.005% P20 and 0.1 mg/ml BSA in the
presence/absence of 100 µM ATP and 1 mM MgCl2, and injected
over all four surfaces at nine concentrations of a 3-fold concentration
series (5 µM - 0.3 nM). Each concentration was injected in duplicate
over all surfaces. Association was measured for 60 s at a flow rate
of 50 µl/min and dissociation was measured for 3 minutes. STRADα
dissociated completely from the MO25α surfaces, thus eliminating the
need for a regeneration step. Sensograms from BIAcore experiments
are provided in Fig. A.3.
2.13.2 Data analysis for the SPR measurements
Data were analysed using Scrubber 2 (BioLogic Software, Campbell,
Australia) and CLAMP (Myszka and Morton, 1998) software (carried
out by Dr Iva Navratilova). Data were double referenced to the refer-
ence surface to subtract any possible non-specific binding and to the
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blank buffer injections to subtract drift of the target from surface.
Data were fitted to a 1:1 or 2:1 binding site model where appropri-
ate. Kinetic association (ka) and dissociation rate (kd) constants were
separately determined from the BIAcore sensograms and equilibrium
dissociation constants (Kd) were calculated using the equation below
that describes the law of mass action at quilibrium.
Kd1 =
kd1
ka1
and Kd2 =
kd2
ka2
(5)
Equlibrium constants were also independently calculated by fitting the
measured response (R) from specific binding to a saturation binding
isotherm (Lungmuir isotherm). At first, dose response curves for cal-
culating the Hill slope (H) of the data were fitted with the following
equation:
R = minimum+
maximum−minimum
1 + 10((logEC50−[STRAD])×H)
(6)
For those datasets with a Hill slope H = 1 ± 0.1 the isotherm was
fitted to the equation below describing binding to one interacting site:
R =
Rmax × [STRAD]
[STRAD] +Kd
(7)
For those datasets displaying a Hill slope H < 1, the isotherm was
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fitted to the equation below describing binding to two interacting sites:
R = (
Rmax1 × [STRAD]
[STRAD] +Kd1
) + (
Rmax2 × [STRAD]
[STRAD] +Kd2
) (8)
Where Rmax1 and Rmax2 are the relative maximal changes in response
for sites 1 and 2 respectively and Kd1 and Kd2 are the equilibrium
dissociation constants for sites 1 and 2 respectively.
2.14 Protein crystallography
2.14.1 General theory
This Materials and Methods section does not include the theory be-
hind the applied crystallographic techniques, as this would go beyond
the scope of this chapter. Therefore, the reader referred to the rele-
vant literature on this topic. For deeper insights into the process of
crystallisation, please refer to the following titles: “Crystallisation of
Biological Macromolecules” (McPherson, 1999), and “Crystallisation
of Nucleic Acids and Proteins” (Ducruix et al., 1999). “Crystallogra-
phy Made Crystal Clear” (Rhodes, 2006) is recommended as a gen-
eral reference for the underlying theory of diffraction experiments. A
more comprehensive and advanced account is provided by the text of
the International Union of Crystallography (IUCr) “Fundamentals of
Crystallography” (Giacovazzo et al., 2002).
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2.14.2 Crystallisation methods
The crystal structures described in this thesis were obtained from crys-
tals grown using the vapour diffusion method in the sitting drop and
the hanging drop setup (Fig. 2.7). The sitting drop method con-
sisted of a reservoir with added 70–80 µl of mother liquor. On the
platform, 0.5-1 µl of protein solutions were pipetted and mixed with
an equivalent amount of mother liquor, and if required, 0.2-0.3 µl of
additive solutions. The wells were sealed using Crystal Clear sealing
tape, thus allowing easy visualisation of the drops. The hanging drop
setup was used mainly for crystal optimization after initial crystalli-
sation hits were established by the sitting drop method. Pre-greased
(24-well) VDX plates were filled with 0.5-0.7 ml of mother liquor so-
lutions. 1.0–1.5 µl of the protein solution and an equivalent volume
of the mother liquor were pipetted onto a siliconised glass cover slip,
which was mounted upside down onto the well. A closed system for
vapour diffusion was created by distributing the vacuum grease be-
tween the cover slip and the top of the well. All crystal visualisation
and screening was done manually using an inverted-lens light micro-
scope.
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A B
Figure 2.7: Schematic diagram of the crystallisation setup used in this thesis
Hanging drop (A) and sitting drop (B) method. The reservoir, mother liquor solution (blue)
contains precipitant. The protein solution (red) is a mixture of protein (in buffer) and diluted
mother liquor. The sealed closed system ensures an equilibrium is reached over time, through
vapour diffusion from the red to the blue solutions. Pictures are courtesy of Davidson College,
Davidson, NC 28035.
2.14.3 Crystal screening
Screening for initial crystallisation conditions was performed using a
wide range (∼500 conditions) of commercially available crystallisation
screens (2.1.4). The screens used, were designed by the sparse matrix
screening technique (Jancarik and Kim, 1991) were non-redundant,
and varied in pH as well as in utilising different salts, buffers and
precipitants over a broad range. Additionally, screens designed specif-
ically for protein-protein complexes (Radaev and Sun, 2002) were also
used (2.1.4).
The protein concentration used for crystallisation condition screen-
ing (stated in the experimental sections of the relevant chapters) was
assessed by concentrating the respective protein to near the solubil-
ity limit, and subsequently diluting this concentration to an extent in
which the protein precipitates in 50–70% of the conditions of Hamp-
ton Crystal Screens 1 & 2. If more than 50% of the screens showed
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clear drops, the protein solution was further concentrated by a factor
of 1.5 If the number of conditions leading to amorphous precipitation
exceeded 70%, the protein was diluted by a factor of 0.7
For crystal optimisation, the sparse matrix conditions were repro-
duced using chemicals of the highest available purity. Generally, crys-
tals were reproduced in grid screens of the initial condition, and some-
times further optimized by additive screens. For grid screening, a sim-
ple matrix was used based on the initial crystallisation hit, in which the
pH of the buffer molecule, and the concentrations of both the salt and
the precipitant (the three common constituents of the commercially
available screens) were altered by 10-20%. The protein concentration
was also changed in parallel screens. Following this optimisation step,
additive screening was performed using the comercially available addi-
tive screen from Hampton Research. These contained a wide array of
biological co-factors, ions, organic molecules and solvents, and various
precipitants such as polymers and detergents. Using a grid-optimised
condition, 1 µl of protein solution was mixed with 1 µl of mother
liquor, and 0.25 µl of the additive was added to each drop. Because
of the higher dilution in the drop from adding the additive, the pre-
cipitant and salt concentrations were increased accordingly. Screening
was performed at 20 oC, with the exception of STRADα trials where
2 Materials and methods 106
screening was also performed at 4 and 30 oC.
2.14.4 Crystallisation of His-STRADα/MO25α complex
The STRADα/MO25α complex was concentrated to 7.5 mg/ml, fol-
lowed by addition of ATP to a final concentration of 10 mM and
MgCl2 (final concentration of 1 mM). The sitting drop vapor diffusion
method (section 2.14.2) was used to grow crystals by mixing 1 µl of
protein solution with 1 µl of mother liquor. For the unmethylated
complex, the optimised mother liquor consisted of 20 mM Li2SO4, 50
mM sodium citrate pH 5.6 and 6% (v/v) PEG4000. For the methy-
lated complex, the mother liquor was composed of 0.1 M MES pH 6.4
and 10% (v/v) PEG8000. For both conditions, 0.25 µl of 1 M NDSB-
256 was added to the crystallisation drop. Rod-shaped crystals of the
unmethylated complex appeared after 3 h and grew to 0.05 mm (max-
imum dimension) after 24 h. The methylated sample yielded bigger
crystals that appeared after 24 h and grew to a maximum length of
0.5 mm after three days. Crystals were flash frozen in liquid nitrogen
after cryoprotection with mother liquor containing 20% (v/v) glyc-
erol (unmethylated) and 25% (v/v) PEG8000 and 10% (v/v) PEG300
(methylated).
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2.14.5 Crystallisation of the LKB1/STRADα/MO25α complex
Both methylated and unmethylated LKB1/STRADα/MO25α com-
plex were concentrated to 8.0 mg/ml followed by the addition of AMP-
PNP and MgCl2 to a final concentration of 5 mM. Crystals were grown
at 20 oC using the hanging drop vapour diffusion method (section
2.14.2). Crystals of the unmethylated sample were obtained by mix-
ing 1.5 µl of protein and 1.2 µl of mother liquor (1.8 M (NH4)2SO4,
0.1 M Tris-HCl pH 9.0) and 0.3 µl of 2 mM NaCl. For the methylated
protein sample, crystals were grown by mixing 1.5 µl of protein with
1.5 µl of mother liquor (1.6 M (NH4)2SO4, 0.1 M Tris-HCl pH 8.25).
In both cases crystals appeared after 36-48 h and reached maximal
size after 4 days. For cryoprotection, 23% (v/v) glycerol was added
to the mother liquor solution.
2.15 Crystal handling
All diffraction experiments were performed using frozen crystals cry-
oprotected in an appropriate solution containing the mother liquor and
a suitable cryo-protectant. These were handled using a small nylon
loop mounted on a metal pin. General cryo-protectants such as glyc-
erol, low molecular weight (200-300 MW) polyethylene glycols (PEGs),
ethylene-glycol, 2-methyl-2,4-pentanediol (MPD), isopropanol, satu-
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rated NaCl and Li2SO4 were routinely tested. Crystals were then
frozen in a gas stream set to 100 K or directly in liquid nitrogen and
stored in a suitable storage/transport dewar.
2.16 General data collection and processing strategies
Data were collected at the European Synchrotron Radiation Facil-
ity (ESRF), indexed and proccessed using software from the CCP4
package (Collaborative Computational Project, 1994) and HKL2000
(Otwinowski and Minor, 1997). The data collection strategy was cal-
culated using PREDICT (M.E.M. Noble, University of Oxford, UK)
and BEST (Popov and Bourenkov, 2003) to collect data with full com-
pleteness and approximate levels of redundancy. During individual
data collections, images were processed and scaled to verify the cor-
rectness of the assumed data collection strategy and this was altered
where necessary. Scaling of a complete data-set was performed, and
the statistics in the highest resolution shell were used to determine
a reasonable resolution cut-off (I/σI > 2 and Rmerge for the highest
resolution shell < 60%). Radiation damage was monitored carefully,
and generally 3-4 fold data redundancy and 90-100% completeness
was aimed for each dataset. Typical X-ray diffraction images for His-
STRADα/MO25α and LKB1/STRADα/MO25α complex crystals are
shown in Fig. 2.8. Summaries of data collection paramaters are given
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in the rescpective chapters, where these structures are discussed.
A B
Figure 2.8: Images from diffraction experiments
X-ray diffraction images acquired during data collection of (A) His-STRADα/MO25α complex
crystals, diffracting to 2.35 A˚ and (B) LKB1/STRADα/MO25α complex crystals, diffracting
to 2.65 A˚.
2.16.1 Determination of the His-STRADα/MO25α complex structure
Data were collected at 100 K on stations ID14-3, ID14-4 and ID23-2 at
the European Synchrotron Radiation Facility (ESRF) and processed
using the MOSFLM and SCALA programs from the CCP4 package
(Collaborative Computational Project, 1994). The structures of the
unmethylated/methylated complexes were solved by a combination of
molecular replacement with MOLREP (Vagin and Teplyakov, 1997)
and real-space searches with FFFEAR (Cowtan, 1998). An initial
molecular replacement run was carried out with MOLREP using the
1.85 A˚ structure (PDBID 1UPK) of MO25α (Milburn et al., 2004) as a
search model. Using the resulting phases, the STRADα molecule was
then located by performing a real-space search with FFFEAR (Cow-
tan, 1998) using the 2.1 A˚ structure (PDBID 1U5R) of TAO2 (Zhou
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et al., 2004). Thus, a solution with one complex in the asymmetric
unit was found and the structure was refined by alternating rounds of
refinement with REFMAC5 (Murshudov et al., 1997) (including TLS
refinement (Winn et al., 2001) during the last macrocycles) and man-
ual model building with the program COOT (Emsley and Cowtan,
2004). For the methylated complex, this resulted in a final model
with an R-factor of 0.206 (Rfree = 0.254) that was validated using
PROCHECK (Laskowski et al., 1993) and MOLPROBITY (Lovell
et al., 2003). STRADα residues 292-347, 383-385, 402-424 and MO25α
residues 337-341 were not associated with clear electron density and
were not included in the model. A summary of diffraction data pa-
rameters, the relevant details of refinement and statistics are provided
in chapter 3, Table 3.1 of this thesis. Coordinates and observed struc-
ture factor amplitudes have been deposited at the Worldwide Protein
Data Bank (wwPDB, http://www.wwpdb.org/), with accession code
3GNI.
2.16.2 Determination of the LKB1/STRADα/MO25α complex structure
Data were collected at 100 K on station ID14-3 at the European Syn-
chrotron Radiation Facility (ESRF) and processed using the DENZO
and SCALEPACK programs from the HKL2000 suite (Otwinowski
and Minor, 1997).
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Structures of the unmethylated/methylated complexes were solved
by a combination of molecular replacement with PHASER (McCoy,
2007) and averaging/automatic model building using RESOLVE (Ter-
williger, 2003). A molecular replacement run was carried out using
the structures of MO25α (PDBID 1UPK (Milburn et al., 2004)) and
the STRADα structure determined in this thesis (PDBID 3GNI) as
search models. This gave a solution with two copies of each model
in the asymmetric unit (asu). The resulting model phases were then
further improved by solvent flattening and two-fold averaging using
RESOLVE (Terwilliger, 2003), which also built four LKB1 fragments
as Cα trace. Using the partially built LKB1 model, the structure of
the AUR2 protein kinase (PDBID 1OL7 (Bayliss et al., 2003), 24.5%
sequence identity to LKB1) was superimposed using the secondary
structure matching function in COOT (Emsley and Cowtan, 2004).
Regions of this initial LKB1 model that did not have any associated
electron density were removed. The structure was further refined by
alternating rounds of refinement with PHENIX (Adams et al., 2002)
and REFMAC (Murshudov et al., 1997) (using strict NCS during the
first macrocycles and TLS refinement (Winn et al., 2001) during the
last macrocycles) and manual model building with the program COOT
(Emsley and Cowtan, 2004). For the methylated complex, this re-
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sulted in a final model consisting of 1835 ordered residues out of 2080
possible residues, with an R-factor of 0.239 (Rfree = 0.290), that was
validated using PROCHECK (Laskowski et al., 1993) and MOLPRO-
BITY (Lovell et al., 2003). A summary of diffraction data parameters,
the relevant details of refinement and statistics are provided in chapter
IV, Table 4.1 of this thesis. Coordinates and observed structure factor
amplitudes have been deposited at the Worldwide Protein Data Bank
(wwPDB, http://www.wwpdb.org/), with accession code 2WTK.
2.17 Data analysis and figure preparations
2.17.1 Structure visualisation, representation and analysis
All structural representations and figures were prepared with the Py-
MOL molecular graphics system available at http://www.pymol.org
(DeLano, 2004). Secondary structure was analysed using DSSP (Kab-
sch and Sander, 1983) and sequence alignments were performed using
MUSCLE (Edgar, 2004), which were edited and displayed using the
program ALINE (Bond and Schu¨ttelkopf, 2009). Structure superpo-
sitions were completed using the program LSQKAB or the program
coot (Emsley and Cowtan, 2004). Electron density maps were gener-
ated using the programs FFT, MAPMASK and MAPMAN, all part
of the CCP4 package (Collaborative Computational Project, 1994).
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2.17.2 Data analysis and statistics
Statistics and non-linear regression analysis were carried out using
GraphPad-PRISM® 5 software, CA, USA (www.graphpad.com) and
Microsoft Excel® from the Microsoft Office 2004 package (www.office.
microsoft.com).
2.17.3 Image annotation and writting
All images shown in this thesis were annotated using Adobe Illustrator
(Adobe System Inc.). This document was prepared using the LaTeX
typesetting system available at http://www.latex-project.org/. Refer-
encing was done in conjuncion with BibTeX available at http://www.
bibtex.org/.
Chapter III
Structure of the STRADα pseudokinase
complexed to ATP and MO25α
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3 Structure of the STRADα pseudokinase complexed
to ATP and MO25α
3.1 Foreword
In the work described below, mutagenesis studies involving expression
of LKB1, STRADα and MO25α in HEK293 cells, pulldown and LKB1
activity assays were a collaborative effort involving Dr Beatrice Maria
Filippi, University of Dundee, who helped with these experiments.
Details of the experimental work are provided in chapter II Materials
and Methods section of this thesis.
3.2 Aims
At the start of this project no structures of pseudokinases were known.
Thus, the aim of this work was to determine the structure of STRADα
pseudokinase and understand the characteristics, functions and evolu-
tion of this subset of the protein kinase family. Particularly, the aim
was to elucidate how STRADα interacts and cooperates with MO25α
to regulate LKB1 activity. To achieve this, the structure of STRADα
was determined in complex with ATP and MO25α, and structural and
biochemical analyses of these findings are described in this chapter.
3 Structure of STRADα/MO25α complex 116
3.3 Overview of experimental procedures
3.3.1 Expression and purification of STRADα/MO25α complex
STRADα comprises a pseudokinase domain (residues 58-394), two
nuclear export sequences (residues 21–29 and 417–426) (Dorfman and
Macara, 2008) and a C-terminal WEF motif (residues 429–431) previ-
ously shown to interact with MO25α (Boudeau et al., 2003a; Milburn
et al., 2004) (Fig. 3.1A). The STRADα pseudokinase domain (residues
59–431, preceded by a 6-His purification tag) and full length MO25α
(residues 1–341) were cloned in a polycistronic vector (Fig. 3.1B) and
co-expressed in E. coli.
MO25αT7
pOPCH (2.7 kb)
STRADαHis-tag
1 431STRADα pseudokinase domain T329
P
MO25α
T419
P
429-431
(WEF motif)
Sites phosphorylated by LKB1 
1 341
P
59 CFT
A B
394 RBS RBS
Figure 3.1: Domain architecture of STRADα and MO25α
A) Boundaries of the STRADα pseudokinase domain and the C-terminal flanking tail (CFT).
Sequence motifs and phosphorylation sites are labelled. Nuclear export signal sequences
(residues 21–29 and 417–426 (Dorfman and Macara, 2008)) are shown as grids. Sites phospho-
rylated by LKB1 (Baas et al., 2003) are labelled. Coloured regions were used for crystallisation.
B) Architecture of the pOPCH vector (Tan, 2001) used to recombinantly co-express the
STRADA/MO25A genes. RBS = Ribosomal binding site.
The His-STRADα/MO25α complex eluted as a heterodimer of the
expected size from a gel filtration column, yielding approximately 60
mg of the complex from 4 l of culture (Fig. 3.2). During purifi-
cation, a minor low molecular weight eluting shoulder to the main
peak was found to consist of mainly uncomplexed His-STRADα (Fig.
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Figure 3.2: Isolation of the heterodimeric STRADα/MO25α complex
A) Gel filtration profiles of His-STRADα/MO25α co-expressed in E. coli and crystallised in this
thesis. The elution profile of separately expressed MO25α monomer as well as the molecular
mass standards Aldolase (158 kDa), Conalbumin (75 kDa), Ovalbumin (43 kDa) Carbonic
anhydrase (29 kDa) and Ribonuclease A (13.7 kDa) are also shown.
B & C) Fractions in which His-STRADα/MO25α dimer and MO25α monomer eluted, were
analysed by SDS-PAGE and stained with Coomassie blue dye. In the His-STRADα/MO25α
purification, a minor low molecular weight eluting shoulder to the main peak was found to
consist of mainly uncomplexed His-STRADα.
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3.2B). As His-STRADα was the subunit used for nickel affinity pu-
rification of the complex, it will be expected to be present in excess.
There was no evidence for large molecular weight aggregates of His-
STRADα/MO25α (Fig. 3.2A).
3.3.2 Crystallisation and structure solution of STRADα/MO25α complex
Initial crystals of the STRADα/MO25α complex in space group P212121
diffracted only to 4.8 A˚ resolution (Table 3.1 and Fig. 3.3A). With
the help of chemical lysine methylation (Walter et al., 2006), diffrac-
tion of these crystals (retaining the same space group and unit cell
dimensions) improved to 2.35 A˚ (Table 3.1 and Fig. 3.3B).
100 μm60 μm
A B C
His-STRADα 
MO25α
Figure 3.3: Crystals of the STRADα/MO25α complex
Crystals of the native His-STRADα/MO25α complex (A), and methylated His-
STRADα/MO25α complex (B).
C) SDS-PAGE gel (Coomassie stained) of LKB1 complex crystals after three subsequent washes
in mother liquor.
Frommass shift calculations between methylated and non-methylated
complex using MALDI-TOF analysis (Appendix Fig. A.1), 9 out of
14 lysines in STRADα and 21/43 lysines in MO25α appeared to be
di-methylated. The structures of both methylated and unmethylated
3 Structure of STRADα/MO25α complex 119
crystals were solved by molecular replacement and revealed the same
packing/ intermolecular interactions (Table 3.1). The high resolution,
methylated form of the complex was refined to a final model with good
statistics (Rfree/Rwork of 0.254/0.206, Table 3.1).
3.3.3 Crystallisation attempts of the STRADα pseudokinase domain
Initially, STRADα (residues 54-431) was expressed in E. coli as a gene
fused to GST and purified for crystallisation (Fig. 3.4). Despite test-
ing several commercial crystallisation screens and buffer conditions
including addition of ATP and ADP, these trials were unsuccessful.
A second attempt was made when the His-STRADα/MO25α was
successfully expressed and crystallised. The STRADα monomer was
isolated from the STRADα/MO25α preparations by washing away
MO25α with buffer containing high salt concentration, as described
in chapter II section 2.8.5 of this thesis. This was then further pu-
rified by size exclusion chromatography. Crystallisation screens were
set up for STRADα (residues 58–431) with and without the 6-His
purification tag and in the presence and absence of ATP. The same
procedure was repeated with the methylated sample without success
in crystallisation. Notably, STRADα formed heavy precipitates in
approximately 90% of the screening conditions. This could be a con-
sequence of the high protein concentrations (8–10 mg/ml) that are
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Table 3.1: Summary of data collection, structure refinement and analysis. Values for
the highest resolution shell are given in brackets.
Native Methylated
Space Group P212121 P212121
Unit cell (A˚)
a 73.3 73.7
b 83.5 82.9
c 134.3 134.3
Molecules/asu
STRADα 1 1
MO25α 1 1
Resolution (A˚) 20-4.8 (4.97-4.80) 20-2.35 (2.48-2.35)
Observed reflections 13019 190928
Unique reflections 4229 (409) 34668 (4988)
Redundancy 3.0 (3.0) 5.5 (5.6)
I/σI 13.6 (1.9) 13.4 (2.9)
Completeness (%) 98.9 (97.1) 99.6 (99.9)
Rmerge 0.094 (0.487) 0.100 (0.617)
Rwork, Rfree - 0.206, 0.254
RMSD from ideal geometry
bonds (A˚) - 0.011
angles (o) - 1.277
B-factor RMSD (A˚2)
(backbone bonds) - 1.063
Average B-factor (A˚2)
protein - 28.59
ligand (ATP) - 34.46
water - 28.36
Ramachandran plot statistics (%)
Most favoured region - 92.4
Addittional allowed region - 6.7
Generously allowed region - 0.7
Disallowed region - 0.2
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typically used in setting up crystallisation conditions. However, lower
protein concentrations (2 mg/ml) did not improve the crystallisation
of STRADα. It is possible that in the absence of MO25α, STRADα
is unstable and/or prone to forming large molecular aggregates that
disfavour crystallisation. In the absence of a STRADα alone crys-
tal structure, the structure of STRADα determined in complex with
MO25α and ATP is discussed in this chapter.
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Figure 3.4: Purification of the STRADα pseudokinase domain
A) UV absorbance (λ = 280 nm; black line) of a typical STRADα (residues 54-431) purifi-
cation using anion exchange chromatography. The red graph is the measured conductivity
representing the ionic strength gradient used to elute STRADα bound to the anion column.
STRADα eluted at approximately 250 mM NaCl concentration.
B) Fractions in which STRADα eluted were analysed by SDS-PAGE and stained with Coomassie
blue dye.
3.4 Structure of the STRADα pseudokinase
3.4.1 STRADα adopts the canonical kinase fold
In the STRADα/MO25α complex structure, STRADα exhibits the
classical bilobal protein kinase fold, with the N-terminal lobe (residues
59–152) organised around a central β-sheet, and a C-terminal lobe
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(residues 153–394) that is largely α-helical (Fig. 3.5A). Residues 402–
424 were not well defined by electron density and thus were not in-
cluded in the final model. These make up the C-terminal flanking tail
(CFT) that terminates with the WEF motif (Fig. 3.1), for which elec-
tron density is present. A well-resolved molecule of ATP was observed
in the cleft between the small and large lobe of the pseudokinase (Figs.
3.5A and 3.6). The ATP molecule displays the canonical binding mode
and retains a similar conformation to that of ATP molecules bound to
active kinases (RMSD = 0.9 A˚ on all atoms compared to ATP bound
to PKA (Knighton et al., 1991b)).
3.4.2 STRADα adopts an active conformation
Although the activation loop of STRADα (residues 212–245) is not
phosphorylated, it is well ordered, a feature normally observed only
in structures of activated protein kinases that are phosphorylated on
their activation loop (Fig. 3.5A and B). Remarkably, Asp232 in the
activation loop occupies a position similar to the activating phospho-
rylated residue found in active kinases, e.g. (phospho)Ser181 in TAO2
(Fig. 3.7). Asp232 appears to play the same structural role as the acti-
vating phosphate group, coordinating the conserved arginine from the
catalytic HRD motif (Arg194 in the STRADα HRS motif) (Fig. 3.7).
Further evidence that STRADα adopts the canonical active conforma-
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αCATP
N-lobe
C-lobe
Activation
loop
αB
β1
β2
β4
β3
β5
αD
β6
β9
β7 β8
αE
αF αEF
αGαI
αH
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A B
C
Figure 3.5: Overall structure of the STRADα pseudokinase domain
A) Overall structure of STRADα shown in cartoon representation (N-terminal lobe coloured
brown, C-terminal lobe coloured green) with transparent molecular surface. For clarity the
WEF motif has been omitted. Secondary structure elements are labelled according to the
structure of PKA (Knighton et al., 1991b). The activation segment is coloured yellow, with
the section that appears to be unique to STRADα/β (residues 221–229) coloured red. The
ATP molecule is shown in sticks representation with yellow carbons. Dotted lines represent
regions that were not well defined by electron density and are not included in the refined model.
B) Final 2Fo-Fc electron density map (coloured blue and contoured at 1.0σ) for part of the
activation segment of STRADα (residues 216–234). The stick model is coloured as described
in (A).
C) Final 2Fo-Fc electron density map (coloured blue and contoured at 1.0σ) for the αC helix
of STRADα (residues 109–125). An alternative view, looking from the C-terminus of αC is
boxed.
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tion stems from the presence of a short anti-parallel β-sheet between
the β6 and β9-strands, which is a characteristic feature of the active
state of kinases (Fig. 3.5A) (Nolen et al., 2004). Furthermore, the
STRADα αC helix is rotated into the “closed” conformation found in
active kinases (Johnson et al., 1996; Huse and Kuriyan, 2002), with the
conserved ion pair between the Glu118 on the αC-helix and Arg100
in subdomain-II formed via two water molecules (Fig. 3.7).
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Figure 3.6: STRADα ATP coordination
Stereo figure of ATP (modeled as sticks with yellow carbons) and STRADα residues that
contribute to ATP binding (coloured according to Fig. 3.5; N-lobe = brown, C-lobe = green,
activation segment = yellow). Unbiased Fo-Fc electron density map for the ATP molecule is
coloured magenta and contoured at 2.5σ. The same map for a water molecule (represented
as a red sphere and labelled W) is contoured at 2.5σ. Hydrogen bonds are shown as dashed
lines. The distances of hydrogen bonds labelled H1-H4 were measured as: H1 = 2.7 A˚, H2 =
2.5 A˚, H3 = 3.0 A˚ and H4 = 3.7 A˚.
3.4.3 STRADα binds ATP using a Mg2+-independent mechanism
Sequence comparison reveals that STRADα lacks numerous essential
catalytic residues found in active protein kinases, namely a conserved
Gly residue in the glycine rich-loop (subdomain-I), the Lys residue of
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VAIK motif (subdomain-II), the catalytic Asp residue of the HRD mo-
tif (subdomain-VIb), a conserved Asn residue (subdomain-VIb) as well
as the entire DFG motif in subdomain-VII (Fig. 3.8). Despite missing
these key residues, STRADα adopts a similar overall conformation to
that of TAO2, (sharing 25% sequence identity and 37% sequence simi-
larity), an active protein kinase of known structure (Zhou et al., 2004)
(RMSD = 1.4 A˚ on 197 Cα atoms). Comparison of the STRADα and
TAO2 structures reveals that a number of substitutions of key cat-
alytic residues are found in STRADα (Fig. 3.7). Met83 replaces one
of the conserved Gly residues in the glycine rich loop, Arg100 substi-
tutes the catalytic Lys residue in the VAIK motif, Ser195 replaces the
Asp residue in the HRD motif, His200 substitutes for the conserved
Asn in subdomain-VIb and the entire DFG motif is replaced by GLR
(residues 213–215) (Fig. 3.7).
In active protein kinases, the DFG motif plays a pivotal role in coor-
dinating two Mg2+ ions—one that orients the γ-phosphate into the po-
sition required for phosphoryl transfer and the other that controls ATP
conformation by interacting with the β/γ phosphates. Consistent with
the lack of the DFG motif in STRADα, no Mg2+ ions were observed in
the STRADα-ATP complex, despite 1 mM MgCl2 being present in the
crystallization mother liquor. However, despite the absence of Mg2+
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Figure 3.7: STRADα “active” site
Stereo view of superposed STRADα and TAO2 (PDBID 1U5R, (Zhou et al., 2004)) active
sites, highlighting key residues required for activity. STRADα residues (labelled) are shown as
stick models with yellow carbon atoms, whereas the corresponding TAO2 residues are shown
with blue, transparent carbon atoms. Water molecules are represented by red spheres and gray
spheres represent Mg2+ ions from the TAO2 structure. The glycine-rich loop and part of the
activation loop have been omitted for clarity.
Figure 3.8: Comparison of STRADα sequence motifs with active protein kinases
Multiple sequence alignment of STRADα and other pseudokinases, highlighting (in yellow)
key motifs that are normally essential in active eukaryotic protein kinases.
ions, the positioning of the β/γ phosphates in STRADα was simi-
lar to that of active TAO2 kinase complexed to MgATP (Fig. 3.7).
The β-phosphate is tethered through interactions with Arg215 from
the GLR (DFG) motif, and His200 (subdomain-VIb), basic residues
that may substitute for one of the positively charged Mg2+ ions (Fig.
3.6). The second Mg2+ ion and its coordinating residues are also miss-
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ing; instead the γ-phosphate is poorly coordinated and only interacts
(weakly; d = 3.7 A˚) with a conserved lysine (Lys197) in the catalytic
loop and a nearby water molecule (Fig. 3.6). Thus, STRADα appears
to have evolved a novel, Mg2+-independent, mechanism to bind the
phosphate groups of ATP. The presence of the two hydrogen bonds
between N1 and N6 atoms of the ATP adenine ring and the protein
backbone (hinge region, residues 148–150) observed in all active pro-
tein kinase structures, further illustrates the conservation of the ATP
binding pocket (Fig. 3.6). Thus, the STRADα structure explains
previous observations that STRADα can bind ATP in the absence
of Mg2+, and its similar affinity for ADP and ATP (Boudeau et al.,
2004).
3.4.4 Attemtps to detect STRADα activity
Despite STRADα binding ATP in the correct orientation for activ-
ity and folding into an active conformation, STRADα (residues 59–
431) expressed in E. coli did not autophosphorylate or phosphorylate
myelin basic protein (MBP, Fig. 3.9). Attempts to detect activity in
the presence and absence of MO25α and/or 10 mM MgCl2 were un-
successful. Mutations converting all the missing catalytic residues on
the STRADα pseudokinase discussed above, to the equivalent residues
found in the active kinase TAO2 were also generated (Fig. 3.9). How-
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Figure 3.9: Attempts at reactivating the STRADα pseudokinase
The indicated STRADα (residues 59–431) active site mutants (A, B, C & D) and those
combined with mutations/deletions from the p+1 site of the kinase (E, F, G & H) were
expressed in E. coli and tested for kinase activity towards the generic substrate MBP. Panels
A, B, E & F were tested in the presence of 0.2 mM γ-32P-ATP and 10 mM magnesium
acetate, whereas panels C, D, G, and H were tested in the absence of Mg2+ and presence of 2
mM EDTA. Where indicated, wild-type MO25α was included in the assay. In all cases, PKA
assayed in the presence of Mg2+ was included as a positive control. (5X = T98A + R100K
+ G213D + L214F + R215G)
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ever, none of these mutants showed autophosphorylation or phospho-
rylated myelin basic protein in the presence or absence of Mg2+ATP
and/or MO25α (Fig. 3.9). Similarly, mutations in the putative (pro-
tein) substrate binding site of STRADα were generated either sepa-
rately, or in combination with other potential catalytic residue muta-
tions. None of these mutations restored catalytic activity of STRADα
(Fig. 3.9). Recent reports have suggested that some pseudokinases
(e.g CASK) may be inhibited by the presence of Mg2+ ions (Mukher-
jee et al., 2008). Repeating the kinase assays mentioned above in
the absence of MgCl2, did not result in detectable STRADα kinase
activity (Fig. 3.9).
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Figure 3.10: STRADα ATPase assay
Crystallisation grade purified STRADα (residues 59-431) was assayed for the ability to hydrolise
ATP. A range of protein (E) concentrations (0.01-2.5 µM) were tested over 4 h at 20 oC.
Bacterially purified TAO2 was used as control.
In order to test wheather STRADα possessed ATPase activity, a
sensitive ATPase assay kit (Innova Biosciences, UK), was employed.
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However, no activity for STRADα was observed, even at longer time
points (up to 4 hours, Fig. 3.10). Nevertheless, it is impossible to cate-
gorically rule out that STRADα will not, highly specifically, phospho-
rylate an as yet unidentified substrate, or need an additional activatory
factor/modification.
C
B
PFPF motif 
WEF motif 
A
Figure 3.11: Previously described and new intermolecular interactions between
STRADα and MO25α
A & B) Molecular surface of MO25α and comparison of STRADα WEF motif, binding to
the MO25α WEF pocket. WEF motifs from the STRADα/MO25α complex structure and
MO25α/peptide complex determined previously by Milburn et al., (Milburn et al., 2004), are
superimposed and shown as stick models with green and yellow carbon atoms respectively.
Unbiased electron density maps (Fo-Fc are shown for the WEF motif determined in this thesis
and contoured at 2.5σ).
C) The PFPF motif of MO25α that binds to a STRADα hydrophobic pocket (molecular surface
coloured wheat), near the ATP binding site is shown as sticks with gray carbons. Electron
density maps are displayed as described above. Part of the ATP molecule is also shown with
yellow coloured carbons.
3 Structure of STRADα/MO25α complex 131
3.5 Analysis of the STRADα/MO25α complex
3.5.1 Identification of the biological STRADα/MO25α complex
The asymmetric unit of the STRADα/MO25α complex crystals con-
tains one molecule of MO25α, with a conformation similar to the pre-
viously published MO25α/WEF peptide complex structure (Milburn
et al., 2004) (RMSD = 0.6 A˚ on 292 Cα atoms), and one molecule of
STRADα (Table 3.1). The position and conformation of the WEF mo-
tif is similar to that in the previously described MO25α/WEF complex
(Milburn et al., 2004) (RMSD = 0.3 A˚ on 35 atoms and Fig. 3.11A
and B). A second, intermolecular interaction was observed between
residues 2-5 of MO25α (Pro-Phe-Pro-Phe, termed the PFPF motif
here) and a hydrophobic pocket adjacent to the ATP binding groove
of STRADα (Fig. 3.11A and C).
Table 3.2: Summary of buried surface areas in STRADα/MO25α crystal packing and
straight line distances from the last visible STRADα residue to the first visible WEF
motif residue. Entries of the total column do not include the surface area buried by
the WEF motif (1050 A˚2), identical for all five possible complexes.
Buried surface area (A˚2)
Complex Distance (A˚) His-tag PSK domain Total
A 49.6 720 2250 2970
B 82.5 0 1450 1450
C 72.4 0 420 420
D 56.0 1170 380 1550
E 31.4 0 50 50
PSK domain = pseudokinase domain
Due to tight crystal contacts (total buried surface on MO25α by
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STRADα and its symmetry mates = 3550 A˚2) it was not immedi-
ately apparent which contacts represented biologically relevant inter-
actions and which were crystallographic packing artefacts. While clear
electron density is present for the last six amino acids of STRADα
(residues 425–431, including theWEFmotif that interacts with MO25α,
Fig. 3.11B), residues 402-424 of STRADα were not visible in the elec-
tron density maps, and it was thus not possible to directly identify the
appropriate symmetry mates of STRADα and MO25α that make up
the biologically relevant binary complex. Analysis of the crystal con-
tacts between symmetry related molecules suggested that there were
five possible ways in which STRADα could interact with MO25α (Fig.
3.12). The five possible STRADα/MO25α complexes were studied
and these were ranked in terms of total buried surface area, a possi-
ble method for distinguishing crystallographic from biological contacts
(Nooren and Thornton, 2003). Discounting the WEF motif interaction
(1050 A˚2 buried surface area), identical in all five possible complexes,
the buried surface area in each of the possible complexes is 2970 A˚2,
1450 A˚2, 420 A˚2, 1150 A˚2 and 50 for complexes A, B, C, D and E
respectively (Table 3.2 and Fig. 3.13). In addition, the distances be-
tween the last well-defined residue of the STRADα C-terminal lobe
and the first well-defined residue of the WEF motif at the extreme C-
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terminus of STRADα were measured for the five possible complexes.
This yielded direct distances of 50, 82, 72, 56 and 31 A˚ for complexes
A, B, C, D and E respectively (Table 3.2 and Fig. 3.12). Taken
together, it appears that complex A (Fig. ??A) is the most likely
biological interaction, since STRADα binds to the (highly conserved)
concave surface of MO25α and has the largest buried surface area,
while also possessing a distance connectable by the missing residues
(23 amino acids) from the C-terminal lobe to the WEF motif (Table
3.2 and Fig. 3.12). Similarly, analysis of the possible complexes with
PISA (Krissinel and Henrick, 2007) yields the highest (1.0) Complex-
ation Significance Score (CSS) for complex A, while predicting that
complexes B, C, D and E will not be stable in solution.
The 6-His purification tag that extends from the N-terminus of
STRADα (720 A˚2 and 1170 A˚2 buried surface area in complex A and D
respectively) forms additional contacts between MO25α and STRADα
(Table 3.2 and Figs. 3.12 and 3.13D). Surface plasmon resonance
(SPR) studies demonstrate that His-tagged STRADα binds MO25α
in vitro with the same affinity as STRADα lacking the His tag (Fig.
A.2 and Table 3.3). Furthermore, MO25α residues 2-5 (PFPF motif)
make hydrophobic contacts in a pocket of a symmetry related copy
of STRADα (Figs. 3.11C and 3.13B). This is unlikely to constitute
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E
Figure 3.12: Crystallographic contacts and possible STRADα/MO25α interactions
Cartoon representations of MO25α (blue) and symmetry related STRADα molecules. The
STRADα WEF motif bound to MO25α is shown as sticks with green carbons. Dashed lines
represent the distance from the last residue of the C-terminal lobe of each STRADα molecule
able to donate the WEF motif, corresponding to 50, 82, 72, 56 and 31 A˚ (straight-line dis-
tances) for molecules A, B, C, D and E respectively. An additional tight crystallographic
contact, through the MO25α N-terminus (“PFPF motif”) is also indicated and further dis-
cussed in section 3.5.1.
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Figure 3.13: Possible STRADα/MO25α complexes
The molecular surface of MO25α is shown and coloured by sequence conservation (dark blue
= conserved, white = not conserved; multiple sequence alignment provided in Fig. 3.20).
The WEF motif bound to MO25α is shown as sticks with green carbons. The five possi-
ble STRADα/MO25α interactions are shown (A-E), with STRADα represented as different
coloured cartoons. Direct distances from the last residue of the C-terminal lobe of each
STRADα molecule able to donate the WEF motif are represented by a line and labelled.
Distances and buried surface areas for each possible complex are sumarised in Table 3.2.
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Figure 3.14: The PFPF motif is not required for MO25α interaction with STRADα or
LKB1
A) The indicated constructs of GST-STRADα and untagged MO25α were expressed in 293
cells. Cells were lysed 36 h post-transfection and GST-STRADα was affinity purified on
glutathione-Sepharose. The purified GST-STRADα preparation (upper panels) as well as the
cell extracts (lower panel), were immunoblotted with the indicated antibodies. STRADα
R227A mutant unable to bind MO25α was used as a control (this is discussed in detail in
sections 3.5.2 and 3.5.3)
B) Wild type GST-LKB1 and indicated forms of Flag-STRADα and untagged MO25α were
co-transfected in 293 cells. Cells 36 h post-transfection were lysed and GST-LKB1 was affinity
purified on glutathione-Sepharose. The purified GST-LKB1 preparations (upper panels) as well
as the cell extracts (lower panel) were immunoblotted with the indicated antibodies.
C & D) 0.5 or 1.0 mg of 293 cell lysates were incubated with 5 µg of the indicated biotinylated
peptides conjugated to Streptavidin-Sepharose. Following isolation and washing of the beads,
the samples were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted with
the indicated antibodies to detect endogenous STRADα and MO25α.
(Experiment was carried out by Dr Je´roˆme Boudeau)
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Figure 3.15: Deletion of the MO25α PFPF motif does not impair LKB1 activity
Activation of the bacterially expressed AMPK complex using wild type or mutant (∆PFPF)
LKB1/STRADα/MO25α complex. The purity of LKB1 complexes was analysed by SDS-PAGE
and colloidal blue-staining.
a physiological STRADα/MO25α interaction, as deleting this motif
did not impair the in vivo interaction of MO25α with either STRADα
alone or a complex of STRADα and LKB1 (Fig. 3.14A and B). More-
over, it was not possible to affinity purify STRADα or LKB1 from a
cell extract employing a PFPF motif containing biotinylated peptide
(Fig. 3.14C and D). A complex of LKB1/STRADα/MO25α(∆PFPF)
still activated the heterotrimeric AMPK complex expressed in E. coli
with similar efficiency as wild type LKB1/STRADα/MO25α (Fig.
3 Structure of STRADα/MO25α complex 138
A B
α1
β2
γ1
STRADα
MO25α
STRADα
(symmetry mate)
α1
α1β2γ1
(symmetry  mate)
Pro2
Phe3
Pro4
Phe5
D
Met193
Tyr194
Ala195
Tyr196
C
Figure 3.16: Similarities between crystallographic contacts of the AMPK subunits and
the STRADα/MO25α comlpex
A) Structure of the AMPK core complex (α1/β2/γ1 subunits) determined by Xiao et al.
(2007) is shown as cartoon model. The molecular surface of a symmetry related α1/β2/γ1
comlpex is also shown and coloured green. Part of the interchanging loop from the β2 subunit
is boxed.
B) STRADα/MO25α complex (cartoon model) and a symetry related STRADα is shown with
the molecular surface coloured green. The PFPF motif is boxed.
3.15). Nevertheless, it is possible that the PFPF docking site on
STRADα does play a role in enabling STRADα to interact with other
regulators or substrates of the LKB1 complex. Intriguingly, a similar
crystallographic interaction can be observed in the structure of the
mammalian AMPK heterotrimeric complex (Fig. 3.16, (Xiao et al.,
2007)). In this case, a similar hydrophobic N-terminal motif “MYAF”
from the β2 domain interacts with the kinase domain from the neigh-
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bouring molecule in the crystal lattice, albeit not near the phospho-
nucleotide binding site.
3.5.2 STRADα interacts with the MO25α concave surface
MO25α is composed of seven structurally similar α-helical repeats
(named R0-R6) that form a horseshoe-shaped molecule with a concave
and convex surface (Milburn et al., 2004). MO25α helical repeats R1-
R6 consist of three α-helices (H1-H3) each, while repeat R0 consists of
only two helices (Milburn et al., 2004). Helices H3 from repeat R1-R5
are arranged in an almost parallel fashion and make up the concave
surface of MO25α (Fig. 3.17). Other helical repeat adaptor proteins,
such as PUM1, β-catenin and importin-α, make use of a similar con-
cave surface to interact with macromolecular partners (Wang et al.,
2001; Graham et al., 2000; Conti and Kuriyan, 2000). Strikingly, the
crystal structure of the STRADα/MO25α complex reveals that, in ad-
dition to the interaction through the WEF motif, a major additional
binding interface involves the STRADα N-terminal kinase lobe and
the MO25α concave surface (Figs. 3.17 and 3.18). Part of the interac-
tion surface on STRADα is N-terminal to the αC helix and comprises
the loop between the αB/αC helices (residues 104-109), termed the
“αB site” here (Figs. 3.17B and 3.18A). This region forms an exten-
sive hydrogen-bonding network centered on Arg227 from the R5-H3 of
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Figure 3.17: STRADα binds to MO25α concave surface of MO25α
A) Stereo view of the structure of complex A where STRADα and MO25α are coloured green
and blue respectively. ATP bound to STRADα is shown as sticks with magenta carbons. The
STRADα activaton segment is coloured red and the regulatory αC helix is boxed.
B) Stereo view of the main STRADα/MO25α interactions centered around helix αC. Residues
that make direct contact are shown as sticks, with hydrogen bonds shown as dotted black
lines.
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MO25α (Fig. 3.17B), burying a total of 245 A˚2 surface area. Residues
Tyr223, Arg227, Lys231 and Asn269 of MO25α engage the side chains
of residues Glu105 and Asn109 of STRADα, while Leu104, Ala106,
Cys107 and Ser108 contribute to the interaction via their backbone
atoms (Fig. 3.17B).
The αC helix of STRADα runs along the concave surface of MO25α
facing the H3 helixes of the MO25α repeats R4, R3 and R2 (Figs.
3.17 and 3.18A, termed the “αC site” here). Tethered by hydrophobic
and hydrogen bonding interactions Fig. 3.17B, the αC helix forms
the major interaction surface, contributing a total of 405 A˚2 buried
surface area on the MO25α concave surface.
C-terminal to the αC helix, a second hydrogen-bonding network with
comparable buried surface area (270 A˚2) to the “αB site” is present,
and involves residues Leu124, Asn126 and Tyr185 from the STRADα
helix αE (Figs. 3.17B and 3.18A, termed the “αE site” here). This
region interacts with Glu93, Lys96 and Phe92 from the R1-H3 helix
of MO25α (Fig. 3.17B). Together, the “αB site” and the “αE site”
appear to act as anchor regions, positioning the αC helix to run along
the H3 helices of R1-R5 of MO25α.
Additional interactions are found between Phe178 of MO25α, form-
ing hydrophobic stacking interactions with residues from the N-terminal
3 Structure of STRADα/MO25α complex 142
R0
R1
R2
R3
R4
R5
R6
WEF motif
N-lobe
C-lobe
0 1
sequence conservation 
A
b
STRADα
MO25αSTRADα/MO25α
WEF motif
C-lobe
β4
β5
Activation
 loop
αE
αC (C-ter)
αBαC (N-ter)
αC
β4-β5
site
WEF pocket
αB site
αC site
Activation 
loop site
αE site
N-lobe
Activation
loop
+90º-90º
B
Putative LKB1
binding groove
R240 site
R240
R240
R240
Figure 3.18: Sites of the STRADα/MO25α interaction and sequence conservation
A) STRADα/MO25α complex and the interaction surface, as defined with the program CON-
TACT from the CCP4 package (Collaborative Computational Project, 1994). Surfaces of atom
pairs closer than 3.9 A˚ are coloured red. The MO25α surface is coloured grey and the N-and
C-lobes of STRADα are coloured brown and lime green, respectively. Arg240 is shown as
sticks. To aid visualization, on the right side of the figure, the complex is “opened up” by
rotating the STRADα molecule about the vertical axes -90o and MO25α +90o with respect
to the binary complex.
B) Sequence conservation (dark blue = conserved, white = not conserved) of STRADα and
MO25α from C. elegans to H. sapiens (sequence alignments provided in Figs. 3.19 and 3.20).
The putative LKB1 binding pocket and the Arg240 site are indicated with an arrow. STRADα
and MO25α are shown in the same orientation as in panel (A) to aid visualization of conserved
areas that are buried in the STRADα/MO25α complex.
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Figure 3.19: STRADα multiple sequence alignement, secondary structure and residues
contributing to the interactions with MO25α
Multiple sequence alignment (dark blue = conserved, white = not conserved) of STRADα from
the indicated species of the metazoan kingdom. Alignments were performed with MUSCLE
(Edgar, 2004) and edited and displayed using ALINE (Bond and Schu¨ttelkopf, 2009). A graph
of residues involved in STRADα/MO25α interaction against their contact area (green bars), is
displayed. Height of the bar represents the contact area (atom pairs closer than 3.9 A˚, analysed
by CONTACT from the CCP4 package (Collaborative Computational Project, 1994)), divided
by the total surface area of the participating amino acid. Key STRADα catalytic motifs and
the WEF motif are boxed. The secondary structure (analysed by DSSP (Kabsch and Sander,
1983)) is shown in red. Dotted lines represent residues missing in the structural model. The
same colouring graph has been applied to the molecular surfaces shown in Fig. 3.18
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Figure 3.20: MO25α multiple sequence alignement, secondary structure and residues
contributing to the interactions with STRADα
Multiple sequence alignment (dark blue = conserved, white = not conserved) of MO25α from
the indicated species of the metazoan kingdom. Alignments were performed with MUSCLE
(Edgar, 2004) and edited and displayed using ALINE (Bond and Schu¨ttelkopf, 2009). A graph
of residues involved in STRADα/MO25α interaction against their contact area (green bars), is
displayed. Height of the bar represents the contact area (atom pairs closer than 3.9 A˚, analysed
by CONTACT from the CCP4 package (Collaborative Computational Project, 1994)), divided
by the total surface area of the participating amino acid. Key STRADα catalytic motifs and
the WEF motif are boxed. The secondary structure (analysed by DSSP (Kabsch and Sander,
1983)) is shown in red. Dotted lines represent residues missing in the structural model. The
same colouring graph has been applied to the molecular surfaces shown in Fig. 3.18
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β4 and β5 strands of STRADα (termed the “β4/β5 site” here, Figs.
3.17B and 3.18A). STRADα and STRADβ also possess an insertion
of ten residues (221-229) in the activation loop that is not observed in
the closely related TAO2 or other STE20 kinases (Fig. 1A). Within
this insertion, His223, Gly224, and Arg226 show weak interactions
with the R0 and R1 helical repeat of MO25α (termed the “activa-
tion loop site” here, (Fig. 3.18A). This interaction perhaps explains
why the STRADα activation-loop is ordered, although a large part
of the activation segment, including the p+1 loop is solvent exposed
(Fig. 3.17A). All of the key STRADα/MO25α interacting residues are
highly conserved between species (Figs. 3.18, 3.19 and 3.20).
3.5.3 The MO25α concave surface is required for STRADα binding
The structure of the STRADα/MO25α complex reveals that in ad-
dition to the WEF binding pocket on the convex surface of MO25α,
a major interaction network between STRADα and the concave sur-
face of MO25α exists. This involves the αB, αC, αE, β4/β5 and
activation loop sites. To test the importance of these additional inter-
actions, mutations of key interacting residues located on the MO25α
concave surface were tested for their ability to interact with STRADα.
MO25α residues present in the novel αB, αC, αE, β4/β5, and acti-
vation loop binding sites as well as the previously characterised WEF
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Figure 3.21: Mutation of MO25α concave surface residues abolishes STRADα binding
Mutant forms of STRADα (A) and MO25α (B) were tested for their ability to form cellular
complexes in a GST pulldown assay. Indicated constructs of GST-STRADα and Myc-MO25α
were expressed in 293 cells. Cells 36 h after transfection were lysed and GST-STRADα was
purified with glutathione-Sepharose. The purified GST-STRADα preparation (upper panels)
as well as the cell extracts (lower panel) were immunoblotted with the indicated antibodies.
Similar results were obtained in 3 separate experiments. Dotted line indicates the junction of
two gels; AL = activation loop.
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pocket were mutated (Fig. 3.21). As reported previously, mutation of
Met260 in the WEF pocket of MO25α abolishes its ability to interact
with STRADα in HEK293 cells (Milburn et al., 2004). However, it was
also observed that mutations in the two anchor regions (Phe92, Glu93,
Lys96 from the αE site and Tyr223, Arg227 from the αB site) abol-
ished MO25α binding to STRADα (Fig. 3.21A). Similarly, mutating
Phe178 in the β4/β5 site, Ile145 and Ser182 in the αC site or Arg107
in the activation loop site, markedly disrupted the MO25α-STRADα
interaction. Mutations of Leu141, Lys231 and Asn269 in the αC site
did not significantly affect binding (Fig. 3.21A). Mutation of the re-
ciprocal interacting residues on STRADα, including Glu105, Asn109,
Asn126, Ile138 and Tyr185, also abolished or markedly reduced bind-
ing to MO25α (Fig. 3.21B). These results confirm the importance of
the network of interactions between the concave surface of MO25α
and STRADα in enabling the stable association between these two
proteins, at least in the absence of LKB1.
Previous work has shown that MO25α mutants where the WEF
pocket was disrupted and that were no longer able to form a com-
plex with STRADα, were still capable of forming a heterotrimeric
complex with LKB1 and STRADα (Boudeau et al., 2003a, 2004).
Similarly, MO25α mutants in which key STRADα binding residues
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Figure 3.22: Mutation of MO25α residues abolishes LKB1/STRADα binding
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells 36 h after transfection were lysed and GST-LKB1 was purified and assayed
for its ability to phosphorylate the LKBtide peptide. Kinase activities are representative of three
independent assays carried out in triplicate (error bars represent the SD for 1 experiment).
Affinity purified GST-LKB1 preparation (upper panel) as well as cell extracts (lower panel)
were immunoblotted with the indicated antibodies.
located within the concave surface were mutated are still capable of
interacting with the LKB1/STRADα complex (Fig. 3.22A). Even
double MO25α mutants in which both the WEF pockets and the αB,
αE, or β4/β5 sites were disrupted were capable of associating with
the LKB1/STRADα complex (Fig. 3.22A). Moreover, the specific
activity of LKB1/STRADα complexes associated with these MO25α
mutants was either normal or only moderately reduced (Fig. 3.22A).
This suggests the presence of additional interactions between MO25α
and LKB1 in the presence of STRADα.
Earlier studies revealed that mutation of a conserved Arg240 residue
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located on the concave surface of MO25α reduced interaction with
LKB1 complexed to STRADα lacking the WEF motif (Boudeau et al.,
2004). Arg240 might be involved in interaction with LKB1, as this
residue is located on the concave surface of MO25α, distant from
STRADα (Fig. 3.18). To further investigate the role of Arg240
in enabling MO25α to associate with LKB1/STRADα, Arg240 was
mutated alone or in combination with residues in either the WEF
pocket (Met260) or the αB STRADα binding sites (Arg227). Mu-
tation of Arg240 alone does not prevent MO25α from interacting
with LKB1/STRADα (Fig. 3.22B). However, a double MO25α mu-
tant lacking Arg240 and a key concave surface-binding site in the αB
site (Arg227), markedly impaired binding to LKB1/STRADα (Fig.
3.22B). A triple mutant of MO25α lacking Arg240, Arg227 and the
WEF pocket sites, failed to associate with LKB1/STRADα and stim-
ulate LKB1 activity (Fig. 3.22B). These observations indicate that
MO25α possesses three sites with which it can interact with the LKB1/
STRADα complex (Fig. 3.18), namely two STRADα binding regions
(extensive concave MO25α surface and WEF pocket) as well as a pu-
tative LKB1 binding site (Arg240).
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3.5.4 The STRADα/MO25α interaction is similar to the CDK/cyclin complex
Inspection of the STRADα/MO25α complex reveals an unexpected
resemblance to the interaction between activated cyclin-dependent ki-
nase 2 (CDK2) and its activating regulatory subunit Cyclin A (Fig.
3.23) (Jeffrey et al., 1995). Although MO25α/β isoforms are not
related to cyclins at the primary sequence level, both proteins con-
sist of multiple α-helical repeats. Crystal structures of CDK2/Cyclin
A complex have revealed cyclin A binds to the so-called “PSTAIRE
(αC) helix” of CDK2 kinase as well as the loop immediately preced-
ing this helix (Jeffrey et al., 1995). Comparisons between free CDK2
and CDK2/cyclin A complex structures have shown that the cyclin
molecule orients a conserved glutamate residue (Glu51) from the αC
helix of the protein kinase to allow formation of an ion pair with a
lysine residue (Lys33) from the conserved VAIK motif (Jeffrey et al.,
1995), that keeps the CDK2 kinase in a closed conformation (Fig.
3.23B). Similarly, the position of MO25α in the STRADα/MO25α
complex is centered on helix αC and the loop preceding this helix (αB
region; Fig. 3.17B). The interaction between Glu118 from the αC he-
lix and Arg100 from the VAIK (VTVR in STRADα) motif (analogous
to the Glu51-Lys33 interaction in CDK2) is maintained, albeit via two
water molecules (Fig. 3.7).
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Figure 3.23: Structural comparison of the STRADα/MO25α interaction
Resemblance of (A) STRADα/MO25α complex with (B) the CDK2/cyclin A complex (PDBID
1FIN) and (C) the EGFR/EGFR kinase domain dimer (PDBID 2GS2). The kinases are shown
as green ribbons, with the binding partners shown as blue ribbons. The αC helix, where binding
of the “activator” is centered is labelled.
D & E) Comparison of the STRADα structure (green) to the active and inactive structures of
CDK2 and EGFR (gray). Residues from the C-lobe of STRADα (152-431) were superimposed
onto the structures of inactive CDK2 (PDBID 1HCK (Schulze-Gahmen et al., 1996)) and
EGFR kinase (PDBID 2GS7), and active CDK2 (PDBID 1JST) and EGFR (PDBID 2GS2).
The activation loop of STRADα has been coloured yellow and the activation loops of CDK2
and EGFR kinases are shown in magenta.
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Another example where this type of interaction is involved in regu-
lating the activity of protein kinases is the ligand-induced dimerisation
of the EGFR family of tyrosine kinases (Fig. 3.23C). Crystal struc-
tures of EGFR kinase domain and biochemical data demonstrate the
importance of a dimer formation that involves the intermolecular in-
teraction of the EGFR αC helix on one monomer and the C-lobe on
the other monomer (Fig. 3.23C) (Zhang et al., 2006b). A compar-
ison between the structure of active, dimeric EGFR kinase with the
monomeric form reveals the role of dimerisation for keeping the EGFR
kinase in the closed and active conformation. Similarly, the structure
of STRADα in complex with MO25α resembles the closed conforma-
tion of both CDK2 and EGFR kinase, with its activation loop and
αC helix positioned in an orientation that is typical of active protein
kinases (Fig. 3.23D and E). Such regulatory mechanism may also ex-
plain why some members of the EGFR family of kinases that lack
kinase activity and are classified as pseudokinases (Her3) are still able
to exert their function (Zhang et al., 2006b), despite their “inactiva-
tory” substitutions, similar to what has been observed for STRADα
(Fig. 3.8).
The interactions in the EGFR homodimer, the CDK2/cyclin A het-
erodimer and the STRADα/MO25α complex are similar only in gen-
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B
C D
A
E K d T NP − ATP (µM) K d ATP (µM) K d ADP (µM)
No Mg2+ 0.5 mM Mg2+ No Mg2+ 0.5 mM Mg2+ No Mg2+ 0.5 mM Mg2+
STRADα 1.1 ± 0.2 1.3 ± 0.8 2.4 ± 0.4 3.0 ± 1.4 2.9 ± 0.5 4.1 ± 1.6
STRADα /MO25α 0.09 ± 0.03 0.23 ± 0.09 0.02 ± 0.002 0.07 ± 0.010 0.03 ± 0.004 0.07 ± 0.01
Figure 3.24: MO25α enhances the ability of STRADα to bind ATP and ADP in a
Mg2+ independent manner
A) Fluorescence emission spectra (excitation 410 nm) of TNP-ATP (5 µM) bound to the
indicated forms of STRADα (2 µM) and/or MO25α (2 µM). A reference cuvette containing
TNP-ATP (5 µM) only was subtracted as background.
B) Saturation binding experiments for STRADα, STRADα complexed to MO25α (WT, wild
type) and MO25α (R227A/M260A) to TNP-ATP. Bound was defined as (Fx/Fmax)[R], where
(Fmax and Fx are maximal and fractional fluorescence (recorded at 540 nm) respectively and [R]
equals the binding capacity, defined by the enzyme concentration, fixed at 1.5 µM. Equilibrium
binding curves were then fitted to the quadratic equation suitable for tight binding interactions
with ligand depletion (Copeland, 2000, p.92) (see chapter II, section 2.12.2). Data is shown
as an average from 3 independent experiments ± SEM.
C & D) Displacement of TNP-ATP by ATP and ADP in the presence and absence of 0.5
mM MgCl2. Concentrations of TNP-ATP (5 µM), STRADα (2 µM) and STRADα/MO25α
(2 µM) complex were fixed and either ATP or ADP was titrated (0.05-500 µM). Emission
at 540 nm was recorded and the fractional occupancy (Fx/Fmax) was plotted as a function
of added nucleotide concentration. Dose response curves were fitted using GraphPad-PRISM
(See chapter II, section 2.12.2). Data are shown as an average from 3 independent experiments
± SEM.
E) Equilibrium binding constants for TNP-ATP, ATP and ADP in the presence and absence
of 0.5 mM MgCl2. Kd values were calculated as explained in chapter II, section 2.12.2.
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eral topological terms. However, it appears that the mechanism of
protein kinase interaction via helix αC with their activity modulators
is wider than previously thought, and not exclusive to the CDK fam-
ily of kinases. Indeed, there are now many examples of how protein
kinases are stabilised in an active conformation via helix αC. These
include members of the MAP kinase family (White et al., 2007), the
AGC family of kinases (Kannan et al., 2007b; Gold et al., 2006; Tay-
lor et al., 2004) and several tyrosine kinases (Filippakopoulos et al.,
2008)). While in these examples the αC helix is stabilised by flanking
N- or C-terminal sequences/domains present in the same polypeptide
chain, the mechanisms of allosteric activation are similar.
3.6 The role of ATP and MO25α binding to STRADα
3.6.1 STRADα ATP binding is markedly enhanced by MO25α
Although MO25α appears to induce a STRADα active conformation
similar to CDK2/cyclin A, the effect of this “active conformation”
cannot be measured through ATPase/kinase activity due to STRADα
being a pseudokinase. Instead, the affinity of ATP for STRADα was
measured and how this was modulated by STRADα interaction with
MO25α was monitored. The fluorescent ATP analogue 2’,3’-O-2,4,6-
trinitrophenyl-ATP (TNP-ATP) was used, since TNP-ATP fluores-
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cence emission is enhanced upon its titration with ATP-binding pro-
teins/enzymes (Hiratsuka, 1982). This feature has previously been ex-
ploited to measure equilibrium binding constants of kinases for ATP
(Mukherjee et al., 2008). Using this approach, the Kd of STRADα
for TNP-ATP in the absence of MO25α was determined to be 1.1
µM (Fig. 3.24A, B and E). Kd values of STRADα for ATP and
ADP were also assessed by their ability to displace bound TNP-ATP
and found to be 2-3 µM (Fig. 3.24C, D and E). Strikingly, addition
of an equimolar amount of MO25α to STRADα enhanced binding
of TNP-ATP by an order of magnitude (Fig. 3.24A, B and E) and
TNP-ATP displacement by two orders of magnitude (Fig. 3.24C, D
and E) indicating significantly stronger affinity compared to the in-
teraction of ATP as a substrate to active kinases. In contrast, the
binding of STRADα to TNP-ATP was not enhanced by addition of
the MO25α(R227A/M260A) mutant that is unable to bind STRADα
(Fig. 3.24A and B). The lack of a Mg2+ binding motif on STRADα
suggests that Mg2+ should not contribute to the STRADα-ATP inter-
action. Indeed, Mg2+ did not affect binding of STRADα to TNP-ATP
or displacement of TNP-ATP by ATP or ADP (Fig. 3.24C, D, E). This
contrasts to the CASK “pseudokinase” where Mg2+ reportedly inhibits
ATP binding and hence kinase activity (Mukherjee et al., 2008).
3 Structure of STRADα/MO25α complex 156
It should be noted that although STRADα does not appear to re-
quire Mg2+ for binding ATP, most cellular ATP is complexed to Mg2+
ions. Although there is no space for Mg2+ to bind in the canonical
protein kinase mode through the DFG motif, Mg2+ ions could reside
in the solvent exposed region of the phosphate moiety. A candidate
water molecule coordinated by negative charges of β/γ phosphates of
ATP and a nearby hydroxyl group (Ser199), that could be replaced
by Mg2+ ions is shown in Fig. 3.6. Alternatively, it is possible that
conformational changes in the structure could accommodate Mg2+,
without affecting the ability of STRADα to bind MO25α (see section
below). As mentioned previously (section 3.4.3, the canonical Mg2+
coordinating residues appear to have been substituted through evolu-
tion with positively charged residues (Arg215 and H200), thus making
redundant the role of Mg2+ ions.
3.6.2 ATP stimulates binding of STRADα to MO25α
To further investigate the functional consequences of ATP binding to
STRADα, quantitative Surface Plasmon Resonance (SPR) measure-
ments were employed. The focus of these measurements was how ATP
influenced affinity of STRADα for MO25α. In the absence of ATP,
the binding of STRADα for MO25α was fitted to a single site binding
equation (Fig. 3.25). From measuring the rate constants for asso-
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ciation and dissociation (Table 3.3 and Fig. A.3), the dissociation
constant (Kd) was calculated as 3.8 µM (Fig. 3.25 and Table 3.3).
However, in the presence of ATP, binding could be fitted to a two site
binding equation (Hill slope of 0.4, Fig. 3.25A and Table 3.3). The
second binding constant (Kd2) was measured as 12 nM, over 2 orders
of magnitude higher than Kd1 calculated as 2.5 µM (Fig. 3.25A and
Table 3.3). MgATP enhanced binding of STRADα to MO25α, to a
similar extent as ATP (Fig. 3.25A). These results indicate that bind-
ing of ATP to STRADα leads to a high affinity MO25α interaction
site being exposed. Mutation of Met260 in the WEF binding pocket
of MO25α did not significantly affect binding of MO25α to STRADα,
nor did it influence the effect of ATP at enhancing interaction (Fig.
3.25B and Table 3.3). It should be noted that this observation con-
trasts with the data obtained from co-expression studies in 293 cells
(Fig. 3.21A) and previous studies (Milburn et al., 2004), where muta-
tion of Met260 inhibits MO25α binding to STRADα, suggesting that
the WEF pocket is required for cellular complex assembly of MO25α
and STRADα. Mutation of Arg227, in the newly identified concave
site of MO25α, which interacts with the αB site of STRADα, virtu-
ally abolished binding of STRADα observed by SPR in the absence of
ATP (Fig. 3.25C and Table 3.3). In the presence of ATP or MgATP,
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no two-site binding of MO25α(R227A) to STRADα was detected, dis-
playing only low micromolar binding to a single site (Fig. 3.25C and
Table 3.3). A double MO25α(R227A/M260A) mutant failed to in-
teract with STRADα even in the presence of ATP (Fig. 3.25D and
Table 3.3). These results indicate that the key STRADα high-affinity
binding site on MO25α lies on the concave surface and is only recog-
nized by STRADα in the presence of ATP. Together with the finding
that MO25α also enhances affinity of STRADα for ATP (Fig. 3.24),
this suggests that the interaction of ATP and MO25α to STRADα is
cooperative. A similar synergistic mechanism is observed for the PKA
catalytic subunit where a nucleotide analogue was shown to stablise
a complex with the PKI inhibitory peptide (Lew et al., 1997). How-
ever, in the case of PKA/PKI interaction the γ-phosphate can not be
transferred because there is no acceptor, whereas in case of STRADα
it can not be transferred because of the lack of a base catalyst.
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Figure 3.25: ATP enhances the ability of STRADα to bind MO25α in a Mg2+-
independent manner.
Binding of STRADα to MO25α was assessed in an SPR BIAcore assay by immobilis-
ing (A) MO25α (WT, wild type), (B) MO25α(M260A), (C) MO25α(R227A) and (D)
MO25α(R227A/M260A) to a CM5 sensor chip and STRADα was allowed to bind over 50
s by injecting different concentrations over a range of 0.4 nM to 5 µM in the presence or ab-
sence of 0.1 mM ATP and/or 1 mM MgCl2. Response levels for specific binding of STRADα
to MO25α were plotted against STRADα concentration (log scale), using, where appropriate,
a variable slope model to determine the Hill slope from the data. Boxed are representative
BIAcore sensograms recorded in duplicate and corresponding to the highest concentration for
each of the labelled STRADα curves. A complete set of primary sensograms are provided in
Fig. A.3. Similar results were obtained in at least two separate experiments.
Table 3.3: STRADα interaction rate constants for wild-type MO25α and MO25α mutants (error values are in brackets). Binding constants (Kd)
were calcualted as Kd = kd/ka and are given in the last two columns
Analyte and condition ka1 (M−1s−1) kd1 (s−1) ka2 (M−1s−1) kd2 (s−1) ± Kd1 (µM) ± Kd2 (µM)
Target: MO25α (WT) ± ±
STRADα 1.7 × 105 (7.0 × 102) 0.63 (3.0 × 10−3) ND ND ± 3.8 ± 0.08 ± ND
STRADα + ATP 1.6 × 105 (5.8 × 102) 0.40 (1.3 × 10−3) 2.5 × 106 (1.1 × 104) 0.03 (0.8 × 10−4)± 2.5 ± 0.01 ±0.012 ± 0.0001
STRADα + ATP + Mg2+ 8.3 × 104 (3.5 × 102) 0.43 (1.4 × 10−3) 7.9 × 105 (2.9 × 103) 0.04 (8.8 × 10−5)± 5.1 ± 0.02 ±0.051 ± 0.0002
His-STRADα + ATP + Mg2+ 1.9 × 105 (1.4 × 103) 0.55 (3.8 × 10−3) 1.1 × 106 (9.9 × 103) 0.08 (4.8 × 10−4)± 2.9 ± 0.03 ±0.070 ± 0.0008
Target: MO25α (M260A) ± ±
STRADα 1.1 × 105 (4.0 × 102) 0.92 (3.0 × 10−3) ND ND ± 8.1 ± 0.02 ± ND
STRADα + ATP 3.5 × 105 (1.9 × 103) 0.52 (2.9 × 10−3) 2.0 × 106 (1.2 × 104) 0.06 (2.2 × 10−4)± 1.5 ± 0.01 ±0.030 ± 0.0002
STRADα + ATP + Mg2+ 1.9 × 105 (7.0 × 102) 0.43 (1.7 × 10−3) 6.1 × 105 (3.8 × 103) 0.05 (2.3 × 10−4)± 2.3 ± 0.01 ±0.082 ± 0.0006
His-STRADα + ATP + Mg2+ 3.3 × 105 (2.4 × 103) 0.77 (4.6 × 10−3) 5.0 × 105 (3.6 × 103) 0.11 (5.3 × 10−4)± 2.3 ± 0.02 ±0.220 ± 0.0019
Target: MO25α (R227A) ± ±
STRADα ND ND ND ND ± ND ± ND
STRADα + ATP 1.1 × 106 (2.0 × 103) 0.66 (1.0 × 10−3) ND ND ±0.6 ± 0.003± ND
STRADα + ATP + Mg2+ 9.1 × 105 (2.0 × 103) 0.72 (2.0 × 10−3) ND ND ±0.8 ± 0.005± ND
His-STRADα + ATP + Mg2+ 7.0 × 105 (3.0 × 103) 1.61 (7.0 × 10−3) ND ND ±1.5 ± 0.030± ND
Target: MO25α (R227A/M260A) ± ±
STRADα ND ND ND ND ± ND ± ND
STRADα + ATP ND ND ND ND ± ND ± ND
STRADα + ATP + Mg2+ ND ND ND ND ± ND ± ND
His-STRADα + ATP + Mg2+ ND ND ND ND ± ND ± ND
ND = Not determined
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Figure 3.26: Design of STRADα mutants incapable of binding ATP
A) The structure of the ATP binding site of STRADα, in which key interacting and nearby
residues, are emphasized.
B) Fluorescence emission spectra (excitation 410 nm) of TNP-ATP (5 µM) bound to wild type
and mutant forms of STRADα (2 µM) and/or wild type MO25α (2 µM). A reference cuvette
containing only TNP-ATP (5 µM) was subtracted as background. A Coomassie stained SDS-
PAGE gel of each form of STRADα analysed is shown (GGK = G76D + G78D + K197E, GGR
= G76D + G78D + R215E, GGKR = G76D + G78D + K197E + R215E).
3.6.3 ATP and MO25α are required for STRADα activation of LKB1
Having established that ATP increases the affinity of STRADα-MO25α
interaction, the question whether ATP binding to STRADα also af-
fects assembly and activity of the LKB1 heterotrimeric complex, was
addressed. Using the STRADα-ATP structure, a number of STRADα
mutants were designed to disrupt binding of the adenine or phos-
phate moieties of ATP (Fig. 3.26A). Four of these were indeed un-
able to interact with TNP-ATP in the presence or absence of MO25α
(Fig. 3.26B). Interestingly, these mutants also affected association
with LKB1 when co-expressed in 293 cells (Fig. 3.27A), suggest-
ing that binding of ATP to STRADα, in the absence of MO25α,
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enhances the ability of STRADα to interact with LKB1. However,
these mutants were capable of forming complexes with LKB1 when
co-expressed with LKB1 and MO25α (Fig. 3.27B), that retained cat-
alytic activity as measured by activation of AMPK (Fig. 3.27B). It is
possible that binding of MO25α to these STRADα mutants compen-
sates for their inability to bind ATP, by inducing a closed “active-like”
conformation of STRADα, capable of binding and activating LKB1.
To explore this idea, mutants of STRADα incapable of binding to
both ATP and MO25α were generated. Strikingly, these combined
STRADα mutants lost their ability to activate LKB1, despite still
being capable of forming a heterotrimeric complex (Fig. 3.28).
Taken together, these observations suggest that the closed “active-
like” conformation of STRADα is maintained through binding to ATP
and/or MO25α, and is required for activation of LKB1. Mutations
that prevent STRADα from binding to ATP or MO25α do not affect
activation of LKB1 (Figs. 3.22 and 3.27B), suggesting that ATP bind-
ing to STRADα can compensate for loss of MO25α interaction and
vice versa. However, loss of both ATP and MO25α binding prevents
STRADα from activating LKB1 (Fig. 3.28. Such mutations may leave
STRADα in the open “inactive-like” conformation incapable of acti-
vating LKB1. Unfortunately, crystallisation trials of STRADα in the
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Figure 3.27: ATP binding to STRADα is required for STRADα/LKB1 interaction in
the absence of MO25α
A & B) Wild type GST-LKB1 and indicated forms of Flag-STRADα were expressed in 293 cells
in the absence (A) and presence (B) of Myc-MO25α. Cells at 36 h post-transfection were lysed
and GST-LKB1 affinity purified on glutathione-Sepharose. Kinase activities are representative
of three independent assays carried out in triplicate (error bars represent the SD for a single
triplicate experiment). The purified GST-LKB1 preparation (upper panel) as well as the cell
extracts (lower panel) were immunoblotted with the indicated antibodies. Similar results were
obtained in three separate experiments. Dotted line indicates where the gel was cut.
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Figure 3.28: Interaction of ATP and MO25α with STRADα controls LKB1 activity
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified and
assayed for the ability to activate heterotrimeric AMPK complex expressed in E. coli as de-
scribed in chapter II, section 2.11.2. Kinase activities are representative of three independent
assays carried out in triplicate (error bars represent the SD for a single triplicate experiment).
Affinity purified GST-LKB1 preparation (upper panels) as well as cell extracts (lower panels)
were immunoblotted with the indicated antibodies.
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absence of MO25α that could have demonstrated this were unsucces-
ful. However, binding of ATP to several kinases, promotes the closed,
active conformation of these enzymes. Moreover, as discussed above,
binding of cyclin to CDK2 is reminiscent of the interaction of STRADα
with MO25α. Interaction of cyclin A is well known to promote the
closed, active, conformation of CDK2 (Jeffrey et al., 1995).
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Figure 3.29: PMSE truncation and the stability of STRADα
A) Structure of STRADα in which the region beyond Asn252 that is truncated in PMSE
patients is coloured in red.
B) 293 cells were co-transfected with the constructs encoding wild type GST-LKB1 and Myc-
MO25α together with constructs encoding wild type or PMSE mutant Flag-STRADα. Cells
at 36 h post-transfection were lysed and GST-LKB1 affinity purified and assayed for ability to
phosphorylate the LKBtide peptide. Kinase activities are representative of three independent
assays carried out in triplicate (error bars represent the SD for a single experiment carried out
in triplicate). Affinity-purified GST-LKB1 preparation (upper panels) as well as cell extracts
(lower panels) were immunoblotted with the indicated antibodies.
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3.7 The PMSE mutation structurally impairs STRADα
Recently, a homozygous deletion of the STRADA/LYK5 gene was
reported to cause PMSE syndrome, a severe human developmental
and epileptic syndrome (discussed in chapter I, section 1.5.3) (Puffen-
berger et al., 2007). The PMSE causing mutation in humans results
in a STRADα truncation at residue 251, thus removing the last 180
amino acids (Puffenberger et al., 2007). Inspection of the STRADα
structure reveals that this mutation would delete almost half of the C-
terminal lobe of the pseudokinase domain, beginning with structurally
vital components such as helix αF (Fig. 3.29A). This could destabilize
the STRADα protein, as helix αF forms numerous hydrophobic inter-
actions within the C-lobe of the pseudokinase domain, which would
become solvent exposed in the PMSE mutant. Attempts to express
the PMSE-STRADα (residues 1-251) mutant in 293 cells revealed this
was expressed at significantly lower levels than full length STRADα
(Fig. 3.29B), consistent with this fragment being unstable. More-
over, STRADα (1-251) failed to interact with or activate LKB1 (Fig.
3.29B). These results confirm that the STRADα mutation found in
PMSE patients represents a loss-of-function mutation that would be
unable to stimulate the LKB1 pathway. This could account for the
elevated mTOR pathway activity that was observed in neuronal cells
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derived from PMSE patients (Puffenberger et al., 2007). Therefore, it
is possible that mTOR inhibitors that are currently in clinical trials
may be beneficial in treating PMSE patients.
It is worth noting that while PMSE patients have lower LKB1 activ-
ity, no PJS-like symptoms were reported by Puffenberger et al. (2007).
It is possible that polyposis and harmatomas may have gone unrecog-
nised, considerng the young cohort (median age 16 years, range 7
months to 28 years), and the lack of colonoscopies for the patients
studied (Puffenberger et al., 2007). Perhaps longer time periods oc-
clusion of LKB1 activity in patients may be required to develop PJS
syndrome. Indeed, PJS and predisposition to malignant cancers may
be a later manifestation of PMSE syndrome, and it will be interesting
if animal models of PMSE syndrome developed these symptoms.
3.8 Conclusions
The first structure of the STRADα pseudokinase and its interac-
tion with MO25α, a heterodimeric interaction within the heterotrimer
LKB1 tumour suppressor complex, is described in this thesis. A key
discovery is the identification of an unexpected extensive interaction
between STRADα and the concave surface of MO25α, previously pro-
posed to harbour a ligand binding site (Milburn et al., 2004). Ar-
madillo repeat proteins that are structurally related to MO25α such
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as PUM1 (Wang et al., 2001), β-catenin (Graham et al., 2000) and
importin-α (Conti and Kuriyan, 2000), also bind their macromolecular
partners along their concave surface. In general topological terms, the
STRADα/MO25α complex resembles the interaction between CDK2
and Cyclin A, and the EGFR/EGFR dimer, and provides another
example of protein kinase regulatory mechanism via helix αC.
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Figure 3.30: Model of how STRADα/MO25α might interact and activate LKB1
The model is based on mutagenesis and structural data discussed in this chapter. Binding
of either ATP and/or MO25α to STRADα induce STRADα to adopt a closed conformation,
leading to the assembly of a fully active LKB1 complex.
The data presented in this thesis show that, despite lacking most es-
sential catalytic residues, STRADα has maintained its ability to adopt
a closed “active-like” conformation, which binds ATP and possesses an
ordered activation loop similar to active protein kinases. This closed
conformation is stabilised through binding of ATP and/or MO25α.
Moreover, binding of MO25α to STRADα markedly enhances affinity
for ATP and binding of ATP to STRADα stimulates interaction with
MO25α. These findings support a model in which binding of either
MO25α or ATP is sufficient to enable STRADα to activate LKB1.
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Consistent with this, mutant forms of STRADα that are incapable of
binding both ATP and MO25α can no longer activate LKB1, whilst
mutant forms of STRADα that retain the ability to bind either ATP
or MO25α still activate LKB1. Thus, the closed “active-like” confor-
mation rather than catalytic phosphoryl transfer activity, is likely to
be the key to the mechanism by which STRADα activates the LKB1
tumour suppressor. A model of how STRADα/MO25α might inter-
act and activate LKB1 based on mutagenesis and structural data is
presented in Fig. 3.30. Future work may establish other examples of
pseudokinases that, like STRADα, regulate signal transduction net-
works through their conformational state alone.
Chapter IV
Structure of the LKB1/STRADα/MO25α
heterotrimeric complex
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4 Structure of the LKB1/STRADα/MO25α
heterotrimeric complex
4.1 Foreword
In the work described below, mutagenesis studies involving expression
of LKB1, STRADα and MO25α in HEK293 cells, pulldown and LKB1
activity assays were a collaborative effort involving Dr Beatrice Maria
Filippi, University of Dundee, who helped with these experiments.
Details of the experimental work are provided in chapter II, Materials
and Methods section of this thesis.
4.2 Project overview and aims
4.2.1 LKB1 is activated by STRADα/β and MO25α/β
In cells, LKB1 is found in a 1:1:1 heterotrimeric complex with the
pseudokinase STRAD (Baas et al., 2003) and the scaffolding protein
MO25 (Boudeau et al., 2003a). Unlike the majority of protein kinases
that are regulated by phosphorylation, binding to STRAD and MO25
(Hawley et al., 2003; Boudeau et al., 2004) activates LKB1 through
an unknown molecular mechanism. As described in chapter III of this
thesis, the structure of STRADα complexed with MO25α, revealed
additional interactions between the concave surface of MO25α and
the regulatory αC helix of STRADα. STRADα, despite being a cat-
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alytically inactive pseudokinase, adopts a closed conformation typical
of fully active protein kinases. The closed conformation of STRADα
is maintained through its cooperative binding to ATP and MO25α.
Mutations that inhibit binding to ATP and MO25α, prevent LKB1
activation, suggesting the active conformational state of STRADα is
required for activation of LKB1 (discussed in chapter III).
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LKB1 kinase domain 4331 43 347318 CFT 
1 431STRADα pseudokinase domain
T329
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59 CFT394
Sites phosphorylated by LKB1 P
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S31 S185 S325 T336 T363 S402 S428
38
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STRADα
MO25α
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P Sites phosphorylated by other kinases
Figure 4.1: Domain architecture of LKB1/STRADα/MO25α and boundaries for co-
expression and crystallisation
A) Overview of the domain architecture of LKB1, STRADα and MO25α. Sequence motifs,
phosphorylation, and prenylation sites are labelled (adopted and redrawn from Alessi et al.
(2006)).The LKB1 nuclear localisation sequence (residues 38-42) is shown as a hatched rect-
angle. Nuclear export signal sequences of STRADα (residues 21-29 and 417-426 (Dorfman
and Macara, 2008)) are shown as grids. Coloured regions were used for crystallisation and the
same colouring scheme is adopted throughout this chapter, unless specified otherwise.
B) Architecture of the MultiBac bacmid (adapted and modified from Berger et al. (2004)),
used to recombinantly co-express the LKB1/STRADA/MO25A genes.
4.2.2 Aims
The aim of this work was to understand the mechanism by which the
tomour suppressor kinase LKB1 is activated. To do this I sought to de-
termine the 3-dimensional structure of the LKB1/STRADα/MO25α
heterotrimer. While there are many examples whereby pseudokinases
contribute to the activation of active kinases, no detailed molecu-
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lar mechanisms have been described. Thus, particularly interesting
was the study of mechanisms by which STRADα, a pseudokinase and
MO25α, a scaffolding protein could activate LKB1. Another aim of
this work was to understand the structure-function relationship of
disease-causing mutations of LKB1, by studying their location on the
LKB1 3-dimensional structure.
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Figure 4.2: Purification of the full length LKB1/STRADα/MO25α complex
A) SDS-PAGE analysis of the purified full length LKB1/STRADα/MO25α heterotrimeric com-
plex.
B) Activity assay using the LKBtide peptide substrate. The specific activity for the preparation
was calculated as 23 U/mg.
4.3 Overview of experimental procedures
4.3.1 Expression and purification of LKB1/STRADα/MO25α complex
Following the successful co-expression of the STRADα/MO25α com-
plex in E. coli (chapter II), the same approach was used for the co-
expression of the LKB1/STRADα/ MO25α complex. The LKB1 gene
(residues 43–347, preceded by a 6-His purification tag) was inserted in
one of the remaining gene expression cassettes of the pOPCH vector
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(Tan, 2001), together with full length STRADα and MO25α genes
(Fig. A.4A). However, attempts to express and purify the LKB1
heterotrimeric complex using this system were unsuccessful (see Fig.
A.4B in the appendix chapter VI). All of the three LKB1 complex
components could be detected and confirmed by peptide mass spec-
trometry, however, the yield and purity of the LKB1 heterotrimer pu-
rified from E. coli were unsuitable for crystallography work. Instead,
the attention was shifted to an eukaryotic cell expression system, us-
ing the Spodoptera frugiperda (Sf) cells as expression hosts, that were
infected with baculoviruses genetically engineered to contain any of
the subunits of the LKB1 heterotrimeric complex. This involved in-
fecting Sf21 cells with three different viruses at once. Although it was
possible to express and purify the LKB1 heterotrimer, the success rate
was very low and the method difficult to reproduce, presumably be-
cause not all three viruses have the same efficiency at expressing each
of the components at similar levels. This may have lead to an over-
all lower complex yield given that the three components are thought
to be present at similar stoichiometry ((Neumann et al., 2007) and
discussed below).
At this stage, it became clear that a system that ensures co-infection
of all three subunits at once was necessary, and a similar system called
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MultiBac had been developed in 2004 by Imre Berger, Daniel Fitzger-
ald and Tim Richmond at ETH Zu¨rich (Berger et al., 2004). Therefore,
the LKB1/STRADα/MO25α heterotrimeric complex was successfully
co-expressed in Sf21 cells, using the MultiBac (Berger et al., 2004)
expression system (Fig. 4.1). At first the full length and active LKB1
co-expressed with full length STRADα and MO25α, were co-purified
at reasonable yield (5-6 mg/l of culture) and good purity (Fig. 4.2).
4.3.2 Identification of construct boundaries for crystallisation
Crystallisation trials, using the full length preparations did not result
in any crystals. It is possible that the non-kinase domains of LKB1
and STRADα, predicted not to contain any well-folded domains, con-
tribute to flexible regions that interfere with the crystallisation pro-
cess. In addition, LKB1 N- and C-terminal regulatory regions contain
multiple phosphorylation/auto-phosphorylation sites and a prenyla-
tion site (Fig. 4.1A), that could also contribute to sample heterogene-
ity and reduce the probability of crystal formation.
Previous work has suggested that the catalytic domain of LKB1
is sufficient to form active complexes with STRADα (Baas et al.,
2003). Biochemical analysis to identify the shortest LKB1 fragment
capable of forming active complexes with STRADα/MO25α were car-
ried out by Dr Jerome Boudeau in the Alessi laboratory. LKB1
4 Structure of LKB1/STRADα/MO25α complex 176
Figure 4.3: Activation of LKB1 by STRADα and MO25α
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified and
assayed for the ability to phosphorylate LKBtide as described in section 2.11.1. (KI, kinase
inactive (D174A) mutant).
residues 43–347 (containing the kinase domain) when co-expressed
with full length STRADα and MO25α and purified from HEK 293
cells, retained the activity of that of full length LKB1 (Dr Jerome
Boudeau, unpublished data). The construct boundaries of STRADα
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and MO25α were identical to the constructs used for crystallisation
studies of STRADα/MO25α complex discussed in chapter III of this
thesis. Therefore, LKB1 (residues 43–347), STRADα (58–431) and
full length MO25α were cloned into the pFBDM (MultiBac) vector
(Berger et al., 2004) for expression and crystallisation studies (Fig.
4.1). Complex assembly and activity of LKB1 with these boundaries
were assayed using a HEK 293 co-expression system and the abilty
of LKB1 to phosphoryalte the LKB1tide substrate was assayed as
described in chapter II, sections 2.8.9 and 2.11.1. The activity of
LKB1 (residues 43–347) complex was comparable to the wild type
LKB1 complex, and the truncated form of STRADα and full length
MO25α were able to activate LKB1 to the same extent as wild type
STRADα/MO25α (Fig. 4.3). In previous overexpression studies us-
ing HEK 293 cells, LKB1 has been reported to autophosphorylate in
three sites Ser185, Thr336 and Ser402, as well as STRADα at residues
Thr329 and Thr419 (Fig. 4.1A) (Sapkota et al., 2002a). Therefore, to
avoid a heterogeneously phosphorylated sample, the catalytically inac-
tive mutant of LKB1 (Asp194Ala) was used for crystallisation studies.
This prevents LKB1 binding to Mg2+ ions required for phosphoryl
transfer, but not its ability to interact with STRADα and MO25α
(Fig. 4.3). The heterotrimeric complex with the catalytically inactive
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mutant of LKB1 was expressed in Sf21 cells giving a good yield (6
mg/l of culture) and was crystallography-grade purified using metal-
affinity, anion exchange and size exclusion chromatography (see chap-
ter II section 2.8.7 for details). LKB1/STRADα/MO25α eluted as a
heterotrimer from a size exclusion chromatography column at the ex-
pected size of a heterotrimer monomer (Fig. 4.4A and B). The sample
purity and dispersity were analysed using SDS-PAGE and dynamic
light scattering (DLS) respectively, revealing >97% purity and low
(13.6%) polydispersity (4.4C and D).
4.3.3 Crystallisation and structure solution of LKB1 heterotrimeric complex
LKB1/STRADα/MO25α crystallised in the presence of the non- hy-
drolysable ATP analogue (AMP-PNP), producing diffraction to 3.0
A˚. This was improved to 2.65 A˚ by chemical lysine methylation (Fig.
4.5A, B and Table 4.1). The presence of LKB1, STRADα and MO25α
was confirmed by SDS-PAGE analysis of crystals after sequential washes
in mother liquor (Fig. 4.5C). The structure was solved by molecu-
lar replacement using the already known MO25α structure (Milburn
et al., 2004) and the STRADα structure described in chapter III of
this thesis. Non-crystallographic symmetry averaging and manual
model building revealed two heterotrimeric complexes in the asymmet-
ric unit, displaying similar structures with an RMSD = 0.5 A˚ on 791
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Figure 4.4: Isolation of the heterotrimeric LKB1/STRADα/MO25α complex
A) Elution profile of the molecular mass standards, Thyroglobulin (669 kDa), Ferritin (440
kDa), Aldolase (158 kDa), Conalbumin (75 kDa) and Ovalbumin (43 kDa).
B) Gel filtration profiles of LKB1/STRADα/MO25α co-expressed in Sf21 cells and crystallised
in this thesis.
C) Fractions in which LKB1/STRADα/MO25α heterotrimer eluted, were pulled together,
analysed by SDS-PAGE and stained with Coomassie blue dye.
D) Dynamic light scattering analysis of the LKB1 complex sample. The theoretical molecular
weight (MW) = 115.8 kDa; PD = polydispersity.
Cα atoms (Fig. 4.6). Both STRADα and LKB1 are in complex with
AMP-PNP displaying binding modes typical of other protein kinases
(Knighton et al., 1991b), with the two hydrogen bonds between atoms
N1 and N6 from the adenine ring and backbone atoms of residues from
the hinge region of the kinase domain (Fig. 4.7). The γ-phosphate for
AMP-PNP bound to LKB1 was not defined by electron density and
therefore it is not included in the final model (Fig. 4.7A). It is possible
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that the Asp194Ala mutation in the LKB1 DFG motif, that impairs
the coordination of Mg2+ ions by the Mg2+ binding loop, accounts
for the disorder of the γ-phosphate of the bound AMP-PNP. Ordered
electron density was also observed for the STRADα C-terminal WEF
motif interacting with a pocket on MO25α as shown previously by
(Milburn et al., 2004) and discussed in chapter III. The connectivity
of the WEF motif with the rest of STRADα is not clear, since the clos-
est (straight line distance) and possible donating monomers belong to
different LKB1 heterotrimers (Fig. 4.6). This is likely to be due to the
crystal packing since there was no evidence of heterotrimer dimers in
sedimentation equilibrium experiments using analytical centrifugation
in the presence and absence of MgATP (Fig. A.5).
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Figure 4.5: Crystals of the LKB1/STRADα/MO25α complex
Crystals of the native LKB1/STRADα/MO25α complex (A), and methylated
LKB1/STRADα/MO25α complex (B).
C) SDS-PAGE gel (Coomassie stained) of LKB1 complex crystals electrophorised after three
subsequent washes in mother liquor.
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Table 4.1: Summary of data collection, structure refinement and analysis. Values for
the highest resolution shell are given in brackets.
Native Methylated
Space Group P3121 P3121
Unit cell (A˚)
a 118.7 118.4
b 118.7 118.4
c 390.0 390.0
Molecules/asu
LKB1 2 2
STRADα 2 2
MO25α 2 2
Resolution (A˚) 29.0-3.0 (3.1-3.0) 20.0-2.65 (2.75-2.65)
Observed reflections 284269 400006
Unique reflections 61869 (6033) 91884 (9144)
Redundancy 4.6 (4.6) 4.4 (4.4)
I/σI 13.6 (1.6) 14.8 (2.6)
Completeness (%) 95.2 (94.6) 99.2 (99.8)
Rmerge 0.079 (0.743) 0.063 (0.648)
Rwork, Rfree - 0.240, 0.291
RMSD from ideal geometry
bonds (A˚) - 0.011
angles (o) - 1.343
B-factor RMSD (A˚2)
(backbone bonds) - 1.03
B (A˚2)
protein - 75.47
ligands (AMP-PNP) - 78.63
water - 26.26
Ramachandran plot statistics (%)
Favoured region - 93.9
Allowed region - 5.2
Outlier region - 0.9
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4.4 General features of the LKB1 heterotrimer
4.4.1 Overall structure of the LKB1/STRADα/MO25α heterotrimer
The LKB1 heterotrimer has an overall compact globular shape with
significant interactions between all of the three subunits (Figs. 4.8
and 4.9). The pseudokinase domain of STRADα binds to the kinase
domain of LKB1. The horseshoe-shaped MO25α acts as a scaffold for
assembly of the heterotrimer, by binding both LKB1 and STRADα
through highly conserved residues on the concave face of its helical
repeats (Figs. 4.8, 4.9 and 4.10). MO25α binds to STRADα through
a large interface (2100 A˚2 buried surface area) centred around the
regulatory helix αC of STRADα (Fig. 4.8 and 4.9). This is similar
to the interaction observed in the structure of the STRADα/MO25α
binary complex discussed in chapter III of this thesis (RMSD = 0.5
A˚ on 529 Cα atoms and Fig. 4.13). The WEF motif interacting with
a pocket on MO25α, for which connectivity can not be unambiguously
identified contributes to an additional 825 A˚2 buried surface area.
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Figure 4.6: Contents of the asymmetric unit in crystals of the LKB1 heterotrimer
A) LKB1/STRADα/MO25α heterotrimers that make up the asymmetric unit. Protein struc-
tures are represented as cartoons and thickness of the cartoons is proportional to the B-factor
value. AMP-PNP molecules bound to STRADα and LKB1 are shown as sticks. The short-
est straight line distance between the last visible residue of STRADα pseudokinase domain
(coloured red) and the first visible residue of the WEF motif is labelled.
B) Stereo view of the contents of the asymmetric unit shown in the same orientation as in
(A).
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Figure 4.7: AMP-PNP binding to LKB1 and STRADα
A) Stereo figure of AMP-PNP (modelled as sticks with yellow carbons) and LKB1 residues that
contribute to AMP-PNP binding. Unbiased Fo-Fc electron density map for the ATP molecule
is coloured magenta and contoured at 2.4σ. Dashed lines represent hydrogen bonds between
AMP-PNP and residues from LKB1 hinge region. The mutated Mg2+ binding residue from the
DFG motif (D194A) is also labelled. The presence of this mutation may explain the absence
of clear electron density for the γ-P of AMP-PNP. Hence the positioning of the phosphate
groups is not optimal for hydrogen bonding with the indicated nearby residues.
B) Stereo figure of AMP-PNP (modelled as sticks with green carbons) and STRADα residues
that contribute to AMP-PNP binding. Unbiased Fo-Fc electron density map for the AMP-PNP
molecule is coloured magenta and contoured at 2.4σ. Dashed lines represent hydrogen bonds.
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Figure 4.8: Overall structure of the LKB1/STRADα/MO25α heterotrimer
A) Cartoon representation of the LKB1/STRADα/MO25α heterotrimeric complex and two bound AMP-PNP molecules are shown in sticks representations
(LKB1, yellow carbons; STRADα, magenta carbons). The γ-P for AMP-PNP bound to LKB1 was not visible due to disorder. The WEF motif at the C-terminus
of STRADα, for which connectivity could not be unambiguously identified due to disorder of the linkers, is shown in cyan.
B) Alternate view centred on LKB1. The C-terminal flanking tail (CFT) and activation loop (A-loop) of LKB1 are coloured red and magenta respectively.
Two anchor points within the activation segment of LKB1, consisting of β6/β9 and β9’/β9” are labelled as 1 and 2 respectively. The LKB1 αEF/αF loop is
coloured yellow. Dashed lines represent areas that were not well-defined by electron density.
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The remaining MO25α concave surface is engaged in contacts with
the LKB1 activation loop and the C-terminus of LKB1 helix αC, bury-
ing a total of 1580 A˚2 surface area (Figs. 4.8 and 4.9). The interface
between LKB1 and STRADα mainly involves the C-lobe of STRADα
and both N- and C-lobes of LKB1 (burying a total of 1840 A˚2 sur-
face area, (Fig. 4.8 and 4.9), comparable in size to the LKB1/MO25α
interaction.
4.5 Analysis of the LKB1/STRADα/MO25α heterotrimer
4.5.1 LKB1 adopts an active conformation in a phospho-independent manner
LKB1, unlike most protein kinases, does not require phosphorylation
of its activation loop to achieve an active conformation (Boudeau
et al., 2004). Instead, activation of LKB1 is thought to be medi-
ated through a conformational change triggered by binding to STRAD
and MO25 isoforms (Baas et al., 2003; Boudeau et al., 2003a, 2004).
The structure of the LKB1 heterotrimer is consistent with this, as
LKB1 lacks phosphorylation of the activation loop, yet the activation
loop is ordered (fully defined by electron density, Fig. 4.14A), a fea-
ture normally seen in structures of protein kinases that crystallise in
the active conformation. In most protein kinases the function of this
phosphorylation event is to anchor the catalytic H(R/K)D motif via
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Figure 4.9: Sites of the LKB1/STRADα/MO25α interaction
A) Surface representation of the LKB1/STRADα/MO25α heterotrimer is shown at three
alternative views: centre, rotated by -90 and 90o in the left and right panels respectively.
B, C & D) MO25α (blue), STRADα (green) and LKB1 (pink) are shown in the same orien-
tations as in panel (A). A map of interaction surfaces as defined by the program CONTACT
(atom pairs closer than 3.9 A˚) is coloured correspondingly. Residues that are discussed further
in the text are labelled to aid orientation and visualisation. For a full list of interacting residues
and their evolutionary conservation, see sequence alignments in Figs. 4.10, 4.11 and 4.12.
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Figure 4.10: MO25α multiple sequence alignment, secondary structure and residues
contributing to the interactions with LKB1/STRADα
Multiple sequence alignment (black = conserved, white = not conserved) of MO25α from
the indicated species of the metazoan kingdom. Alignments were performed with MUSCLE
(Edgar, 2004) and edited and displayed using ALINE (Bond and Schu¨ttelkopf, 2009). A graph
of residues involved in LKB1/STRADα interaction against their contact area (green bars =
STRADα, pink bars = LKB1) is displayed. Height of the bar represents the contact area
(atom pairs closer than 3.9 A˚, analysed by CONTACT from the CCP4 package (Collaborative
Computational Project, 1994)), divided by the total surface area of the participating amino
acid. The secondary structure (analysed by DSSP (Kabsch and Sander, 1983)) is shown in
red.
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Figure 4.11: STRADα multiple sequence alignment, secondary structure and residues
contributing to the interactions with LKB1/MO25α
Multiple sequence alignment (black = conserved, white = not conserved) of STRADα from
the indicated species of the metazoan kingdom. Alignments were performed with MUSCLE
(Edgar, 2004) and edited and displayed using ALINE (Bond and Schu¨ttelkopf, 2009). A
graph of residues involved in LKB1/MO25α interaction against their contact area (blue bars
= MO25α, pink bars = LKB1), is displayed. Height of the bar represents the contact area
(atom pairs closer than 3.9 A˚, analysed by CONTACT from the CCP4 package (Collaborative
Computational Project, 1994)), divided by the total surface area of the participating amino
acid. Key STRADα “catalytic” motifs and the WEF motif are boxed. The secondary structure
(analysed by DSSP (Kabsch and Sander, 1983)) is shown in green.
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Figure 4.12: LKB1 multiple sequence alignment, secondary structure and residues
contributing to the interactions with STRADα/MO25α
Multiple sequence alignment (black = conserved, white = not conserved) of LKB1 from the
indicated species of the metazoan kingdom. Alignments were performed with MUSCLE (Edgar,
2004) and edited and displayed using ALINE (Bond and Schu¨ttelkopf, 2009). A graph of
residues involved in STRADα/MO25α interaction against their contact area (green bars =
STRADα, blue bars = MO25α), is displayed. Height of the bar represents the contact area
(atom pairs closer than 3.9 A˚, analysed by CONTACT from the CCP4 package (Collaborative
Computational Project, 1994)), divided by the total surface area of the participating amino
acid. Key LKB1 catalytic motifs are boxed. The secondary structure (analysed by DSSP
(Kabsch and Sander, 1983)) is shown in pink. Disease-causing mutations are displayed at the
corresponding amino acid position and have been coloured red.
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Figure 4.13: Superposition of the STRADα/MO25α dimer with the LKB1 het-
erotrimer
Stereo view of a superposed STRADα/MO25α complex (coloured gray; discussed in chapter
III) and the LKB1/STRADα/MO25α heterotrimer. RMSD = 0.5 A˚ on 529 Cα atoms.
hydrogen bonding with the R/K residues as well as contribute to an
overall closed conformation of the kinase domain by interacting with
basic residues from helix αC (Johnson et al., 1996; Huse and Kuriyan,
2002). Interestingly, the position of Thr212 is very similar to that of
the phospho-threonine of other protein kinases (such as PKA) that re-
quire an activatory phospho-residue in the activation loop (Fig. 4.15).
However, the negative charge that would otherwise be provided by
the phosphate group is now replaced by Glu199 from β9, that is in
hydrogen bonding distance with Lys175 (Fig. 4.15). Interestingly, the
majority of eukaryotic protein kinases have preference for a positively
charged residue at this position (usually a lysine residue, (Kannan
et al., 2007b); see also Fig. 3.8, PKA position 168), presumably to
counteract the negative charge from a phosphorylated residue.
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Figure 4.14: LKB1 adopts an active conformation
A) Stereo figure of the final 2Fo-Fc electron density map, (coloured blue and contoured at 1σ
level), for the LKB1 activation segment (residues 197–220). Residues are shown as sticks with
green coloured carbons and those discussed in the text are labelled.
B) Stereo view of LKB1 structure (pink cartoons with activation segment coloured magenta)
superimposed onto the structure of PKA (PDBID 1ATP; gray cartoons with activation segment
coloured cyan). The conserved ion bridge between the glutamine (αC helix) and lysine (VAIK
motif, β3 sheet) is labelled. The PKA inhibitor peptide (PKI) bound to the PKA substrate
binding site (Knighton et al., 1991b) is coloured red.
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Figure 4.15: LKB1 activation loop requires no phosphorylation
A) Detailed stereo view of anchor points 1 (β6/β9) and 2 (β9’/β9”). Backbone atoms
of residues 208–210 and 230–234 are shown, whereas residues Asp208, Thr230 and Ser232
mutated in PJS are labelled and their side chains displayed. A salt bridge between Glu199 and
Lys175 depicted as dashed lines, represent the interaction of LKB1 activation segment with its
catalytic loop (C-loop). The corresponding interaction found in PKA (PDBID 1ATP) between
the phospho-threonine 197 (pThr) and Arg165 is also shown, with PKA residues represented as
transparent sticks (carbon atoms coloured cyan). The typical “activatory” threonine (Thr202)
present in LKB1 A-loop is labelled. Secondary structure elements are labelled according to
the structure of PKA (Knighton et al., 1991b). Dashed lines represent hydrogen bonding
interactions
B) Stereo view of the LKB1 kinase domain shown in the same orientation as in (A).
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Furthermore, the LKB1 structure displays many similarities with
other protein kinases that have been crystallised in the active confor-
mation. The formation of a short β6/β9 sheet between catalytic and
activation loops—one of the hallmarks of active conformations of pro-
tein kinases (Nolen et al., 2004),—provides the first anchoring point
for the activation segment and is present in LKB1. Anchor point
1 (AP1) is found near the N-terminus of the activation segment of
LKB1, beginning with three residues C-terminal of the Mg2+ binding
motif (Figs. 4.8B and 4.15). Towards the N-terminus of the activa-
tion segment of LKB1, a second anchoring point (AP2) is also present
(Fig. 4.8B). Residues 208–210 (activation loop) and residues 231–233
(αEF/αF loop) make backbone interactions in the form of a short an-
tiparallel β-sheet, here referred to as β9’/β9” sheet (Fig. 4.15). The
side chain of Asp208 also contributes to the strength of this anchoring
point by hydrogen bonding with Ser232 and Tyr234 backbone atoms.
The presence of AP2 is a structurally conserved feature of tyrosine
protein kinases envisaged to contribute to the stability of substrate
binding (Levinson et al., 2008), since this contributes to the position-
ing of the p+1 loop through its interactions with the αEF/αF loops.
Furthermore, the LKB1 αC helix is rotated into the canonical closed
conformation (Johnson et al., 1996; Huse and Kuriyan, 2002), with the
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conserved ion pair between Lys78 (the so-called VAIK motif in sub-
domain II) and Glu100 (αC helix in subdomain III, Fig. 4.14B). The
structure suggests that this active conformation of LKB1 is achieved
through contributions of both STRADα and MO25α.
4.5.2 STRADα binds both N- and C-terminal lobes of LKB1
As shown in chapter III of this thesis, the STRADα/MO25α complex
structure have revealed that the STRADα N-lobe is extensively en-
gaged in MO25α binding (chapter III, Fig. 3.18). Moreover, ATP and
MO25α binding to STRADα promote an active conformation of the
pseudokinase, required for LKB1 activity (discussed in chapter III, sec-
tion 3.6.3). Together, these results suggest that structural components
typical of an active conformational state such as the activation seg-
ment will be involved in LKB1 binding and/or activation. Consistent
with these observations, in the structure of LKB1/STRADα/MO25α
heterotrimer, two residues from STRADα activation loop, Phe233 and
His231, bind to the β2/β3 (N-lobe) and β7/β8 (C-lobe) of LKB1 re-
spectively (Fig. 4.16). Additional key contacts between Gln251 from
the αEF/αF loop and LKB1 backbone atoms (residues Cys73–Arg74,
β2/β3 loop) are also present (Fig. 4.16). The p+1 loop of STRADα
also contributes to interactions with LKB1 β2/β3 loop mainly via hy-
drophobic contacts between Leu241 (STRADα) and Leu72 (LKB1).
4 Structure of LKB1/STRADα/MO25α complex 196
αEF
αF
AMP-PNP 
(STRADα)
AMP-PNP 
(LKB1)
p+1 
loop
H231 F233
Q251
β8
β7 β3
β2
A-loop
R74
L72 T71
C73T186
β7/β8
loop β2/β3
loop
L241
 αEF/αFloop
β5
β4 LKB1 
CFT
αEF
αF
AMP-PNP 
(STRADα)
AMP-PNP 
(LKB1)
p+1 
loop
H231 F233
Q251
β8
β7 β3
β2
A-loop
R74
L72 T71
C73T186
β2/β3
loop
β7/β8
loop
L241
 αEF/αFloop
β5
β4 LKB1 
CFT
MO25α 
STRADα 
LKB1 
STRADα 
LKB1 
MO25α 
A
B
Figure 4.16: Details of the LKB1/STRADα interaction
A) Detailed view of LKB1/STRADα interaction. STRADα p+1 and αEF/αF loops are
coloured green and orange respectively. The MO25α structure was removed to aid visuali-
sation.
B) Stereo view of the LKB1 heterotrimeric complex shown in the same orientation as in (A).
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Another site of LKB1/STRADα interaction is between the CFT
region of LKB1 and the αG helix of STRADα. Thus, it appears that
structural elements on the STRADα C-terminal lobe that normally
make up the substrate binding site in active protein kinases (i.e. αG
helix (Dar et al., 2005; Komander et al., 2008), p+1 loop (Knighton
et al., 1991b)), interact with LKB1 (Fig. 4.17).
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AMP-PNP
C-terminal flanking tail
β2/β3 loop
β7/β8
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Active site
K239/D81 
ion bridge  
LKB1 
STRADα 
K239
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AMP-PNP
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β7/β8
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STRADα 
Figure 4.17: LKB1/STRADα interaction and STRADα “active site”
Sites of STRADα/LKB1 interaction are labelled and STRADα is displayed as cartoon (A)
and surface models (B). The activation loop of STRADα is coloured red and αEF/αF loop is
coloured orange. STRADα K239 from the p+1 loop and D81 from β1/β2 loop that appear
to interfere with accessibility of the γ-P are displayed as green sticks and surface.
4.5.3 STRADα is an allosteric activator of LKB1
To understand the role of STRADα binding to LKB1, alanine mu-
tations of interacting residues were made and the effects that these
had on LKB1 complex formation and activity were studied. Muta-
tion of residues in the substrate-binding region of STRADα (Leu241
in the p+1 loop and Gln251 in the αEF/αF loop) markedly inhib-
ited interaction with LKB1, whilst mutation of Gln286 (αG helix)
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had a moderate effect (Fig. 4.18A). Combining the Gln251 (αEF/αF
loop) mutation with an additional mutation on STRADα that has
been shown to disrupt the MO25α-STRADα interaction (Tyr185Phe;
chapter III, Fig. 3.21A), suppressed LKB1 activation without affecting
complex assembly (Fig. 4.18B). Residues on the STRADα activation
loop (His231/Phe233), that bind to β7/β8 (C-lobe) and the β2/β3
(N-lobe) of LKB1, respectively (Fig. 4.16), were also mutated. In
the absence of MO25α, mutation of His231 and/or Phe233 prevented
STRADα from binding to LKB1 (Fig. 4.18A). However, in the pres-
ence of MO25α, only the His231/Phe233 double mutant significantly
reduced LKB1 activation and complex assembly (Fig. 4.18B). Com-
bining the His231/Phe233 double mutant with the Tyr185 mutation
that disrupts interaction with MO25α, resulted in a mutant STRADα
that is unable to form a complex with LKB1 and MO25α (Fig. 4.18B).
These experiments define the regions on STRADα that interact with
LKB1 and MO25α and contribute to the assembly of an active LKB1
complex. Because His231 and Phe233 interact on either lobe of the
kinase domain, and their contribution is required for LKB1 activity,
it is possible that this interaction “wedges” the LKB1 kinase domain
into an active conformation. Moreover, anchoring of these two partic-
ular β-sheets (β2/β3 and β7/β8) is of significant importance, as two
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catalytically indispensable motifs are found in β3 (VAIK motif) and
preceding the β7 strand (HRD motif).
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Figure 4.18: Characterisation of the LKB1/STRADα interactions
A) The indicated constructs of GST-LKB1 and Flag-STRADα were expressed in 293 cells in
the absence of MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity
purified on glutathione-Sepharose. The purified GST-LKB1 preparation (upper panel) as well
as the cell extracts (lower panel) were immunoblotted with the indicated antibodies. Similar
results were obtained in three separate experiments.
B) 293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα
and Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified
and assayed for the ability to activate the heterotrimeric AMPK complex expressed in E.
coli as described in section 2.11.2. Kinase activities are representative of three independent
assays carried out in triplicate (error bars represent the SD for a single triplicate experiment).
Affinity purified GST-LKB1 preparation (upper panel) as well as cell extracts (lower panel)
were immunoblotted with the indicated antibodies.
4.5.4 The C-terminal flanking tail of LKB1 is essential for formation of an
active complex
A common feature of many protein kinase folds (e.g. the AGC kinases)
is a C-terminal flanking tail (CFT) that interacts with the N-terminal
lobe of the kinase (Kannan et al., 2007a). This tail either serves di-
rectly as an auto-activatory mechanism or provides a docking site for
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regulatory interacting partners (Kannan et al., 2007a). The struc-
ture reveals that LKB1 possesses a proline-rich CFT (residues 311–
347) running along the STRADα/LKB1 interface, interacting with the
STRADα helix αG as well as the LKB1 N-terminal lobe (Fig. 4.19).
An LKB1 mutant (residues 1–318), lacking part of the CFT motif
(∆CFT) failed to interact with STRADα in the absence of MO25α
(Fig. 4.20A). Mutation of individual residues in/interacting with the
CFT (Trp332/Tyr340/Arg74) did not affect assembly of the LKB1
complex, however LKB1(∆CFT) formed a complex with markedly re-
duced catalytic activity when co-expressed with STRADα and MO25α
(Fig. 4.20B). Furthermore, mutation of Arg74 (that interacts with the
CFT, but also with STRADα, (Figs. 4.16 and 4.19) on LKB1 abol-
ished interaction with STRADα in the absence of MO25α (Fig. 4.20A)
and also resulted in a heterotrimeric complex possessing reduced cat-
alytic activity (Fig. 4.20B).
The CFT region present in LKB1 also contains two characterised
phosphorylation sites—Ser325 (Sapkota et al., 2002a), which may be
phosphorylated by ERK MAPK kinase (Zheng et al., 2009; Esteve-
Puig et al., 2009) and Thr336, an autophosphorylation site (Sapkota
et al., 2002a). The LKB1 complex structure suggest that these are
surface exposed and phosphorylation of these sites would not be pre-
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Figure 4.19: LKB1 CFT region runs through the LKB1/STRADα interface
A) Stereo view of the LKB1 CFT interacting with STRADα and LKB1 N- and C-lobes. The
proline-rich CFT is coloured red.
B) Stereo view of the LKB1 heterotrimeric complex shown in the same orientation as in (A).
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dicted to influence association of the CFT with the LKB1 kinase do-
main. This is consistent with previous work suggesting that these
sites do not directly affect LKB1 catalytic activity (Sapkota et al.,
2002a) or complex assembly (Boudeau et al., 2004), but could affect
association of LKB1 with substrates or regulators.
These results reveal an important role for CFT in LKB1/STRADα
interactions and LKB1 activity and are suggestive of a potential role
for other, as yet unidentified, LKB1 regulators that may utilise this
region.
4.5.5 LKB1/STRADα interaction and evolution of pseudokinases
As already mentioned in the introduction (chapter I) and chapter III
of this thesis, a significant number of human genes code for protein ki-
nases that lack essential residues in their catalytic machinery and have
been termed pseudokinases (Manning et al., 2002; Boudeau et al.,
2006). Although some predicted pseudokinases have recently been
shown to be in fact catalytically competent (Min et al., 2004; Mukher-
jee et al., 2008; Kawagoe et al., 2008), others remain “true” pseudok-
inases and are either incapable of binding ATP (Labesse et al., 2009;
Scheeff et al., 2009) or catalysing phosphoryltransfer (e.g. STRADα).
This raises a number of intriguing possibilities concerning their func-
tion and evolutionary origins. It is possible that STRADα evolved
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Figure 4.20: Characterisation of LKB1 interacting residues
A) The indicated constructs of GST-LKB1 and Flag-STRADα were expressed in 293 cells in
the absence of MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity
purified on glutathione-Sepharose. The purified GST-LKB1 preparation (upper panel) as well
as the cell extracts (lower panel) were immunoblotted with the indicated antibodies. Similar
results were obtained in three separate experiments.
B) 293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα
and Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified
and assayed for the ability to activate heterotrimeric AMPK complex expressed in E. coli as
described in section 2.11.2. Kinase activities are representative of three independent assays
carried out in triplicate (error bars represent the SD for a single triplicate experiment). Affin-
ity purified GST-LKB1 preparation (upper panel) as well as cell extracts (lower panel) were
immunoblotted with the indicated antibodies.
from a catalytically competent protein kinase, capable of phospho-
rylating and activating LKB1. During evolution, the mechanism by
which STRADα stimulated LKB1 activity may have changed to favour
regulation through direct interaction, rather than phosphorylation.
This notion is supported by the observation that STRADα interacts
with LKB1 using structural elements in its C-lobe that are normally
utilised by active protein kinases to bind their substrates (e.g. the
p+1 loop/αG helix). Protein kinases generally need to be in their
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active conformation to bind their substrates. As it has already been
described in chapter III of this thesis, STRADα has to adopt an “ac-
tive” conformation, stabilised through ATP and MO25 in order to
activate LKB1. The finding that LKB1 interacts with STRADα as
a “pseudosubstrate” accounts for this requirement of the active con-
formation of STRADα. This allosteric mechanism of activation may
have resulted in loss of evolutionary pressure to retain STRADα cat-
alytic activity, thus explaining the loss of at least six essential catalytic
residues on STRADα. It is possible that other pseudokinases that lack
critical catalytic residues evolved in a similar way.
In order for LKB1 to phosphorylate AMPK substrates, the active
site cleft of LKB1 has to be accessible. Indeed, the structure of the
heterotrimer shows that the C-terminal lobe of LKB1 is not engaged
in interactions with STRADα or MO25α that would impair substrate
interaction (Figs. 4.8 and 4.14B). Moreover, the region around the γ-
phosphate (disordered in our structure) of ATP is solvent exposed in
LKB1—this contrasts with the equivalent region on STRADα, which
is inaccessible due to interactions with LKB1, with the γ-phosphate
being shielded by Lys239 of STRADα (Fig. 4.17).
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4.5.6 MO25α stabilises the LKB1 activation loop
Most protein kinases are activated by phosphorylation of their activa-
tion loop, producing a conformation competent for substrate binding,
with the formation of short β6/β9 and β9’/β9” sheets between cat-
alytic and activation loops (Nolen et al., 2004; Levinson et al., 2008).
Despite the lack of activatory phosphorylation, the LKB1 activation
loop is well-ordered (fully defined by electron density) and adopts a
conformation typical of active protein kinases (Fig. 4.14). Key to this
is the interaction of the LKB1 activation loop (residues 204–206) with
residues from the concave surface of MO25α (Fig. 4.21). Residues
Met246, Ile250, Val280 and Pro285 form a hydrophobic pocket on
MO25α, accommodating Phe204 on the LKB1 activation loop (Fig.
4.21). Individual mutation of these residues did not affect LKB1 com-
plex formation or activity (Fig. A.6). However, mutation of Phe204
together with Arg74, a residue required for LKB1/STRADα inter-
action (Fig. 4.16 and 4.20A), resulted in LKB1 species that were
incapable of forming a heterotrimeric complex (Fig. 4.20B).
Additional interactions occur between Arg240/Phe243 on MO25α
with the backbone of Ala205/Ala206 of LKB1 that act as a molecular
“peg”, to orient the activation loop of LKB1 and stabilise its active
conformation (Fig. 4.21). Although mutation of both Arg240 and
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Figure 4.21: Details of the LKB1 activation loop and MO25α concave surface inter-
action
A) Stereo view of LKB1/MO25α interaction. The LKB1 activation loop is coloured magenta
and the αEF/αF loop is coloured yellow. For clarity, STRADα is not shown.
B) Stereo view of the LKB1 heterotrimeric complex shown in the same orientation as in (A).
4 Structure of LKB1/STRADα/MO25α complex 207
Phe243 did not affect the ability of MO25α to interact with STRADα
and LKB1, the resulting complex is inactive, establishing the impor-
tance of this interaction in stimulating LKB1 (Fig. 4.22).
Taken together, these data suggest that MO25α stabilises the acti-
vation loop of LKB1 in an optimal conformation required for phos-
phorylation of substrates such as AMPK.
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Figure 4.22: Characterisation of the LKB1/MO25α interactions
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified and
assayed for the ability to activate heterotrimeric AMPK complex expressed in E. coli as de-
scribed in section 2.11.2. Kinase activities are representative of three independent assays
carried out in triplicate (error bars represent the SD for a single triplicate experiment). Affin-
ity purified GST-LKB1 preparation (upper panel) as well as cell extracts (lower panel) were
immunoblotted with the indicated antibodies.
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Figure 4.23: Possible ligand coordination by LKB1, STRADα and MO25α
A) Stereo view of unbiased Fo-Fc electron density map (contoured at 2.5σ) indicating a
possible small molecule/ligand that is coordinated by positively charged residues from LKB1,
STRADα and MO25α.
B) Stereo view of the LKB1 heterotrimeric complex shown in the same orientation as in (A).
C) 293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα
and Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified
and assayed for the ability to activate the AMPK complex. Kinase activities are representative
of three independent assays carried out in triplicate (error bars represent the SD for a single
triplicate experiment). Affinity purified GST-LKB1 preparation (upper panel) as well as cell
extracts (lower panel) were immunoblotted with the indicated antibodies.
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4.6 A possible ligand coordination by LKB1, STRADα and
MO25α
Inspection of the electron density for the LKB1 complex revealed clear
positive density at an unexpected region of the asymmetric unit that
excludes disordered protein residues (Fig. 4.23). Attempts at as-
signing the occupancy to small molecules that were part of buffer
components were unsuccessful, leaving open the possibility that a
small molecule/metabolite present in the expression host cells was
carried along during the LKB1 complex purification. This unidenti-
fied small molecule appears to be coordinated by positively charged
LKB1 (Lys108 from the HPN loop), STRADα (His223) and MO25α
(Arg107, Arg152 and Arg195) residues (Fig. 4.23A and B). Inter-
estingly, a Lys108Arg mutation is found in PJS patients (Olschwang
et al., 2001) suggesting a change in the chemical environment around
this putative ligand could affect LKB1 signalling. Furthermore, re-
verse charge mutations of MO25α contributing residues, either alone
or in combination with His232Asp (STRADα) and Lys108Pro (LKB1)
reduced the ability of LKB1 to activate AMPK (Fig. 4.23C). However,
it remains unclear whether an as yet unidentified negatively charged
small molecule/metabolite, is involved in regulating LKB1 activity
and more data are needed to support this observation.
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Figure 4.24: LKB1 acidic C-terminal tail and positively charged N-terminal pocket
A) Multiple sequence alignment (dark blue = conserved, white = not conserved) of the LKB1
C-terminal regulatory domain (CRD; residues 311-433) from the indicated species.
B) Electrostatic potential of the LKB1 kinase domain (semi-transparent) surface, analysed by
APBS (N.A. Baker and McCammon, 2001). Blue areas (+10 kT) represent positively charged
surfaces and red areas (−10 kT) represent negatively charged surfaces. The CFT is shown as
a green cartoon. STRADα and MO25α are shown as semi-transparent cartoons.
C) Interaction of the AGC kinase PKA (PDBID 1ATP (Knighton et al., 1991b)) C-terminal tail
and hydrophobic motif with the N-lobe and hydrophobic pocket. The PKA surface is shown
as in (B) and the C-terminal tail as a green cartoon.
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Figure 4.25: LKB1 contains an acidic C-terminal tail and a positively charged N-
terminal pocket
Electrostatic potential of (A) MARK2 (PDBID 2R0I (Panneerselvam et al., 2006)) and (B)
human AMPKα2 kinase domain (PDBID 2H6D (Littler et al., 2006)), analysed by APBS
(N.A. Baker and McCammon, 2001) and shown as transparent surfaces. Blue areas (+10
kT) represent positively charged surfaces and red areas (−10 kT) represent negatively charged
surfaces.
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4.7 The LKB1 N-lobe contains a positively charged pocket
Inspection of sequence conservation among different species and be-
tween the different spliced isoform (LKB1 short; found predominantly
in testis (Towler et al., 2008; Denison et al., 2009)), reveals some in-
teresting features of the C-terminal regulatory domain (Fig 4.24A).
The CRD comprises the C-terminal non-kinase domain (residues 311-
433) of LKB1 (Fig 4.24A). Residues 311-370 are identical between the
LKB1 short and long isoforms (Towler et al., 2008; Denison et al.,
2009), and this is referred to here as the invariable region of CRD.
Residues beyond 370 differ between the short and long isoforms and
this region is referred to here as the variable region of CRD. The
CRD invariant region can be further subdivided into a proline-rich tail
(residues 311-347, referred here as the proline-rich CFT and discussed
in section 4.5.4 of this chapter) and an acidic tail (residues 348-370),
that contains stretches of aspartic and glutamic acids (Fig. 4.24A),
three large hydrophobic residues (Phe354, Tyr362 and Phe366) and a
mapped phosphorylation site (Thr363) Sapkota et al. (2002a). Inter-
estingly, the proline-rich CFT immediately preceding the acidic tail
(not present in the crystallised construct) is found close to the N-lobe
of the kinase domain, nearby a highly positively charged area of LKB1
(Fig. 4.24B). This basic “barrel” is formed by charge contributions
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from clusters of Lys/Arg residues present in the αB helix (residues
81–84 and 85–87) and lysine residues from β2 (Lys62, Lys64) and
β5 (Lys124) strands, that are part of the N-terminal β-barrel of the
kinase domain (Fig. 4.12). It is plausible to hypothesise that the
acidic tail of LKB1 will be binding to this positively charged region
in an analogous manner that AGC kinases such as PKB (Yang et al.,
2002), PKCι (Messerschmidt et al., 2005) and PKA (illustrated in
Fig. 4.24C). These kinases use their C-terminal tail to bind to the
N-lobe and regulate their activity. However, AGC kinases typically
have (so-called) turn and hydrophobic motifs (reviewed by Komander
et al., 2006) that bind to corresponding pockets and are also regu-
lated by phosphorylation (Hauge et al., 2007). While the functions
and molecular mechanisms for the hydrophobic and turn motif bind-
ing/phosphorylation have been well studied for the AGC kinases, no
analogy to this system has been described for other groups of protein
kinases. However, the mechanism of action is well conserved through-
out the human kinome, since the binding of the hydrophobic motif
to the hydrophobic pocket, regulates the rotation of the αC helix, a
feature first described for CDK2 activation by cyclins (Jeffrey et al.,
1995) and later for AGC kinases (Bayliss et al., 2003), tyrosine ki-
nases (Filippakopoulos et al., 2008) and even pseudokinases such as
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STRADα (described in chapter III of this thesis). Therefore, it is pos-
sible the acidic tail, also containing a phosphorylation site (Thr363),
interacts with positively charged/hydrophobic pockets in the LKB1 N-
lobe, analogous to the turn and hydrophobic motifs of AGC kinases.
However, the function of this binding is unclear, since LKB1 (43-347)
lacking the acidic tail forms complexes with STRADα/MO25α and
phosphorylates a peptide substrate to the same extent as the WT-
LKB1 (Fig. 4.3). Thus, LKB1 is unlikely to use the acidic tail/basic
“barrel” to regulate its activation. Instead LKB1 may be using its
acidic tail, and/or its basic “barrel”, for docking with/to interact-
ing partners, similar to the upstream AGC activating master kinase,
PDK1 that binds to the hydrophobic motif of its downstream targets
using it N-lobe hydrophobic pocket (Biondi et al., 2002).
Intriguingly, downstream targets of LKB1, for which structures are
known, MARK2 and AMPK, possess similar positively charged pock-
ets in their N-lobe (Fig. 4.25). Interestingly, the AMPKα2 kinase do-
main (Littler et al., 2006) contains two such highly positively charged
pockets, a primary pocket present in the β barrel, and a secondary
pocket present between the αB–αC helices (Fig.4.25B).
Further work is required to establish the role of the acidic tail of
LKB1. A crystal structure of the LKB1 kinase containing this region
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will be useful to understand the interactions between the acidic tail
and the N-lobe of the kinase domain, that could also reveal the pos-
sible role of the LKB1 basic “barrel”. In addition, investigating the
ability of LKB1 that lacks the acidic tail, to interact with, and activate
AMPK and the AMPK related kinases, could provide more insights
into the molecular mechanism of LKB1 activation of these kinases.
4.8 Structural basis of Peutz-Jeghers syndrome
Following the key discovery of mutations in the LKB1 gene as the main
cause of Peutz-Jeghers syndrome (Hemminki et al., 1998) a decade
ago, at least 50 missense mutations derived from PJS patients and
sporadic cancers have been mapped to the LKB1 kinase domain and
the CFT loop (see chapter I, section 1.4.2). The study carried out
by Boudeau et al., (2004), characterised the effects that 32 of these
mutations have on the ability of LKB1 to form active heterotrimeric
complexes with STRADα and MO25α (Boudeau et al., 2004). The re-
maining 18 mutations were characterised in this thesis, together with
6 of the previously tested mutations (Boudeau et al., 2004), to ensure
reproducibility of the assay. The location of these mutations, how they
may affect LKB1 structure or function, and the experimental data on
LKB1 complex assembly and activity are summarised in Table 4.2,
Figs. 4.26 and 4.27. The structural map reveals that the majority of
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mutations are located in the C-lobe of the LKB1 kinase domain and
are residues important for structural integrity of LKB1 (Fig. 4.26A).
From these, there are two hydrophobic clusters, named hydrophobic
cluster 1 (Phe157, Leu242, Leu285, Trp308) and hydrophobic cluster 2
(L164, I177 and L182) (Fig. 4.26A). Many of these mutations resulted
in low LKB1 expression levels, suggestive of generating unstable pro-
tein species, and all LKB1 mutants were incapable of forming active
complexes with STRADα and MO25α (Fig. 4.27 and Table 4.2). In
addition, at least 10 mutations involve residues required for catalysis
or substrate binding (Fig. 4.26). While these mutants properly assem-
bled into complexes with STRADα and MO25α, these were devoid of
catalytic activity (Fig. 4.27 and Table 4.2).
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Figure 4.26: Map of oncogenic mutations on the LKB1 kinase domain
A) Location of LKB1 residues that are mutated in PJS and other types of cancer. The CFT
region is coloured red and dashed lines represent areas that were not well-defined by electron
density.
B) Surface exposed residues mutated in PJS and other types of cancer.
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Figure 4.27: Effect of the oncogenic mutations on LKB1 activity
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified and
assayed for the ability to activate rat heterotrimeric AMPK complex expressed in E. coli
as described in the Materials and Methods. Kinase activities are standardised relative to the
activity of the wild type LKB1/STRADα/MO25α complex (−, <5%; +, 5-25%; ++, 25-50%;
+++, >50%) and represent the average of six independently purified complexes, assayed in
duplicate (error bars represent the SEM). Representative Western blots of affinity purified
GST-LKB1 preparations (upper panel) as well as cell extracts (lower panels), probed with the
indicated antibodies are also shown. Asterisk indicate mutation was previously investigated by
Boudeau et al., (2009).
Table 4.2: Cancer causing mutations found in the LKB1 tumour suppressor kinase domain and the C-terminal flanking tail
Mutation Disease Location and functional significance Comp. Act. Reference
Y49D PJS β1, possible destabilisation of the N-lobe Yes + (Rowan et al., 1999)
V66M∗ PJS, Cervix β2, possible destabilisation of the N-lobe Yes +++ (Kuragaki et al., 2003)
L67P PJS β2, possible destabilisation of the N-lobe No − (Hemminki et al., 1998)
R86G∗ PJS, NSCLC αB, basic (Arg-rich) region; solvent exposed Yes +++ (Strazisar et al., 2009)
K108R PJS HKN loop Yes +++ (Olschwang et al., 2001)
Q123R∗ NCLS β4-β5 loop; solvent exposed Yes +++ (Ji et al., 2007)
G135R PJS Hinge region, ATP binding Yes − (Rowan et al., 1999)
F157S∗∗ PJS Part of hydrophobic cluster 1: L245, M289, I303, F309, L285 No − (Ylikorkala et al., 1999)
D162N PJS Structural role; forms ion pair with R304 Yes +++ (Westerman et al., 1999a)
G163D∗ PJS, NSCLC Presence of side chain may distort the LKB1 catalytic loop No − (Westerman et al., 1999a)
L164M PJS Mutation may misposition the catalytic HRD motif Yes +++ (Westerman et al., 1999a)
Q170P∗ PJS Structural role, possible distortion of helix αE No − (Forbes et al., 2008)
G171S∗∗ PJS May interfere with the correct positioning of R240 Yes ++ (Dong et al., 1998)
H174R∗ NSCLC Part of the catalytic HKD motif Yes − (Blons et al., 2008)
D176N PJS Catalytic residue, HKD motif Yes − (Mehenni et al., 1998)
D176Y∗ PJS Catalytic residue, HKD motif Yes − (Koivunen et al., 2008)
I177N∗∗ PJS Part of hydrophobic cluster 2: L160, L164, L182 No − (Resta et al., 2002)
N181Y PJS Hydrogen bonding with catalytic residue D176 and ATP Yes − (Ylikorkala et al., 1999)
N181E∗ PJS Hydrogen bonding with catalytic residue D176 and ATP No − (Ylikorkala et al., 1999)
L182P PJS Part of hydrophobic cluster 2; possible disruption of β6-β9 sheet No − (Olschwang et al., 2001)
D194N/V/Y PJS, NSCLC Mg2+ binding residue, catalysis Yes −
(Westerman et al., 1999a; Avizienyte et al.,
1999; Guldberg et al., 1999)
E199K∗∗ PJS Interacts with backbone atoms from LKB1 A-loop Yes + (Dong et al., 1998)
E199Q∗ PJS Interacts with backbone atoms from LKB1 A-loop Yes +++ (Blons et al., 2008)
A205T∗ HNSCC Possible distortion of LKB1 activation loop Yes +++ (Qiu et al., 2006)
D208N PJS Activation segment, interacts with the αEF-αF loop Yes +++ (Dong et al., 1998)
G215D PJS p+1 loop, substrate binding Yes − (Dong et al., 1998)
Continued on next page. . .
Table 4.2 - Continued
Mutation Disease Location and functional significance Comp. Act. Reference
S216F∗ PJS, NSCLC p+1 loop, substrate binding Yes − (Ji et al., 2007)
E223V∗ NSCLC Part of the PPE motif; forms ion pair with R297 Yes − (Matsumoto et al., 2007)
T230P∗ PJS Short β-strand with A-loop Yes +++ (Forbes et al., 2008)
S232P∗∗ PJS Short β-strand with A-loop; interacts with D208 Yes +++ (Yoon et al., 2000)
W239C PJS Structural role; interacts with L290 and the PPE motif No − (Scott et al., 2002)
G242W/V PJS Structural role; αH No − (Olschwang et al., 2001)
L245R∗ PJS Structural role; Possible clashes with W308, L282 No − (Forbes et al., 2008)
T250P∗ NSCLC Structural role; C-terminal of helix αF No − (Matsumoto et al., 2007)
G251S PJS Possible distortion of the hinge region Yes +++ (Resta et al., 1998)
E256S PJS, NSCLC Solvent exposed. Binding of possible interactors/substrates Yes +++ (Yoon et al., 2000)
Y272H∗∗ PJS αG-αH loop. Solvent exposed Yes + (Boardman et al., 2000)
D277Y∗ PJS, NSCLC αG-αH loop. Solvent exposed Yes +++ (Koivunen et al., 2008)
P281L PJS Provides turn between αG-αH loop into αH helix Yes +++ (Nishioka et al., 1999; Wang et al., 1999)
L285Q∗ NSCLC Part of hydrophobic cluster 1 No − (Forbes et al., 2008)
R297S PJS Ion pair with E223 from the PPE motif (helix αEF) No − (Westerman et al., 1999a)
R297K PJS Ion pair with E223 from the PPE motif (helix αEF) No − (Boardman et al., 2000)
R304W PJS Structural role; hydrogen bonds with D162, E165 No + (Resta et al., 1998)
W308C PJS Part of hydrophobic cluster 1 No − (Mehenni et al., 1998; Onozato et al., 2007)
P314H PJS C-terminal flanking tail; binding of possible interactors/substrates Yes +++ (Resta et al., 1998)
P315S∗ PJS C-terminal flanking tail; binding of possible interactors/substrates Yes +++ (Scott et al., 2002)
P324L PJS C-terminal flanking tail; binding of possible interactors/substrates Yes +++ (Park et al., 1998; Westerman et al., 1999b)
∗Mutants tested in this study; ∗∗Mutants tested in this study and by Boudeau et al. (2004)
Comp., Complex formation
Act., LKB1 activity (−, <5%; +, 5-25%; ++, 25-50%; +++, >50%)
PJS, Peutz-Jeghers syndrome
NSCLC, non-small cell lung carcinoma
HNSCC, head and neck non-small cell carcinoma
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Other mutations present in the activation loop (Ala205Thr and
Asp208Asn), the αEF/αF loop (Thr230Pro, Ser232Pro) and CFT re-
gion (Pro314His, Pro315Ser and Pro324Leu) did not markedly affect
the ability of LKB1 to assemble into an active complex (Table 4.2).
There are also a number of oncogenic mutations in solvent-exposed
residues (Arg86Gly, Gln123Arg, Pro315Ser, Tyr272His, Asp277Tyr)
that do not affect complex assembly or activity (Fig. 4.27 and Table
4.2). Thus, out of 50 mutations analysed, 18 are still capable of form-
ing a complex with STRADα and MO25α that possesses significant
LKB1 activity (Table 4.2). Assuming these are cancer driving rather
than passenger mutations, some of these mutations may be involved in
interacting with other regulators or substrates of the LKB1 pathway.
Although the data described in this chapter show that STRADα
and MO25α are required for activation of LKB1 using a novel al-
losteric mechanism of activation, it is worth noting that none of the
LKB1 oncogenic mutations identified to date, lie on the direct in-
terfaces between LKB1 and STRADα/MO25α. However, this is in
agreement with our site directed mutagenesis data (Figs. 4.18, 4.20,
4.22, A.6 and A.7), showing that single mutations that disrupt any of
the dimeric interfaces are not sufficient to disrupt formation of an ac-
tive heterotrimeric complex. While we have shown that it is possible
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to engineer an inactive double mutant of LKB1 that disrupts the inter-
faces with both STRADα and MO25α, this is unlikely to occur spon-
taneously. Similarly, redundancy of the MO25A/B and STRADA/B
genes may also explain why no oncogenic mutations have been identi-
fied in these genes to date (Alhopuro et al., 2005).
4.9 Concluding remarks
The structure of the LKB1 complex has revealed how LKB1 is acti-
vated through a phosphorylation-independent mechanism, involving
direct interaction with STRADα and MO25α. The active conforma-
tion of LKB1 is induced by binding to the C-lobe and activation loop
of STRADα. MO25α binding to the activation loop of LKB1 further
stabilises this active conformation. MO25α and ATP binding play
an important role in stabilising STRADα active conformation, that is
crucial for interaction with LKB1 (chapter III of this thesis). Thus,
MO25α plays a central role in stabilising association of STRADα and
LKB1, as well as controlling their active conformations. A cartoon
figure summarising key interactions within the LKB1 heterotrimeric
complex is provided in Fig. 4.28
The results discussed in this chapter provide insights into how a
subset of protein kinases may have evolved as pseudokinases, incapable
of phosphoryltransfer. Instead, pseudokinases such as STRADα have
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Figure 4.28: Summary of LKB1/STRADα/MO25α interactions and LKB1 activation
The model is based on structural and mutagenesis data discussed in this chapter. STRADα
interacts via its activation loop residues H231 and Phe233 with either lobe of LKB1, “wedg-
ing” them apart and promoting an active kinase conformation. This is stabilised by MO25α
interacting mainly via residues Arg240 and Phe243 with the activation loop of LKB1. Two
key interacting residues from LKB1 are shown, Arg74 and Phe204 located in the STRADα
and MO25α interaction sites respectively.
retained an active conformation required to interact with regulators
in a similar manner by which active kinases bind their substrates.
The mechanism by which LKB1 is activated, represents a novel way
in which kinases can be regulated allosterically and independently of
activation loop phosphorylation. Finally, the data provide insights
into how cancer mutations affect LKB1 function by impairing complex
assembly, catalytic activity and potential interactions with substrates
or regulators.
Chapter V
Discussion and future perspectives
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5 Discussion and future perspectives
5.1 Pseudokinases
5.1.1 Origin of pseudokinases
A large number of protein kinases in metazoan organisms are predicted
to be inactive (Manning et al., 2002; Boudeau et al., 2006). However
no comprehensive phylogenetic studies for the pseudokinase family
have been conducted thus far. The recent publication of the genome
sequence of the choanoflagellate Monosiga brevicollis (King et al.,
2008)—a protist believed to be the closest relative to metazoans—
could help in shedding light to the evolution of these enigmatic pro-
teins. The M. brevicollis tyrosine kinome has provided interesting
insights in tyrosine signalling by revealing an unexpected expansion
of genes containing tyrosine kinase domains (Manning et al., 2008).
Analysis of the available sequences (128 in total) of the M. brevicollis
tyrosine kinome (Manning et al., 2008) reveal eight tyrosine kinases
with degenerate HRD and DFG motifs, strongly suggesting inactivity
for these kinases (Fig. 5.1). This represents 6% of the total tyrosine
kinome and considering the number of human pseudokinases (∼10%)
is an overestimate, the 6% approximation could be a ratio similar to
the human pseudokinase fraction.
In an attempt to answer the question of whether clear examples
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The M. brevicollis 
tyrosine kinome
Predicted pseudokinase
Human homologues
Figure 5.1: The M. brevicollis tyrosine kinome
Neighbour-joining distance tree of protein tyrosine kinases from M. brevicollis. Predicted
pseudokinases are coloured red. Tyrosine kinases conserved in humans (Manning et al.,
2008) are coloured blue. Sequences were downloaded from The Salk Institute for Bio-
logical Studies website (http://kinase.com/), and aligned using MUSCLE (Edgar, 2004).
The tree (calculated using MUSCLE) was displayed using FIGTREE downloaded from URL:
http://tree.bio.ed.ac.uk/software/figtree/
of pseudokinases exist in species lower than protozoans, the yeast
kinome (Hunter and Plowman, 1997) was analysed (Fig. 5.2). In-
spection of the sequences of 126 kinase domains revealed 13 members
(10%) of the yeast kinome, have at least one degraded conserved mo-
tif (Fig. 5.2 and Table 5.1). A similar study of the Dictyostelium
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Atypical kinase
Predicted pseudokinase
STRAD, AMPK and LKB1 homolgues
The yeast kinome
Figure 5.2: The yeast kinome
Neighbour-joining distance tree of protein kinases from S. cerevisiae. Predicted pseudokinases
are coloured red and those with clear homologues in humans (SCY1, GCN2) are indicated with
an asterisk. YKL161C (Mpl1) has been shown to function as a pseudokinase in yeast (Kim
et al., 2008) and is similarly indicated with an asterisk. Sequences were downloaded from
the KINOMER server, http://www.compbio.dundee.ac.uk/kinomer/index.html (Martin et al.,
2009a), and aligned using MUSCLE (Edgar, 2004). The tree (calculated using MUSCLE) was
displayed using FIGTREE downloaded from URL: http://tree.bio.ed.ac.uk/software/figtree/.
For further information on individual groups of S. cerevisea kinases, please refer to the yeast
kinome publication by Hunter and Plowman, 1997.
discoideum kinome found 29 of the total 285 (11%) predicted genes
containing kinase domains, were classified as pseudokinases (Goldberg
et al., 2006). These fractions are similar to the 10% approximate frac-
tion of predicted pseudokinases in humans (Manning et al., 2002).
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Interestingly two of the predicted pseudokinases in yeast (SCY1 and
GCN2) have several substitutions in multiple catalytic and ATP bind-
ing motif, and both SCY1 and GCN2 have clear homologues in humans
(Table 5.1), suggesting important conserved functional roles as pseu-
dokinases. In humans there are three SCY1 homologues (SCYL1-3).
SCYL1 binding, via a short C-terminal sequence to the membrane
trafficking coatomer (COPI) is required for COPI-dependent vesicle
trafficking from Golgi to the ER interface (Burman et al., 2008). It is
argued these SCYL1 functions explain the phenotypic characteristics
of SCYL1 mutations in “muscle deficient”mdfmice models of a human
neuromuscular disease, characterised by spinocerebellar and neurode-
generation (Schmidt et al., 2007; Burman et al., 2008). Intriguingly,
SCYL1-3 isoforms have multiple (1-4) heat repeats (distantly related
to MO25 repeats) fused to their pseudokinase domains. Interestingly,
ULK4 is another pseudokinase in the human kinome with a detectable
heat repeat. It remains unknown if association of these helical repeats
regulate SCYL(1-3)/ULK4 conformation in an analogous manner to
the regulation of STRAD by MO25. It is worth mentioning a previ-
ous study carried out by Conner and Schmid show SCYL1 (referred
to by these authors as CVAK104) is involved in clathrin coated vesicle
trafficking and can associate and phosphorylate the clathrin adaptor
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protein 2 (AP2) in vitro (Conner and Schmid, 2005). Thus, there are
still questions of whether the SCYL family of pseudokinases possess
intrinsic catalytic activity or whether their role is mainly of interacting
nature.
Table 5.1: Degradation of conserved motifs in the S. cerevisiae kinome. Pseudokinases
discussed in text are highlighted.
Kinases GxG VAIK/R HxDxK∗ N DFG Human homolog
YBL009W (ALK2) GxS YVVP HxNxT H DMK Haspin (Active)
ALK1 SxG LSLQ HxNxK N DFK Haspin (Active)
SCY1 − VLIG HxNxQ A GLG SCYL1-3 (Inactive)
VPS15 − IVIK HxDxK N DFA PI3R4 (?)
CAK1 RxD FEVS HxDxK N DFG CDK7 (Active)
KSP1 SxK ICLE HxDxK N DWG AGC group
YGR052W QxG VALK HRDxK N DWG STK36 (Active)
SSN3 (CDK8) ExL − HxDxK N DLG CDK8 (Active)
YKL161C (Mpl1) GxG VAIR HRDxK N NFG ERK5 (Active)
GCN2 (N-ter) PxS YLLS HxCxN T DFG GCN2 (C-ter; Inactive)
AKL1 KxG ACLK HRDxK N DWG BMP2K (Active)
ARK1 TxG ACLK HRDxK N DWG BMP2K (Active)
PRK1 TxG ACLK HRDxK N DWG AAK1 (Active)
∗Lysine position is conserved for all Ser/Thr kinases
5.1.2 The “non-catalytic” activity of pseudokinases
A third member of yeast pseudokinases YKL161C (Table 5.1) also
known as Mpk1 like (Mpl1) kinase because of its close homology to
the yeast MAP kinase Mpk1 (SLT2; Fig. 5.2), is thought to influence
gene transcription by a non-catalytic mechanism (Kim et al., 2008).
Interestingly, Kim et al., demonstrate that both Mpk1 and Mpl1 form
complexes with the transcription factors Swi4/Swi6 respdependentec-
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tively. The formation of these complexes (detected at the FKS2 (Glu-
can synthase 2) promoter) drive FKS2 gene expression (Kim et al.,
2008). The authors show that a Lys54Arg mutation in the VAIK mo-
tif of Mpk1—a naturally occurring mutation in Mpl1 (Table 5.1) that
is devoid of Mpk1 catalytic activity (Martin et al., 1993; Zarzov et al.,
1996; Madden et al., 1997), is still able to induce FKS2 gene expres-
sion (Kim et al., 2008). By contrast a double mutant that changes
phosphorylation site residues present in the activation loops of both
Mpk1/Mpl1, was unable to associate with Swi4/Swi6 and drive FKS2
gene expression (Kim et al., 2008). This suggests that the active
“closed” conformation normally induced by phosphorylation of the
activation loop is important, instead of the catalytic activity. Mpk1
and Mpl1 are homologues of the human extracellular signal-regulated
kinase 5 (ERK5), known to be catalytically active (Table 5.1). Re-
markably the authors were able to demonstrate the same behaviour
with human ERK5 overexpressed in a yeast mpk1∆/mpl1∆ strain,
suggestive of similar non-catalytic functions for the ERK5 MAP kinase
(Kim et al., 2008). Altogether, these results are in agreement with the
findings and conclusions presented in chapter III of this thesis, that
pseudokinases can exert their functions through their conformational
state alone. Moreover, the correct positioning of the activation loop
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either through phosphorylation/ATP binding and/or activity modula-
tors appears to be a common regulatory mechanism for pseudokinases.
5.1.3 Pseudokinases regulated by nucleotide binding
Nucleotide pocket occupancy of a kinase/pseudokinase domain has
not been fully appreciated in terms of regulating their conformational
states, despite its obvious implications and already known examples
in other classes of enzymes that bind nucleotides (e.g. G-proteins are
regulated by guanine nucleotide-induced conformational changes). In
chapter III of this thesis, structural, biophysical and mutagenesis data
demonstrate the importance of nucleotide binding to STRADα in in-
fluencing STRADα ability to interact with its biological partners, as
well as the ability of STRADα to activate the LKB1 tumour suppres-
sor kinase.
Recently, conformational regulation of a kinase domain through nu-
cleotide pocket occupancy has been described for catalytically active
kinases. For instance in the case of IRE1, its phosphoryl transfer
activity is functionally dispensable (Lee et al., 2008). Indeed, Lee
et al., could demonstrate that ATP and ADP were both able to in-
duce dimerisation of IRE1 kinase domains thus bringing together two
Kinase Extension Nuclease (KEN) domains that together function as
a nuclease (Lee et al., 2008). The kinase domain dimerisation oc-
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curs mainly through the N-lobe, including helix αC, and does not
involve the activation loop (Lee et al., 2008). The authors suggest,
the pseudokinase RNaseL that lacks its activation segment, could be
regulated by occupation of the nucleotide pocket despite its catalytic
inactivity (Lee et al., 2008). In addition, very recent reports, show
binding of ATP and ATP-competitive inhibitors control the conforma-
tion of active AGC kinases such as PKB and PKC (Okuzumi et al.,
2009; Cameron et al., 2009). This makes them better substrates for
upstream kinases (Okuzumi et al., 2009; Cameron et al., 2009) and
explains observations of so-called “activating” inhibitors.
An example of a pseudokinase influenced by ATP binding is the
family of receptor guanylyl cyclases (RGC), an important cell surface
receptor family that produces the second messenger cGMP in response
to the binding of several natriuretic factors (reviewed in (Sharma,
2002)). These lack the HRD motif that provides the catalytic base
residue, although ANP-RGC receptors are able to bind ATP leading
to further amplification of receptor activity. It is thought that both
activity of the guanyl cyclase domain, C-terminal to the pseudokinase
domain, as well as receptor ligand affinity are influenced by ATP bind-
ing (Joubert et al., 2005). The ATP-dependent activity of the receptor
is not affected when non-hydrolysable forms of ATP (e.g. ATP-γ-S)
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are used and is sensitive to point mutations in the glycine-rich loop
and VAIK motifs that affects ATP interaction with the pseudokinase
domain (Bhandari et al., 2001; Sharma, 2002). Moreover, Jaleel at al.,
2006 raised a monoclonal antibody that recognises the pseudokinase
domain of guanylyl cyclase receptor 2C (GC-C) and showed that the
immunoreactivity was compromised upon ATP binding, suggesting
large conformational shifts between the ATP bound/unbound forms
of this domain (Jaleel et al., 2006). Fine epitope mapping revealed
the site of antibody recognition was Lys516 (VAIK) motif and nearby
residues C-terminal to the VAIK motif. In the absence of structural
data, it is difficult to envisage the exact conformational changes that
would occur due to ATP binding, although in the majority of kinases
the VAIK motif (β3) is followed by the αC helix, a well known region
that undergoes large conformational changes upon formation of the
conserved Lys(β3)/Glu(αC) ion bridge. Future studies in this area
may demonstrate that the active/inactive conformations of the pseu-
dokinase domain are indeed required for RGC activity via a regulatory
mechanism similar to the one described in this thesis for STRADα.
5.1.4 Pseudokinases interacting with active kinases
Interestingly, there are a number of membrane receptors that contain
a cytoplasmic pseudokinase domain, including members of the ephrin
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receptor EphB6 and EphB10 as well as members of the epidermal
growth factor receptor family ErbB3/Her3. As already discussed in
Chapter III section 3.5.4 the four members of the EGF receptor kinases
(ErbB1-4) are envisaged to trans-activate by forming so-called asym-
metric heterodimers, upon ligand binding rather than phosphorylation
(Zhang et al., 2006a; Jura et al., 2009). This lack of evolutionary pres-
sure to conserve phosphoryl transfer activity may also be responsible
for the loss of catalytic activity by ErbB3.
Another example where a pseudokinase forms complexes with active
kinases are members of the kinase suppressor of Ras 1 and 2 (KSR1/2),
that are essential for Ras induced activation of the RAF-MEK-ERK
module in MAP kinase signalling. The pseudokinases act as scaffolds
bringing together the three components of the MAP kinase pathway
(MAPKKK, MAPKK and MAPK), thus regulating signalling output
and potentiation (Kolch, 2005; McKay et al., 2009; Dougherty et al.,
2009). The role of scaffold proteins in MAP signalling is well studied
in budding yeast and the importance of Ste5p scaffold for bringing to-
gether the MAPK components module is well established (Elion, 2001;
Bhattacharyya et al., 2006a; Good et al., 2009). It appears the Ste5p
scaffolding roles for MAP kinases in higher organisms have been sub-
stituted by KSR1 and KSR2 (Morrison and Davis, 2003; Kolch, 2005).
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The pseudokinase domain of KSR1 binds MEK and RAF, whereas
ERK is recruited to the signalling complex via a conserved domain
N-terminal to the pseudokinase domain (Kolch, 2005). In addition,
recent work that established KSR2 as an important scaffold (similar
to KSR1) of MAP kinase signalling, reveals KSR2 can be regulated by
dephosphorylation by calcineurin in response to changing Ca2+ levels
(Dougherty et al., 2009). The lack of structural information makes
it difficult to precisely understand the mechanism by which KSR1/2
contribute to these scaffolding complexes. In light of the findings pre-
sented here for the STRAD pseudokinase, it will be interesting to
investigate ligand (ATP) binding capabilities of KSR1/2 and see if
this is required for MAP kinase signalling.
Perhaps the most studied pseudokinase domain belongs to the mem-
bers of Janus tyrosine kinase (JAK) family. The JAK isoforms include
JAK1, JAK2, JAK3 and TYK2 all of which contain an N-terminal
pseudokinase domain (JH2) followed by a kinase domain (JH1). This
characteristic feature of containing two kinase domain gives JAKs their
name, referring to the two-faced Roman God Janus. JAKs respond
upon receptor binding to cytokines and phosphorylate the cytoplas-
mic region of these cytokine receptors, thus creating sites of interaction
for downstream signalling molecules. The pseudokinase domain is re-
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quired for JAK2 auto-inhibition and is essential for JAK2 cytokine
activation (Saharinen and Silvennoinen, 2002; Saharinen et al., 2003).
Strikingly, a gain-of-function mutation (Val617Phe) in the JAK2 JH2
domain is a cause of myeloproliferative disorders in humans (Baxter
et al., 2005; James et al., 2005; Levine et al., 2005). Structural mod-
elling and biochemical data suggest the N-lobe of JH2 domain where
Val617 resides, is in close proximity to the JH1 domain (Saharinen
et al., 2003). Recently gain-of-function somatic mutations of another
residue present in the JH2 domain (Arg683Gly/Ser/Lys) were found
in 18% of patients suffering with Down’s syndrome-associated acute
lymphoblastic leukaemia (Malinge et al., 2007; Bercovich et al., 2008;
Kearney et al., 2009). The exact location of these disease causing
mutations and how their position relates to the JH1 domain are not
known. It will be interesting to see if structural studies of JH1/JH2
domains will reveal the molecular mechanism of action of these muta-
tions, and whether these resemble any of the STRAD/LKB1 interac-
tions.
5.1.5 Pseudokinases as elastic scaffolds
Structural studies of predicted pseudokinases have shed light to the
mechanisms of protein kinase inactivity. Recently, the structure of
VRK3 was published by Scheeff et al., explaining how non-conservative
5 Discussion and future perspectives 237
substitutions of catalytic motifs compromised VRK3 catalytic compe-
tence (Scheeff et al., 2009). The VRK3 structure is similar to the
closely related active kinase VRK2 structure. However, VRK3 lacks
catalytic activity (Scheeff et al., 2009). Similar to the STRADα pseu-
dokinase discussed in this thesis, VRK3 appears to attain a “closed”
conformation that resembles active protein kinases (Fig. 5.3A and B).
Interestingly, this is achieved in the absence of ATP, and the so-called
hydrophobic spine is completed by nearby hydrophobic residues that
compensate for the loss of the ATP adenine ring (Scheeff et al., 2009).
Scheeff et al., studied the surface conservation of the VRK3 catalytic
domain and identified a conserved area, away from the active site,
that could be important for binding macromolecular partners (Scheeff
et al., 2009), thus suggesting that VRK3 may have a scaffolding role,
rather than functioning as a protein kinase.
STRADα VRK3 ROP2 and ROP8
A B C
αEF/αF
insertion
p+1 loop
p+1 loop
p+1 loop
Figure 5.3: Structures of pseudokinases
Carton representations of (A) STRADα from the LKB1/STRADα/MO25α complex (chapter
III), (B) VRK3 (PDBID 2V62; (Scheeff et al., 2009)) and (C) superposed ROP2 (PDBID
3BYV) and ROP8 (PDBID 3DZO) pseudokinases (Labesse et al., 2009; Qiu et al., 2009).
The activation segments are coloured red and the p+1 loops are labelled. A short (αEF/αF)
insertion present in ROP2 and ROP8 is circled.
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Two other pseudokinase structures, members of the Rhotropy (ROP)
family, ROP2 and ROP8 from the intracellular parasite Toxoplasma
gondii (Labesse et al., 2009; Qiu et al., 2009), appeared in print during
the last year of this study. Of the eight members of the ROP family,
five are predicted to be pseudokinases, namely ROP2, ROP4, ROP5,
ROP7 and ROP8. Both structures of ROP2 and ROP8 attain similar
conformations, with activation and p+1 loops in the canonical confor-
mation typical of active protein kinases (Fig. 5.3C). One noticeable
difference is the presence of a short insert within the αEF/αF loop,
that may also account for specific binding of macromolecular part-
ners. This insertion blocks the active site of ROP2/8, by sitting on
the top of the p+1 loop (Fig. 5.3). Interestingly, this is analogous
to the blocking of the active site of STRADα by LKB1 (discussed
in chapter IV of this thesis), which may also explain why these ki-
nases are inactive. Unlike VRK3, the ATP pocket is empty in ROP2
and ROP8 structures, although Labesse et al., reported ROP2 could
not interact with ATP (Labesse et al., 2009). It is unclear if the nu-
cleotide pocket harbours a true ligand binding site and whether the
ROP pseudokinases are regulated by ATP binding.
Overall, the structures of VRK3, ROP2/8 and those presented in
this thesis support the notion put forward by Boudeau et al., 2006,
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that pseudokinases function as scaffolds, bringing together compo-
nents of a signalling pathway (e.g. KSR1/2 (McKay et al., 2009;
Dougherty et al., 2009)), and/or activity modulators (e.g. STRADα/β,
chapter III, IV of this thesis and ErB3/Her3 (Zhang et al., 2006a)).
In addition, data presented in chapter III of this thesis suggest a reg-
ulatory mechanism for pseudokinase function, modulated by ligand
(ATP) binding as well as macromolecular binding partners, that to-
gether impinge on activation loop conformation. The importance of
this conformational state regulation is supported in chapter IV, by the
structure of the LKB1 complex and mutagenesis data, demonstrating a
key role for residues present in the STRADα activation loop in binding
and activating LKB1. Thus, it is possible to envisage pseudokinases
as “elastic” scaffolds, the function of which can be regulated by post
translational modification, as well as allosterically through binding of
micromolecular/macromolecular ligand binding.
5.1.6 Phylogenetic studies of the STRAD pseudokinase
STRAD appears to be conserved throughout evolution with clear ho-
mologues present in primitive species such as budding yeast (Fig. 5.4).
Phylogenetic analysis of the STRADα gene reveals two important fea-
tures. Firstly, STRAD evolved as a pseudokinase in the early meta-
zoan evolution since orthologous genes with degraded catalytic motifs
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Figure 5.4: Evolution of the STRAD pseudokinase
Neighbour-joining distance tree of STRAD gene family from eukaryotic species. The
general family name for the species belonging to each clade is labelled and a common
name is given in brackets. The number of degraded catalytic motifs is shown in red.
Sequences were downloaded from TREEFAM (http://www.treefam.org/) and UNIPROT
(http://www.uniprot.org/) databases and aligned using MUSCLE (Edgar, 2004). The
tree (calculated using MUSCLE) was displayed using FIGTREE downloaded from URL:
http://tree.bio.ed.ac.uk/software/figtree/
were also identified in the choanoflagelate M. brevicollis (Table. 5.2),
that as mentioned above is believed to be the closest unicellular or-
ganism to animals. Secondly, STRADα and STRADβ diverged as
two separate genes much later in metazoan evolution, possibly due to
a gene duplication event (Fig. 5.4). Interestingly, changes in catalytic
motifs of the STRADα pseudokinase, unlike STRADβ, are strictly
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conserved among species (Table 5.2), possibly reflecting a central bi-
ological role for this gene. Surprisingly, STRAD emerged as a pseu-
dokinase with three degraded motifs (out of the five conserved motifs)
in M. brevicollis and similar changes are present throughout evolution
(Fig. 5.4). Interestingly, this organism has two candidate genes that
may be STRAD precursors. MbSTRAD1 is inactive and resembles
STRADα3 and STRADβ2 splice isoforms, lacking the WEF motif.
MbSTRAD2 contains a conserved WEF motif and is predicted to be
active.
STRAD orthologues, predicted to be active are present in D. dis-
coideum and yeast species (Fig. 5.4 and Table 5.2)—these all contain
a WEF motif, suggestive they may interact with MO25. Indeed clear
genetic interaction for STRAD with MO25 has been demonstrated in
yeast between the active Kic1 and Hym1 (Jorgensen et al., 2002; Nel-
son et al., 2003). The STRADα pseudokinase homologues have been
shown to interact with LKB1 and function upstream of AMPK kinase
in C. elegans (Narbonne and Roy, 2009).
5.1.7 Evolution of pseudokinases
The ultimate question is how did pseudokinases evolve? In general
it is plausible to believe that kinases evolved from ATP binding en-
zymes, since nucleotide binding must have preceded catalytic function.
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Table 5.2: Catalytic motif degradation of the STRADα pseudokinase
ATP binding Catalytic loop Mg2+ loop
Species GxG VAIK/R HRDxK N DFG Altered motifs
S. cerevisiae GxG YAIK HRDxK N DFG 0
D. discoideum GxG VAIK HRDxK N DFG 0
M. brevicollis GxG VAIR HNRxG S NFH 3
D. melanogaster KxG LAVK HGSxR H NFS 4
C. elegans GxC VAIK HRDxK H GFR 3
A. gambiae AxC VAVK HRSxR H GFR 4
C. intestinalis GxC LAVK HRGxK H GHR 4
STRADβ
T. nigroviridis GxG VAIK HRSxK H GLH 3
D. novemcinctus GxG VTIK HRSxK L GLS 3
X. tropicalis GxG VTVR HRNxK H GLS 3
E. europaeus GxR VTIK HRSxK H GLS 4
G. gallus GxG VAVR HRNxK H GLN 3
O. anatinus GxG VAVR HRSxK S GFS 3
B. taurus GxG VTIK HRSxK H GLF 3
M. musculus GxG VTVK HRSxK H GLS 3
H. Sapiens GxG VTVK HRSxK H GLS 3
STRADα
S. purpuratus GxN VAVR HRSxK H GLR 4
O. cuniculus GxG VTVR HRSxK H GLR 3
D. rerio GxG VAIR HRSxK H GLR 3
E. europaeus ? ? HRSxK H GLR 3-5?
X. tropicalis GxG VCIR HRSxK H GLR 3
G. gallus GxG VTVR HRSxK H GLR 3
D. novemcinctus GxG VTVR HRSxK H GLR 3
B. taurus GxG VTVR HRSxK H GLR 3
M. musculus GxG VTVR HRSxK H GLR 3
H. Sapiens GxG VTVR HRSxK H GLR 3
Therefore it is not surprising that ligand (ATP) binding plays a key
regulatory component for pseudokinase/kinase function. As a con-
sequence there are two possibilities—either pseudokinases represent
“would-be” active kinases, or they represent kinases that have lost
their catalytic activity.
The first scenario could be true for proteins that are well con-
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served as pseudokinases throughout eukaryotic kinase evolution such
as SCYL1-3 and GCN2 (discussed in section 5.1.1). For instance,
ATP-binding precursors of yeast SCY1 and GCN2 may have failed
to “mature” as active protein kinases capable of phosphoryl transfer.
Instead, important non-catalytic functions were conserved through-
out evolution for these pseudokinases. In GCN2 this could have been
aided by loss of evolutionary pressure for kinase maturation, since an-
other kinase domain is present in the same polypeptide chain. In the
case of SCY1, gene duplication events leading to SCYL1-3 in higher
organisms may have fulfilled the same purpose.
However, the reasoning above can not account for the larger group
of pseudokinases that do not have clear pseudokinase homologues in
primitive species (e.g. STRADα, KSR1/2, Erb3 etc...). Therefore
these may have evolved via a different route. One possibility is that
pseudokinases have evolved from active kinases once capable of phos-
phorylating and activating their substrates. These may have lost their
activity during evolution. The process of using previously catalyti-
cally competent domains as scaffolds is plausible from an evolutionary
perspective—active enzymes know how to bind their substrates—and
also observed in other classes of enzymes such as pseudophospho-
tases (Conner et al., 2006; Moorhead et al., 2009). The structures
5 Discussion and future perspectives 244
of STRADα and VRK3 show that despite being inactive, these pseu-
dokinases are able to assume an active conformation with a highly or-
ganised active site poised for phosphoryl transfer. This suggests that
pseudokinases like STRAD were able to phosphorylate substrates at
some stage during evolution. In addition, the structure of the LKB1
heterotrimer reveals that LKB1 can bind STRAD as a substrate, by
utilising regions of the activation segment and αG helix, both of which
are commonly used by active kinases to interact with substrates. It is
tempting to suggest that LKB1 binding to STRAD as a pseudosub-
strate blocking the STRAD active site, resulted in the degradation of
catalytic motifs seen in STRAD. If this was the case, the number of de-
graded catalytic motifs in STRAD should increase from lower species
such as M. brevicollis to more complex organisms such as primates.
However, this is not observed in the phylogenetic analysis in Fig. 5.4
and Table 5.2 Instead, it is more likely that STRAD may have been an
upstream kinase for LKB1 and (by becoming a pseudokinase through
gene duplication events and spontaneous mutations) evolved as an
allosteric activator of LKB1 rather than an activator by phosphoryla-
tion. This would ensure the indispensable functions of LKB1-AMPK
axis remained unaltered.
To support this theory, kinase active STRAD homologues in organ-
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isms like D. discoideum (FRAY2), S. cerevisiae (Kic1) could be tested
for the ability of phosphorylating and activating LKB1 homologues
in these species. Additional, interesting candidates are the M. brevi-
collis MbSTRAD1 and MbSTRAD2 isoforms. Perhaps this organism
has an active STRAD (MbSTRAD1) capable of activating MbLKB1
by phosphorylation and an inactive STRAD (MbSTRAD2) that acti-
vates LKB1 via interaction. Future studies may generate more data
in support of the idea that pseudokinases evolved from active protein
kinases.
5.2 The STRADα WEF motif—is it crystal clear?
5.2.1 The STRADα WEF motif could be a “recruiting/docking” motif
At the start of this work, the most well known interaction within
the LKB1 heterotrimer, was that of the STRADα WEF motif with
the convex surface of MO25α (Boudeau et al., 2003a, 2004; Milburn
et al., 2004). The crystal structures presented in Chapters III and
IV of this thesis, are in agreement with these initial observations.
Clear electron density for the WEF motif binding in the same manner
as previously reported by Milburn et al., (2004) was observed (Figs.
3.11 and 4.9). However, the connectivity of the WEF motif with the
rest of the STRAD molecule in the structure of STRADα/MO25α
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complex is uncertain (Fig. 3.13) whereas in the structure of the LKB1
complex, is most probably swapped between the heterotrimers (Fig.
4.6). This could be due to crystallographic packing, since the WEF
motif, located in a mobile loop, is free to bind the nearest MO25
molecule available. This raises the question of whether this is also the
case in vivo. Thus far, work carried out in this thesis does not suggest
the possibility of an LKB1 heterotrimer dimer, maintained via the
WEF motif (See figures 4.4 and A.5). Similarly, work of others with
purified LKB1/STRADα/MO25α complex from E. coli has suggested
the presence of an LKB1 heterotrimer monomer (Neumann et al.,
2007).
The structures discussed in this thesis have uncovered an additional
area, 2.5 times larger than that of the WEF motif (2100 A˚2 vs. 825 A˚2
of buried surface area) participates in STRADα/MO25α interaction.
Moreover, extensive mutagenesis work carried out in this thesis as well
as in other studies (Boudeau et al., 2003a, 2004) does not suggest the
binding of the WEF motif to MO25 is absolutely required for LKB1
activity. These findings, together with the fact that STRADα3 and
STRADβ2 isoforms do not contain a WEF motif (Fig. 1.12), leads to
a number of possibilities for future exploration in the study of LKB1
regulation.
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Figure 5.5: The human STE kinase family
Neighbour-joining distance tree of the human STE family of kinases. pseudokinases are
coloured red. Kinases with possible WEF motifs are coloured green, whereas kinases with
WEF motifs at their CFT similar to the STRAD isoforms are coloured blue. Sequences were
downloaded from The Salk Institute for Biological Studies (http://kinase.com/), and aligned
using MUSCLE (Edgar, 2004). The tree (calculated using MUSCLE) was displayed using
FIGTREE downloaded from URL: http://tree.bio.ed.ac.uk/software/figtree/
For instance, a complex formed with the STRAD∆WEF isoforms
results in an unoccupied WEF pocket on the MO25 surface. This free
pocket can be used by other protein kinases that contain a WEF motif
at their CFT to bind MO25. Analysis of the STE group of kinases,
most similar to STRAD, reveals one STE7 and three STE11 protein
kinases contain probable WEF motifs at their N- and C-terminal re-
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gions (Fig. 5.5). Furthermore, three members of the STE20 germinal
centre group of kinases contain WEF motifs at their CFT that are very
similar to STRAD (Fig. 5.5). These are MST3, MST4 and YSK. In-
terestingly, MO25 was shown to bind MST4 resulting in MST4 translo-
cation from Golgi vesicles to apical membranes, that leads to Ezrin
phosphorylation and brush border formation (ten Klooster et al., 2009)
(Fig. 5.6). The sites of MST4/MO25 interaction remain unknown, al-
though it is possible that conserved residues between STRAD and
MST4, including the WEF motif could be involved in MO25 inter-
action. Similarly, the involvement of LKB1 in Ezrin phosphorylation
(ten Klooster et al., 2009) remains unexplained.
Another possibility is that the STRAD WEF motif can be a re-
cruiting or docking motif for other proteins. STRAD is involved in
interactions with E-cadherin, postulated to regulate LKB1 complex
localisation and AMPK phosphorylation at adherens junctions (Seb-
bagh et al., 2009). The mode of interactions between E-cadherin and
STRAD are unclear however, considering the STRAD N-lobe and ac-
tivation sites are engaged in interactions with MO25 and LKB1 re-
spectively, it is possible, the C-lobe and the STRAD CFT, including
the WEF motif, interact with E-cadherin (Fig. 5.6).
Finally, STRADα interacts with Exportin-7 and CRM1 leading to
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Figure 5.6: Possible interactions of the WEF motif
LKB1 relocalises to the cytoplasm via STRAD interactions with the karyopherins Exportin-7
and CRM1 (Dorfman and Macara, 2008). Possible interactions of the STRADα WEF motif
with known STRAD interactors are shown and marked with a question mark. Similarly, MST4
known to interact with MO25 (ten Klooster et al., 2009) and contain a WEF motif at its CFT
is shown. NLS = nuclear localisation signal, NES = nuclear export signal, NRD = N-terminal
regulatory domain and CRD = C-terminal regulatory domain.
LKB1 transport from the nucleus to the cytoplasm (Dorfman and
Macara, 2008). Exportin-7 and CRM1 bind nuclear export signals
that are present in the STRAD N- and C-terminal flanking tails (Fig.
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5.6). One of these NES signals is located two amino acids N-terminal
to the WEF motif. Again, it remains unclear if the WEF motif is
involved in interactions with Exportin-7 and CRM1.
5.3 MO25—a bridging scaffold within the LKB1 complex
The importance of MO25 functions as a scaffolding protein are made
evident by its high degree of conservation (discussed in section 1.5.4).
Its role in activating LKB1 is clear from various studies (Boudeau
et al., 2003a, 2004) including the results presented here. MO25α
serves as a bridge for both STRADα and LKB1 (see for instance
the interaction footprint on the MO25α concave surface in Fig. 4.9).
Through allosteric binding, MO25 stabilises the active conformations
of both STRADα and LKB1 (discussed in chapters III and IV). How-
ever, until now the role of MO25 in activating LKB1 has been over-
shadowed by the activatory role of STRAD, since in the absence of
STRAD, LKB1/MO25 interaction is undetectable in co-expression as-
says (Boudeau et al., 2003a, 2004). Therefore, it is plausible to assume,
the STRAD/MO25 complex binds and activate LKB1. The role of
STRAD in this case is to bring MO25 into close proximity of LKB1,
and/or by interacting with LKB1, STRAD indirectly induces a con-
formational change (for instance exposing the LKB1 activation loop)
that is better suited for LKB1/MO25 interaction. To understand this
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fully, a structure of LKB1 alone, STRAD alone and LKB1/STRAD
complex may be necessary. Obtaining the structures of LKB1 and
STRAD alone has been hindered by the lack of recombinant expression
of LKB1, and inability to crystallise STRAD in the absence of LKB1
and MO25 (section 3.3.3). These are suggestive of unstable conforma-
tions of these two proteins when MO25 is not present. Therefore, it is
likely that MO25 binds STRAD and LKB1 through a mixture of con-
certed and cooperative mechanisms, ultimately “fixing” both STRAD
and LKB1 in their active conformations.
5.4 Interaction of LKB1 with its substrates
A challenge in the field of LKB1 signalling is how LKB1 recognises
AMPK and the AMPK related kinases. Attempts to co-crystallise an
AMPK peptide derived from the AMPKα2 activation loop resulted in
no crystals (data not shown). Similarly, crystal soaking experiments,
designed to obtain a structure of the LKB1 complex with a substrate
peptide did not result in a kinase/substrate complex structure, despite
several attempts and collection of multiple datasets (data not shown).
The failure of the latter experiments could be a result of the high
salt concentration of (NH4)2SO4 present in the crystallisation condi-
tion, reducing the solubility of the peptide as well as the affinity of
kinase/substrate interaction.
5 Discussion and future perspectives 252
LKB1 
STRADα 
LKB1 C-terminal 
loop (CFT)
αG
αEFαF
AMP-PNP 
LKB1/STRADαFUS3/Ste5 peptide
FUS3
Ste5 peptide
BA
Figure 5.7: Comparisons of the STRADα/LKB1 with Ste5/Fus3 interactions
A) The structure of Fus3 MAP kinase complexed to a peptide from the Ste5 scaffold (PDBID
2F49; (Bhattacharyya et al., 2006b)).
B) STRADα/LKB1 interaction within the LKB1 heterotrimer. The LKB1 activation loop is
coloured magenta.
A key feature of the LKB1 complex structure is the LKB1 active
site, which as expected for an active complex, is fully exposed. The
binding of STRAD to the back of the kinase domain ensures there is
no steric hindrance of the LKB1 catalytic and substrate binding sites.
This may be one of the reasons why STRAD has evolved this unique
activation mechanism, regulating interlobe dynamics by interacting
with both lobes of the LKB1 kinase domain. The only example dis-
tantly resembling this type of interaction is between the scaffold pro-
tein Ste5 and the MAP kinase Fus3, that are components of the yeast
mating pathway (Fig. 5.7 (Bhattacharyya et al., 2006b)). Therefore,
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it is unlikely that STRADα will contribute directly to interactions
with the AMPK kinase family, although this can not be categorically
ruled out. Interestingly, MO25α binding to the LKB1 activation loop,
brings MO25α in close proximity to the LKB1 substrate binding site.
Some of these features are similar to the CDK2/Cyclin A complex
(Fig. 5.8). CDK2 like most kinases interacts with the substrate pep-
tide via the p+1 loop (Fig. 5.8A). It is reasonable to assume that
LKB1 can interact with the activation loop of AMPK-related kinases
in a similar way (Fig. 5.8B). However, in the case of CDK2/cyclin
A, a second recruiting site is also present on the surface of the Cy-
clin molecule (Fig. 5.8A). The MO25α surface may indeed provide
a docking site for the downstream targets of LKB1 similar to cyclins
that participate in this type of interaction. However, data are needed
to support this idea. A structure of the LKB1 complex with either
AMPK or an AMPK-related kinase would be the ultimate proof, al-
though a structure of the LKB1/STRAD/MO25 complex with sub-
strate peptides could help shed some light to the mechanism of LKB1
substrate recognition.
As mentioned in section 1.5.6, LKB1 contains N- and C-terminal
regulatory regions with multiple phosphorylation sites. These are not
present in the crystallised fragment of LKB1 described in this the-
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Figure 5.8: Substrate binding to CDK2 and LKB1
A) Structure of CDK2/cyclin A bound to an 11 residue recruitment peptide (green sticks)
derived from the retinoblastoma associated protein (PDBID 1H25; (Lowe et al., 2002)). A
substrate peptide bound to the p+1 loop (PDBID 1QMZ (Brown et al., 1999)) is also shown
in sticks and coloured cyan. The activation segment is coloured magenta.
B) Structure of the LKB1 complex. LKB1 is shown in the same orientation as CDK2 and the
same substrate peptide (A) is modelled on the LKB1 p+1 loop. LKB1 activation segment is
coloured magenta.
sis, thus their relative position to the LKB1 kinase domain and/or
STRADα and MO25α remain unknown. Although recent reports
(Zheng et al., 2009; Esteve-Puig et al., 2009) have claimed part of
the LKB1 CFT could interact with AMPK, this requires further in-
vestigation.
Recently, concentration-dependent dimerisation of AMPK via helix
αG was described by Sholz et al., (Scholz et al., 2009). The authors
report that LKB1 helix αG (residues Ile260 and Phe264) and AMPK
helix αG (residues Val219 and Phe223) are involved in LKB1/AMPK
interactions. In the LKB1 structure Ile260 and Phe264 are facing the
p+1 loop of LKB1 and Phe260 in particular, makes important contri-
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butions to ensure the right conformation of the p+1 loop. The authors
claim that the AMPK αG helix interacts with residues Ile260 and
Phe264 of LKB1 (Scholz et al., 2009). Since by definition the activa-
tion loop of AMPK should bind to the p+1 loop of LKB1, it is unclear
how helix αG of AMPK as well as the activation loop could be accom-
modated, without significant changes of the LKB1 active/substrate
binding sites.
5.5 Final conclusions and remarks
The structures of the 82 kDa STRADα/MO25α complex and the 116
kDa LKB1/ STRADα/MO25α complex have been determined at 2.35
and 2.65 A˚ resolution respectively. This represents the first struc-
tural analysis of the LKB1 tumour suppressor and the pseudokinase
STRAD. The work described in this thesis reveals for the first time
how the conformation of a pseudokinase can be regulated by ligand
(ATP) binding as well as via activity modulators such as the scaffold
protein MO25, in an analogous fashion to the CDK/Cyclin complexes.
Moreover, this work reveals that pseudokinases serve as elastic scaf-
folds bringing together regulatory components of signalling pathways.
Unlike the conventional scaffolding proteins, pseudokinases may have
an advantageous feature, as their conformation can be modulated be-
tween the active and inactive states similar to catalytically competent
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protein kinases. Central to this regulation is the movement of helix
αC and the conformation of the activation loop. Thus, the STRADα
pseudokinase may serve as an example for other pseudokinases that
are also involved in regulating important signalling pathways.
The structure of the LKB1 heterotrimeric complex reveals for the
first time, a novel molecular mechanism by which a protein kinase is
activated independently of activation loop phosphorylation. This is
achieved by a concerted action of the scaffolding protein MO25, that
mediates the active conformations of both STRAD and LKB1. An
“active” STRAD serves two main functions: it brings MO25 in close
proximity to LKB1 and possibly induces a conformational change on
LKB1, thus making LKB1 more likely to interact with MO25. Impor-
tantly, MO25 stabilises the active conformation of the LKB1 activation
loop, leading to a fully active LKB1, capable of phosphorylating its
downstream targets.
Despite the numerous phosphorylation events between kinase do-
mains in a cell, crystal structures of a kinase domain bound to an-
other substrate kinase domain are not available. The structure of
LKB1 bound to STRADα using typical active site elements of the
later, may represent the closest example to date. Intriguingly, this
may also represent an ancient kinase/substrate interaction, that could
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also be significant in explaining the evolution of pseudokinases.
Because of the intrinsically transient nature of kinase/substrate in-
teraction, data are lacking into the exact mechanism of how LKB1
recognises its substrates (e.g. AMPK). Similarly, the functions for
the N- and C-terminal regulatory regions of LKB1, not present in the
structure described here, are unclear. The ultimate goal will be to
crystallise the LKB1 complex with a kinase substrate, like AMPK or
a member of the AMPK family of kinases.
Finally, the LKB1 structure provides insights into the molecular
mechanisms of how oncogenic mutations that occur in patients with
PJS and more aggressive types of cancers affect LKB1 structure and
function.
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Figure A.1: MALDI-TOF analysis of His-STRADα/MO25α complex before and after
lysine methylation
Mass over charge spectra for the (A) unmethylated and (B) methylated His-STRADα/MO25α
complex. The His-STRADα and MO25α peaks and their corresponding measured molecular
weights are labelled. The theoretical molecular weights (MW) are given in brackets.
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Figure A.2: His tagged STRADα and untagged STRADα bind MO25α with similar
affinity
Binding of STRADα to immobilised (A) MO25α(WT, wild type), (B) MO25α(M260A), (C)
MO25α(R227A) and (D) MO25α(R227A/M260A) was assessed by SPR analyses. Equivalent
concentrations of His-STRADα or untagged STRADα, were allowed to bind over 50 s by
injecting different concentrations over a range of 0.4 nM to 5 µM, in the presence of 0.1
mM ATP and 1 mM MgCl2. Response levels for specific binding of STRADα to MO25α
was plotted against STRADα concentration (log scale). Boxed are representative BIAcore
sensograms recorded in duplicate and corresponding to the highest concentration for each of
the labelled STRADα curves. A complete set of primary sensograms are provided in Fig. A.3.
Similar results were obtained in at least two separate experiments.
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Figure A.3: Primary BIAcore sensograms from SPR analysis of the STRADα/MO25α
interaction
Association/dissociation curves from the STRADα/MO25α interaction measurements and
analysis. The experimantal procedure is described in chapter II, section 2.13 and data were
analysed as described in section 2.13.2. Similar results were obtained in two separate experi-
ments carried out in duplicate. Kinetic fits in panels A, C and E correlate well with equilibrium
fits in panels B, D and F respectively, as it is expected for specific binding that follows law
of mass action. The SPR measurments were carried out by Dr Iva Navratilova, University of
Dundee.
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Figure A.4: Attempts for the expression and purification of the
LKB1/STRADα/MO25α complex in E. coli
A) Architecture of the pOPCH vector (Tan, 2001) used to recombinantly co-express the LKB1,
STRADA and MO25A genes. RBS = Ribosomal binding site.
B) SDS-PAGE analysis of the NiNTA purification of the LKB1 complex. Eluted fractions, and
NiNTA beads before and after elution are labelled. The indicated bands were analysed by
tryptic peptide-mass spectrometry (MS/MS) and positively identified as LKB1, STRADα and
MO25α.
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B LKB1/STRADα/MO25α  (0.75 mg/ml) 
A Me-LKB1/STRADα/MO25α  (0.75 mg/ml) 
C LKB1/STRADα/MO25α + ATP (3.0 mg/ml)
Figure A.5: Sedimentation experiments of the LKB1/STRADα/MO25α complex
A & B) Analytical ultracentrifugation experiments for the methylated (A) and unmethylated
(B) forms of the LKB1 heterotrimeric complex (0.75 mg/ml; theoretical MW = 115.8 kDa)
that was used for crystallisation studies in this thesis. A peak corresponding to 92.5 kDa
(unmethylated) and 83.4 kDa (methylated), both indicative of a monomeric form of the het-
erotrimer is labelled.
C) Analytical ultracentrifugation experiments for the unmethylated form of the LKB1 het-
erotrimeric complex (3.0 mg/ml; theoretical MW = 115.8 kDa) in the presence of 0.1 mM
ATP and 1 mM MgCl. A peak corresponding to 81.5 kDa and indicative of a monomeric form
of the heterotrimer is labelled. The experiment was carried out by Dr Mark Agacan, University
of Dundee.
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Figure A.6: Mutation of MO25α hydrophobic pocket that interact with LKB1 activa-
tion loop (Phe204) do not affect LKB1 activity
293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-STRADα and
Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity purified and
assayed for the ability to activate heterotrimeric AMPK complex expressed in E. coli. Kinase
activities are representative of three independent assays carried out in triplicate (error bars
represent the SD for a single triplicate experiment). Affinity purified GST-LKB1 preparation
(upper panel) as well as cell extracts (lower panel) were immunoblotted with the indicated
antibodies.
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Figure A.7: Mutation of the LKB1/STRADα/MO25α interfaces
A & B) 293 cells were co-transfected with the indicated constructs of GST-LKB1, Flag-
STRADα and Myc-MO25α. Cells at 36 h post-transfection were lysed and GST-LKB1 affinity
purified and assayed for the ability to activate heterotrimeric AMPK complex expressed in E.
coli. Kinase activities are representative of three independent assays carried out in triplicate
(error bars represent the SD for a single triplicate experiment). Affinity purified GST-LKB1
preparation (upper panel) as well as cell extracts (lower panel) were immunoblotted with the
indicated antibodies.
